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FOREWORD
The ROSIE study played an important role in developing and informing drugs policy in Ireland. The study was 
commissioned to establish the current impact of methadone treatment on the health of individuals and on 
offending behaviour. The fact that over 8,700 people are now included in the methadone programme represents 
a signifi cant achievement and illustrates the focus that the Government is putting on tackling the problem of 
drugs misuse.
The outcome of this research shows that treatment does work. There were signifi cant reductions in drug use after 
one year in treatment and those in treatment also reported that their involvement in crime had reduced very 
signifi cantly. A number of those in treatment have also undergone training and some have gained employment.
I wish to thank the people involved in the study for their co-operation and for giving the time to facilitate the work 
of the Research Team. I want to congratulate the Research Team, NUI Maynooth, and in particular Dr Catherine 
Comiskey and her co-authors, on their achievement in maintaining contacts and completing interviews with so 
many of the participants. I also thank the National Advisory Committee on Drugs who commissioned the work 
and, in particular, its Chairperson, Dr. Des Corrigan.
John Curran T.D.
Minister of State with Responsibility for the National Drugs Strategy
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PREFACE
It is one of the core tasks of the NACD to advise Government about the treatment of problem drug-taking in 
Ireland. In addition, Action 99 of the 2001-2008 National Drug strategy required the NACD to commission outcome 
studies within the Irish setting to establish the current impact of methadone treatment on both individual health 
and on offending behaviour. As a result the NACD, in 2002, commissioned Professor Catherine Comiskey and her 
team at NUI Maynooth to conduct what has become known as the ROSIE Study. Most of the 404 opiate users 
recruited into the study between September 2003 and July 2004 were in receipt of methadone while some were  
in detoxification, others in abstinence-based treatment and a small number were attending needle exchange. They 
were followed up for 3 years.
The outcomes from the ROSIE study show drug treatment works and that investment in drug treatment is paying 
dividends. Significant reductions are shown in the key outcome areas of drug use, involvement in crime and 
injecting drug use. In addition improvements were seen in employment and training. We were thus able to advise  
the Minister that investment in opiate treatment services leads to benefits to the individual drug user, to their 
family and to the rest of the community and that this investment must be continued.
In the area of physical and mental health some improvements were made over the 3 years. However, results were 
mixed. This may be to do with the measures used or the poor health condition of the study cohort from the outset 
or poly substance use or indeed lack of treatment for dual diagnosis. In 2004 the NACD published a report entitled 
“Mental Health and Addiction Services and the Management of Dual Diagnosis in Ireland” in which we highlighted 
the difficulties faced by individuals dependent on drugs who had a co-existing mental health problem. The NACD 
recommended then that the Addiction and Mental Health Services need to develop guidelines based on best 
international practice for the management of dual diagnosis in Ireland. Despite our disappointment with the  
lack of change envisaged for those with dual diagnosis as set out in A Vision for Change, the NACD stands by its 
recommendation on the need for dialogue and an agreed set of guidelines. We also reiterate our recommendation 
that patients in receipt of methadone prior to admission to a psychiatric facility should be continued on that 
prescription while in psychiatric care.
Arising from the results of the ROSIE Study the NACD has advised the Government through the Minister of State that:
n Whilst there are still areas for further study it is clear that continued investment in drug treatment  
is required. It is anticipated that implementation of the rehabilitation strategy will give more good 
outcomes in the years to come.
n The development of an exit form for those completing treatment as part of the NDTRS would greatly 
enhance the quality of the data available in the future and reduce the need for longitudinal studies over 
time. In particular having a unique identifier would also enhance the quality of data analysis and our 
understanding of the interplay between factors affecting the lives of problematic drug users. Having  
a unique identifier in use would also enable a greater understanding of the impact of problematic  
drug use on services and on communities thus facilitating better planning.
The success of this study is due to the expertise and commitment of Professor Comiskey and her team. Much credit 
is also due to Dr Eamon Keenan, Chair of the NACD’s Treatment subcommittee and his colleagues on the Research 
Advisory Group for the project including Liam O’Brien, Dr Derval Howley, Dr Ide Delargy, Dr Aileen O’Gorman, Professor 
Shane Allwright and our two External Advisors, Professor John Strang and Dr Michael Farrell both of the National 
Addiction Centre, Institute of Psychiatry, London. A special thanks is due to the former Director of the NACD,  
Ms Mairead Lyons for her tireless inputs into this work from its inception onwards. The NACD’s Research Officer,  
Dr Gemma Cox was originally the Project Manager of ROSIE before she joined the NACD and has been heavily involved 
in both the actual research and in bringing the various Bulletins and this final report to publication. As ever my colleagues 
and I are enormously grateful to the staff of the NACD who have contributed in no small way to the completion of 
this report. They may be small in number but they work incredibly hard to bring all of the NACD’s work to finality.
Dr Des Corrigan FPSI 
Chairperson, NACD
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EXECUTIVE SUMMARY
Background
Recognition of the harms associated with opiate dependency and the chronic nature of this condition has 
led to an increased availability of, and access to, treatment and/or rehabilitative services under the National 
Drugs Strategy (2001-2008). At an international level, a number of outcome studies, for example the Drug Abuse 
Treatment Outcome Study (DATOS) in the United States, the National Treatment Outcome Research Study 
(NTORS) in England and Wales and the Drug Outcome Research in Scotland (DORIS) have supported the overall 
effectiveness of established treatment options available for heroin users. To date, no national longitudinal data 
have been available to determine the overall effectiveness of such treatment options in the Irish context. This lack 
of information, coupled with the increased recognition of the need for treatment and care services to be informed 
by evidence-based research, contributed to the National Advisory Committee on Drugs (NACD) commissioning 
a national drug treatment outcome study in Ireland. The tender was awarded to Dr Catherine Comiskey at the 
National University of Ireland, Maynooth in 2002.
Objective
The Research Outcome Study in Ireland Evaluating Drug Treatment Effectiveness (ROSIE) was the fi rst national, 
prospective, longitudinal drug treatment outcome study in Ireland. The primary objective of the study was to 
evaluate the effectiveness of treatment and other intervention strategies for opiate use in Ireland. This was to 
be realised by the achievement of the following fi ve goals:
1. To develop a research model, instrument and study based on the NTORS (http://www.dtors.org.uk/
NTORS.aspx) and the Maudsley Addiction Profi le questionnaire (Marsden et al, 1998).
2. To defi ne, derive and measure a set of demographic and drug-using life history measures at national 
level for opiate users in Ireland.
3. To defi ne, derive and measure a set of treatment outcome measures for opiate users in Ireland.
4. To present fi ndings that highlight current opiate treatment outcomes in Ireland.
5. To compare the Irish national fi ndings at international level.
Methods
The study design was based on the established tradition of longitudinal drug treatment outcomes research and 
thus employed a “before and after” research methodology, whereby individuals are used as their own refl exive 
control. To this end, study participants were interviewed at treatment-intake or as soon as possible 
thereafter and then at six months, one year and three years after treatment-intake.
Drug services were selected from both inpatient and outpatient settings and from three 
modalities; methadone maintenance, structured detoxifi cation, and abstinence-based 
treatment programmes. In addition, a sub-sample of individuals was recruited from needle 
exchange interventions. These modalities were selected as they were considered to 
be the principal interventions available to opiate drug users in Ireland.
Using a structured questionnaire, 404 individuals were recruited from 54 
services provided by 44 separate agencies and/or organisations between 
September 2003 and July 2004. Participant eligibility criteria were to 
(a) be over 18 years of age, (b) be an opiate user, (c) be commencing 
a ‘new treatment episode’, (d) be prepared to consent to the 
tracking/follow-up procedures and (e) be prepared to 
provide a range of locator information.
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The main outcome measures included in the study were drug-using behaviour (including drug type, frequency  
and quantity of use), health (physical and mental), social functioning (employment, accommodation and family 
relations), harm (injecting-related risk and overdose), mortality and crime.
Key Outcomes
The location and interview rates of participants obtained by ROSIE at the 3-year follow-up time point exceeded 
levels seen in comparable international studies and were in direct contrast to the usual trend of decreasing  
follow-up rates as time progresses. At the 3-year time point, 97% of all original participants were located and  
88% of participants successfully completed interviews, with just 4% choosing not to be interviewed. This is an 
improvement on the 1-year follow-up; some respondents who had refused to participate at that stage decided  
that they would like to take part in the study at the subsequent time point. At 3-years, 1.5% of participants were 
deceased and one participant was in a coma. Of those participants who were located but not interviewed, four 
were living in another country and eight were part of a methadone programme. No member of this sub-group  
of respondents was in prison.
The ROSIE 1-year mortality rate was 0.5%; two participants died in the first year. This was low when compared  
with the NTORS equivalent rate of 1.2% or Smyth et al’s (2005) mortality rate of 1.8% in their follow-up study of 
opiate users seeking inpatient treatment in Dublin. However, this is not unexpected since mortality rates following 
inpatient detoxification treatment are known to be higher than those associated with outpatient treatments. In all, 
six of the 404 participants died between the start of recruitment in September 2003 and the end of the 3-year 
follow-up interview period in July 2007, leading to a 3-year mortality rate of 1.5%.
Treatment Status
It was observed that 38% of the participants recruited in methadone were still in their intake treatment setting  
at 3-years. Research suggests that retention in methadone treatment is associated with more positive outcomes 
(Lawless and Cox 2001) and the findings presented here are very encouraging for methadone treatment services, 
particularly given that, at 3-years, it was observed that 59% of those interviewed were currently receiving 
methadone treatment.
Of those participants recruited in the detoxification and abstinence modalities, approximately 70% completed 
their intake treatment. This compares with studies conducted in the UK that show completion rates varying from 
25% to 50% (Gossop et al, 1999; Keen et al, 2001) and is particularly noteworthy in the light of work by Ravndal et al 
(2005), in which it is stated that the completion of treatment is an important indicator for improved outcomes.
Drug Use
It was observed that there were significant differences reported in the use of all drugs from intake to 3-years  
with heroin use reducing from 77% to 46%, cannabis use reducing from 64% to 49%, cocaine use reducing from  
44% to 20%, benzodiazepine use reducing from 44% to 32%, non-prescribed methadone reducing from 41% to 14%  
and crack cocaine usage reducing from 15% to 7%. However, while use of benzodiazepines was lower at 3-years  
than at intake, it was found that the proportion using this drug increased significantly from 1-year to 3-years.  
The percentage drug-free from all illegal drugs in the last 90 days increased significantly from 9% at intake to  
28% at 1-year and 29% at 3-years. It was observed that the proportion consuming alcohol both at 1-year and at  
3-years decreased significantly from intake. Overall, the main conclusion was that reductions observed in the 
proportions using a range of drugs, and in the mean number of days on which drugs were used, between intake  
and 1-year were sustained at 3-years.
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Crime
Significant improvements in crime outcomes observed between intake and 1-year were still evident at the 3-year 
time point. The number of those selling/supplying drugs fell from 30% to 13% and the number handling stolen 
goods fell from 25% to 10%. Once initial improvements were achieved between intake and 1-year, it seems that 
participants experienced a period of stabilisation with respect to criminal activity and this outcome did not  
change significantly between 1- and 3-years. For those who were experiencing legal problems other than being 
arrested, significant improvements were evident for three of the eight legal problem categories. Most notably, 
those experiencing no legal problems increased at 1-year follow-up and increased slightly again at 3-year follow-up.
Health and Risk Behaviour
Although the reported physical health outcomes improved slightly at 3-years, little change was observed in 
symptoms of mental health reported for the same period. For physical health outcomes, only poor appetite 
showed a significant decline at 3-years. However, non-significant increases were observed in six of the ten 
symptoms with stomach pains in particular showing a significant increase at 3-years. With regard to mental  
health outcomes, the frequencies of anxiety-related and depression-related symptoms were considerably  
different at 3-years. Significant improvements were observed at 3-years for depressive symptoms such as feeling 
hopeless about the future, feelings of worthlessness, feeling no interest in things and feeling lonely. However,  
of those who experienced anxiety symptoms, only “feeling tense” showed a significant reduction at 3-years.
Improvements were evident in injecting-related risk behaviour of participants throughout the study period. 
Reductions in both the proportion of participants injecting any drug and in the frequency of injecting in the  
last 90 days (particularly for those injecting between 25 and 79 days) occurred at 3-years. Of the participants  
who reported injecting drugs, the percentage of respondents who never shared or borrowed needles was close  
to 90% at treatment-intake and remained stable at 3-years. Likewise, the proportion of participants who never 
shared other injecting paraphernalia remained consistently high throughout. There was a non-significant reduction  
in the reported number of times on which respondents injected daily, declining from four times a day to three 
times a day. Incidents of non-fatal overdose also remained fairly constant with figures for overdose between 
treatment-intake and 3-years remaining stable.
Social Functioning
Under the National Drugs Strategy (2001-2008), the importance of rehabilitation, employment and social 
functioning of drug users has been recognised. A significant increase in the numbers of participants undertaking 
training courses at 1-year and 3-years in comparison to intake was observed with the percentage increasing from 
16% at intake to 29% at 1-year and 33% at 3-years. In addition, improvements in participants’ recent employment 
status were found with a significant increase (p<0.001) between intake and 3-years for those currently employed 
and the percentage working rising from 16% at intake to 29% at 3-years. It was also observed that the number of 
participants deemed ‘usually not working in the last 90 days’ decreased from 42% at intake to 31% at 3-years.
In terms of social functioning, accommodation and family, a significant increase was observed in the number of 
participants reporting living in their own or rented accommodation in the last 90 days when comparing intake  
and 1-year, and intake and 3-years, with figures rising from 34% at intake, to 45% at 1-year, and 49% at 3-years.
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Per-protocol Group
The per-protocol group was defined as those participants who completed all three interviews at intake, 1-year  
and 3-years. This group consisted of 289 individuals or 72% of all those who were recruited to the study. The  
per-protocol group is particularly useful when tracking changes over the 3-year follow-up period as data for  
these individuals are available at each of the three time points. As follow-up rates at 1-year and 3-years were  
very high, findings within the per-protocol population reflected the results presented on specific outcomes  
for the full population.
Conclusions and Recommendations
The results presented on outcomes are positive and encouraging from the perspective of not only the individual 
opiate user but the community, the treatment provider and society. Improvements observed at 1-year were 
generally sustained. However, some measures did deteriorate. For this reason, more research is required on the 
long-term mental and physical health outcomes of opiate users in treatment. In addition, while the majority of  
the participants demonstrated improvements in outcomes, there remained a group of participants who did not 
respond to treatment. Further research using data from ROSIE may assist in determining the factors that influence 
positive treatment responses. The results presented here are a first look at the wealth of data that were collected 
by the ROSIE study. It is hoped that treatment users, treatment providers and policy makers will see this study as 
their resource and that this resource will continue to be used for the benefit of all those who contributed to the 
success of the ROSIE study.
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CHAPTER ONE: INTRODUCTION
1.1 Aims
The primary objective of the study was to evaluate the effectiveness of different kinds of treatments 
and interventions currently available to opiate users in Ireland. To this end the aims were:
n To undertake the fi rst national, prospective longitudinal drug treatment outcome study;
n To describe the characteristics of people seeking treatment for their problem drug use;
n To examine treatment outcomes at six months, one year and three years after participants 
commenced their index treatment and;
n To provide an economic cost-estimate for the problems associated with drug use among the cohort.
This chapter describes the rationale for this evaluation and key contents of the forthcoming chapters 
are highlighted.
1.2 Background and Rationale
In the recent past a growing number of drug prevention activities have been carried out across the globe, 
throughout Europe and in Ireland. Many of these projects however have not been effectively evaluated. 
There is an urgent need to increase current knowledge about the process of evaluation and to pool 
experience and results. This has been well recognised internationally; the European Monitoring Centre 
for Drugs and Drug Addiction (EMCDDA) has published its Guidelines for the Evaluation of Drug Prevention, 
a manual for programme planners and evaluators (EMCDDA 1997a, 1997b, 1997c, 2001), while the National 
Institute on Drug Abuse of the United States Department of Health and Human Services has published 
research-based guidelines on the principles of drug addiction treatment (NIDA 1999) and has initiated 
a series of related projects in various states. The need for evaluation of drug treatment programmes at 
global and European level has also been well documented by the World Health Organisation (WHO) 
and the United Nations Drug Control Programme (UNDCP) (Marsden et al, 2000). With ever increasing 
drug-using population in Ireland (Comiskey, 2001; Kelly et al, 2004) and subsequent increases in the 
demand for treatment services, there is a growing need to evaluate treatment for opiate use in Ireland 
in a national context.
In response to the acknowledged gaps in the literature, the United States, Australia and many European 
countries undertook drug treatment evaluation programmes. In the United States, the Drug Abuse 
Treatment Outcome Study (DATOS) reported national patterns of treatment effectiveness during 
the 1990s (Simpson, 2003). The Australian Treatment Outcome Study (ATOS) was the fi rst large scale 
prospective treatment outcome study on heroin dependence in that country (Darke et al, 2005) and 
in England and Wales, the importance of research on the outcome of treatment for substance use 
problems was also recognised. Marsden et al (1998) highlighted that priority must be given to 
developing valid and reliable instruments to assess treatment outcomes and consequently 
conceived the Maudsley Addiction Profi le (MAP) instrument. This instrument contains 
measures of physical and mental health symptoms and three aspects of personal 
and social functioning. Gossop et al (1998) provided an overview of fi ve years’ of 
treatment outcome research in the UK and stressed the importance of deciding 
how best to allocate scarce national resources to tackle drug use treatment 
problems. In Scotland, the Drug Outcome Research in Scotland (DORIS) 
study followed a cohort of 1,007 opiate users over a period of 33 months 
(McKeganey et al, 2006).
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In Ireland, the Alcohol and Drug Research Unit (ADRU) of the Health Research Board (HRB) maintains the 
National Drug Treatment Reporting System (NDTRS) and holds a valuable collection of data on the nature 
of the drug problem (http://www.hrb.ie). However, in spite of these excellent international and national 
developments, as of 2002, no large scale treatment evaluation had been undertaken in Ireland. The National 
Advisory Committee on Drugs (NACD) was established to advise the Government in relation to prevalence, 
prevention, treatment, rehabilitation and consequences of problem drug use in Ireland and commissioned 
ROSIE as a response to the evaluation need.
1.3 Best Practice in Evaluation Studies
The WHO (Marsden et al, 2000) states that evaluations systematically answer common questions  
about interventions, including:
n Is this intervention properly targeted?
n Is it working in the way it was designed to?
n To what extent is it effective?
n What does it cost?
n Are there any unexpected problems?
To answer these questions, there are three types of evaluation. Firstly, there is an implementation 
evaluation, also called a process evaluation or programme monitoring. This type of evaluation assesses  
how the intervention is being implemented. Secondly, an impact or outcome evaluation is carried  
out: this assesses the impacts of an intervention on the target population and other people. Outcome 
evaluation studies report changes that service participants may experience over time. A drug treatment 
outcome evaluation addresses questions regarding treatment for drug use, including whether respondents 
are better off after treatment and whether drug use was reduced as a result of treatment (Marsden  
et al, 2000). Finally, an economic evaluation assesses whether an intervention is good value for money.  
A comprehensive evaluation can comprise of all three types, however, in practice, resource and other 
constraints mean that some elements will be emphasised more than others. The primary focus and scope 
of an evaluation will depend on what kind of assessment is required by whom, at what time, and using 
which available resources. ROSIE is the first national outcome evaluation for the treatment of opiate use  
in Ireland, commissioned by the NACD in 2002 for what was ultimately a three year study period, for the 
benefit of treatment clients, service providers and policy makers.
1.4 Study Outline
In Chapter Two, methodological details on the study design, implementation and execution are presented. 
Information in this chapter includes how to estimate sample sizes required for such a study, how to design 
effective data management and quality control procedures including database construction, follow-up 
procedures and field operations. Details of the relevant types of data analysis required and presentation  
are also included.
Chapter Three presents results relating to the study design and execution. Recruitment numbers and 
geographical coverage are reported. Detailed information is given regarding participant follow-up and 
numbers and location procedures, including discussion of loss to follow-up and mortality. The results  
from the data quality assurance audit are presented here also.
Chapters Four, Five, Six, Seven and Eight present the results of key outcome measures in ROSIE. These  
are under the headings of treatment pathways, drugs, crime, health and social functioning. Chapter Nine 
introduces and provides results for the per-protocol population.
Finally, Chapter Ten discusses the key results observed in ROSIE. It places these results in an international 
context and makes recommendations for treatment service policy makers and future researchers.
In general, throughout this document, percentages greater than five are rounded to the nearest integer  
in the text, while percentages in tables are given to one decimal place.
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CHAPTER TWO: STUDY DESIGN, RESEARCH 
METHODOLOGY AND MANAGEMENT
2.1 Introduction
Prior to any data collection, the design, research methodology and management of the study must be 
clearly laid out for the study to be successful. Failure to perform in-depth research into these three branches 
of the early part of the study may result in situations where the data are effectively useless. For example, 
insuffi cient consideration into the design of the study may result in collection of, for example, the wrong 
data, insuffi cient data or biased data. Poor research may lead to an inappropriate design being applied to 
the study. Poor management can result in the divulgence of private information which may lead to legal 
considerations. Mismanagement of data can result in incorrect conclusions being drawn from data analysis.
The aim of this chapter is to describe the design, research methodology and management of ROSIE and 
thus to provide a set of methodological guidelines for future similar longitudinal evaluations. Each aspect 
of the methodology, from ethics, study design, interdisciplinary collaboration and networking, data analysis, 
database construction and management, fi eldwork, security, quality control, tracking procedures and 
successful project completion is discussed in detail.
Each of the three branches of the early study development process is considered in turn. The chapter 
begins by presenting the rationale for the study in terms of how to evaluate treatment effectiveness 
and describing the various treatment modalities and settings to be evaluated. The subjects, population 
defi nition and the analysis sub-group as well as selection of recruitment sites are next considered with 
a description of the research instrument used in the study also given.
An in-depth discussion of designing the study is then presented. The type of experimental design is considered 
and described, as are the formulae for the statistical power and sample size calculations. The Statistical 
Analysis Plan follows with a detailed discussion on the analytical techniques used in this research.
The data management process is considered in Section 2.4 and begins with a brief discussion of the Data 
Protection Act and its relevance to ROSIE. Next, the set-up of the database containing the respondent 
information and the Data Management Plan are presented. The quality control and auditing process is also 
described. Following this, the fi eldwork and follow-up procedures are considered. The ROSIE databases 
used for follow-up purposes are discussed, as well as the sources for respondent follow-up and diffi culties 
encountered while tracking respondents. Diffi culties encountered while conducting interviews are described 
next, with the fi eldwork and follow-up section ending with a discussion on ethical concerns and safety 
of interviewers. The chapter concludes by emphasising the necessity for an evaluation to be an evolving 
process which needs to be fl exible and open to the changes in circumstances it will encounter during 
the longitudinal study period.
2.2     Objectives and Evaluating Treatment Effectiveness
The primary objective of the study was to evaluate the effectiveness of different kinds 
of treatments and interventions currently available to opiate users in Ireland. To this 
end the aims were:
n     To undertake the fi rst national, prospective longitudinal drug treatment 
     outcome study;
n     To describe the characteristics of people seeking treatment for their 
     problem drug use;
n     To examine treatment outcomes at six months, one year and 
     three years after participants commenced their index treatment 
     and;
n     To provide an economic cost-estimate for the problems 
     associated with drug use among the cohort.
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Accordingly, the study was designed to describe the nature of treated opiate use in Ireland across 
modalities that reflect the delivery of care in Ireland. The following five goals were identified and their 
achievement would realise the ROSIE aims:
1. To develop a research model, instrument and study based on the National Treatment Outcome 
Research Study (NTORS) (http://www.dtors.org.uk/NTORS.aspx) and the Maudsley Addiction  
Profile questionnaire (Marsden et al, 1998).
2. To define, derive and measure a set of demographic and drug-using life history measures at  
national level for opiate users in Ireland.
3. To define, derive and measure a set of treatment outcome measures for opiate users in Ireland.
4. To present findings that highlight current opiate treatment outcomes in Ireland.
5. To compare the Irish national findings at international level.
Evaluation of opiate treatment effectiveness involves measuring outcomes for individuals who enter 
treatment. There are several levels at which these outcomes can be defined, i.e. individual, family, 
community and society. These levels are examined in this document in the contexts of health, social  
and economic (time rather than units of currency) impacts. The key strands within the survey instrument 
measure and assess changes under these three headings. At each level, one key outcome variable was 
prioritised. In summary, a threefold definition of target outcomes was defined and is shown below  
(Table 2.2(a)).
 Table 2.2(a) Summary of Targeted Outcomes and Key Variables at the Individual, Community 
and Societal Levels
Outcome Level Health Social Economic
INDIVIDUAL Key: Risk of death due  
to overdose or suicide.
Improvements in general 
health, risk of harm and 
mental health.
Reduced aggression, anxiety, 
group conflict, criminal 
activity.
Unemployment.
FAMILY & 
COMMUNITY
Key: Risk of harm to closest 
dependant.Decreased risk 
of transmission of harm  
to others (drug use and 
infectious disease).
Improved social relations 
with family and community, 
reduced aggression with 
others.
Reduced community debt.
SOCIETY Change in health service 
utilisation.
Reduced public nuisance, 
police force involvement.
Key: Reduction in cost  
to society. Crime, health 
costs, loss of revenue.
By answering key questions regarding treatment episodes, evaluation of treatment effectiveness at these 
levels is possible. The particular questions that ROSIE wished to address were:
(i) Has opiate users’ drug use reduced following treatment?
(ii) Has opiate users’ physical and mental health improved following treatment?
(iii) Has opiate users’ opiate related harm reduced following treatment?
(iv) Have opiate users’ living, social and family circumstances improved following treatment?
(v) Have opiate users’ crime levels reduced following treatment?
In answering these questions, the impact of treatment not only on the individual, but on their immediate 
community, in terms of their family and friends, and on society, including in terms of the impact on victims 
of crime and usage of medical and legal resources available has been assessed.
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A range of outcome criteria was defined and measured by asking questions on the following outcomes:
a) Substance use
1) Use of opiate drugs (including heroin and similar).
2) Frequency of use of opiate drugs (including heroin and similar).
3) Number of days of use in the last 90 days.
4) Amount used on a typical day.
5) Frequency of use and/or consumption of all other drugs (non-opiate and including alcohol).
6) For each other drug (non-opiate and including alcohol):
I. Number of days of use in the last 90 days.
II. Amount used on a typical day.
b) Risk behaviour
1) Frequency of needle sharing.
2) Number of days injected in the last 90 days.
3) Typical number of times injected in one day.
4) Number of times used or passed a used needle in the last 30 days.
5) Number of days used someone else’s filter, spoon or flush water in the last 30 days.
6) Frequency of unprotected sex in the last 90 days.
7) Number of accidental overdoses in the past 90 days.
c) Physical and mental health
1) Frequency of physical and mental health symptoms (including anxiety, depression and suicidal 
ideation).
2) Number of times attempted suicide in the past 90 days.
3) Number of times attempted suicide in the last six months.
4) Number of days in contact with medical services (including hospital, accident and emergency,  
GP and community treatment) in the last 90 days.
d) Personal/social functioning
1) Frequency of criminal behaviour (including selling drugs, shoplifting and others).
2) Number of weeks of non-criminal employment in the past 90 days.
3) Contact with dependant, partner, family/relatives and friends.
4) Type of relationship with children, if any.
5) Number of days conflict with partner (if any) in the last 90 days.
6) Number of days conflict with relatives in the last 90 days.
7) Number of days conflict with friends in the last 90 days.
As the study evolved, minor changes were made in plan implementation but the core strategy and overall 
objectives remained unchanged. For the purposes of data analysis and interpretation, in some circumstances 
it was necessary to recode new variables from those collected during the study, for example, the reported 
amount of alcohol intake was recoded into units of alcohol. As further data analysis was conducted, limitations 
in some questions and their responses became apparent in terms of their tractability for analysis.
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2.2.1 Treatment Settings and Modalities
ROSIE participants were to be recruited within residential (or inpatient) and outpatient community settings. 
Four modalities of treatment intervention were included; methadone (maintenance and reduction were not 
distinguished), structured detoxification, abstinence programmes and needle exchange. These were selected as 
they reflected the treatment interventions available at a national level at the time of the study implementation.1
 Methadone
The provision of methadone, a long-acting opiate agonist, under medical supervision is the main 
pharmacological substitution intervention for opiate users in Ireland. Initially, a low commencing dose 
(usually between 10mls and 40mls) is prescribed, aimed at achieving a level of comfort while reducing  
the likelihood of overdose. By the end of six weeks of treatment, the individual is usually stabilised on  
an appropriate therapeutic dose. Methadone maintenance is a long-term treatment option of no fixed 
duration, usually forming part of a wider process of assisting an individual to reduce various forms of  
drug-related harm and to address social, legal and financial problems until the person is ready and willing  
to withdraw from the drug substitution therapy. There are different models of maintenance prescribing, 
ranging from low-threshold programmes to highly structured regimes (Cox et al, 2007c).
The ROSIE methadone modality includes both maintenance and reduction approaches. At the start of the 
study, when treatment centres were contacted, it was observed that many of the clinics, while aspiring to 
methadone reduction programmes, were mostly providing methadone maintenance. Thus, the Research 
Advisory Group (RAG) included methadone maintenance and methadone reduction as one modality to 
capture this dichotomy from the client and provider perspective.
 Structured Detoxification
Structured detoxification is a process whereby individuals are systematically and safely withdrawn from 
opiates, under medical supervision. The most common method of opiate detoxification in Ireland is to  
use methadone and slowly taper the individual down from the usual dose to zero over a period of time. 
Structured detoxification programmes are provided in both inpatient and outpatient facilities and can vary  
in duration from approximately four to 12 weeks. ROSIE recruitment for this modality was carried out in 
centres where detoxification was part of a treatment programme over a specific period of time up to a 
maximum of 12 weeks (Cox et al, 2007a). This differentiates from the ten to 15 day detoxification that 
occurs, for example, in the prison context, which is not aimed at delivering treatment but instead at 
managing acute withdrawal from opiates on arrival in prison.
 Abstinence
ROSIE defined the abstinence modality as being any structured programme which required individuals to be 
drug-free (including free from any pharmacological intervention) in order to participate in, and remain on, the 
programme. Such programmes provide intensive psychological support and a structured schedule of daily 
activities that clients are obliged to attend. Treatment can occur in an inpatient (often referred to as residential 
rehabilitation) or an outpatient (i.e. structured drug-free day programmes) setting. Inpatient abstinence-based 
treatment programmes can differ markedly in their underlying philosophy, structure, intensity and duration.
Programmes may be either short-term (usually between four and 12 weeks) or long-term (usually between 
three and 12 months). ROSIE study participants were recruited from the three main types of residential 
rehabilitation programmes identified in the international literature: 12-step/Minnesota model programmes, 
Christian houses and a therapeutic community (Cox et al, 2007b).
 Needle Exchange
While needle exchange is not a treatment modality in itself, it was felt that capturing the journey of  
those accessing needle exchange interventions and their progress through the services was important  
for completeness. Hence, some interviewees were recruited from needle exchange services.
1 Initially, counselling was to be included as a modality. Upon commencing recruitment, however, it was found that very few opiate 
users were receiving only counselling as a form of treatment. Consequently, the RAG took the decision to omit counselling as a 
treatment modality.
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2.2.2 Subjects’ Inclusion Criteria
In terms of participant eligibility, only those opiate users defined as presenting for a new treatment episode 
were recruited to ROSIE, where ‘new treatment episode’ is defined as incorporating those who had never 
presented for treatment before, those who had presented for this type of treatment previously but were 
not in receipt of this type of treatment in the last six months and those who had presented for other types 
of treatment previously. Following talks with the NACD Treatment sub-committee and the RAG, it was 
decided that a new treatment episode participant was a pragmatic choice of definition given the possible 
lack of availability of participants presenting for their first ever treatment. In addition, if opiate users who 
were currently in treatment were selected, the comparability of intake data between participants would 
have been compromised as intake would refer only to the beginning of the recruitment process, not to the 
beginning of the treatment episode. It should be noted, however, that this choice of participant definition 
imposed the limitation that, in some circumstances, such participants could be difficult to identify and 
recruit due to a possible lack of availability of treatment places.
Inclusion criteria for participants were to (a) be over 18 years of age, (b) be starting a new treatment episode 
as defined above, (c) have used opiates, (d) be prepared to consent to the tracking/follow-up procedures 
and (e) be prepared to provide a range of locator information. Involvement in ROSIE was voluntary and  
it was made clear to potential respondents that refusal to participate would not affect the treatment 
received. Participants were informed that they could, at any time, withdraw from the study. Confidentiality 
was assured and individuals were informed that all answers and comments provided would remain 
anonymous. The intake interview took approximately one hour, interviews took place in a variety of 
settings (treatment services, prisons, cafés, participants’ homes) and participants were not financially 
reimbursed for completing an intake interview. Participants did, however, receive a gift voucher to the value 
of €20 at the follow-up interviews in recognition of their time, contribution and commitment to the study. 
Trained ROSIE fieldworkers carried out all interviews.
2.2.3 Site Selection and Coverage
ROSIE was designed, not as a randomised control trial with specific numbers of respondents allocated  
to a treated or control group within certain geographical locations, but as a study that reflects the 
availability and distribution of treatment service provision in Ireland. Ideally, all health regions would have 
been included in some capacity, however not all treatment modalities were available within all regions. 
Consequently, only regions with available opiate services were included. ROSIE, therefore, reflects the 
availability and distribution of existing national treatment service provision in 2003, the time of recruitment.
All agencies providing treatment to opiate users in Ireland were contacted and informed about the ROSIE 
study. Information was sought from services regarding the nature of the organisation and the range of 
services provided. Thereafter, all methadone clinics within the greater Dublin area that had the capacity  
to facilitate treatment-intake during the recruitment period were included in the site selection process. 
Many clinics outside Dublin were known to be full to capacity but these were still contacted for recruitment 
purposes. In addition, all General Practitioners (GPs) prescribing under the Methadone Protocol were 
informed of the research and their assistance in study recruitment was requested. GPs were contacted  
via the Central Treatment List and followed-up with telephone calls and letters (see Section 2.5.2). All 
residential drug treatment facilities in the country that provide services for opiate users were included  
in the selection process. The co-operation of both the methadone central treatment list holders and  
the GP co-ordinator was critical to the project. Finally, study recruitment was also to be carried out in  
the main inpatient facilities in the country and in an outpatient detoxification facility.
2.2.4 Research Instruments and Pilot Phase
The ROSIE intake research instrument was adapted from the Maudsley Addiction Profile (MAP) and the 
DORIS instrument. The MAP is a brief, interviewer-administered questionnaire for treatment outcome 
research applications that measures problems in the four domains of substance use: health risk behaviour, 
physical and mental health and personal/social functioning (Marsden et al, 1998). The DORIS instrument  
is an extension of the MAP and includes extra quantitative and qualitative components (private communication, 
Neil McKeganey and Gordon Hay, Centre for Drug Misuse Research, Glasgow, 2002).
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Every question on the DORIS intake instrument was scrutinised and edited where necessary by the senior 
project management team to confirm its suitability for use in the ROSIE project. The phrasing and time 
frame of each question was checked to ensure the question captured the required data within the correct 
time reference. Prior to the roll-out of ROSIE recruitment, the newly developed instrument was approved 
by the RAG and was piloted in a range of settings. Results are presented below.
 Pilot Study
The ROSIE pilot interview instrument and pack were devised in the spring of 2003. This followed a 
comprehensive consultation and research phase in the winter of 2002, during which a detailed study design 
protocol and data protection, management and quality assurance plans were agreed. The questionnaire 
relied on self-reporting, which is accepted as being valid and reliable for the collection of data on drug  
use, criminality and HIV risk behaviour (Darke, 1998; Del Boca & Noll, 2002). The instrument was pre-piloted 
within the research team and was formally tested by a researcher in the field for eight weeks from early 
March to early May 2003. The instrument was tested in a range of non-residential settings including a large 
statutory health clinic, two smaller community treatment centres and with a GP. A total of 18 respondents 
were interviewed during the period. The mean time taken per interview was 47 minutes with a range of 28 
to 87 minutes.
The 87-minute interview was an extreme case as it involved a respondent who was continually falling 
asleep. Without this interview the average time to complete the interview was 39 minutes.
Of the 18 respondents interviewed during the pilot phase, 13 were male and five were female. The ages  
of this group ranged from 20 to 35 years with a mean age of 27.5 years. Of the 18 respondents, 17 were  
in receipt of methadone treatment and one was using a needle exchange. Respondents had sought 
treatment for a range of drugs used. Of the 18 respondents 14 had previously had treatment for drug use.  
Ten respondents had used some opiate the day prior to the interview. When asked about overdoses 13  
of the 18 respondents had a drug overdose at some time in their life. The average number of overdoses  
per respondent was three with a range of three to ten. Eight respondents had also attempted suicide.  
Three respondents had attempted suicide at least once in the last six months. With respect to questions 
regarding sexual behaviour, 12 of 17 respondents reported that they had had sex in the past 90 days, of 
whom eight said they had never used condoms. No respondent had bought or sold sex within the last six 
months, while eight of 17 respondents said they were single and not in a relationship. Regarding children,  
11 of 17 said that they were parents and three said they or their partner were expecting a baby. Respondents’ 
number of children ranged from one to four. Seven of 17 respondents said that they were not currently in 
trouble with the law, however respondents had committed a range of crimes in the last 90 days. The most 
frequent crime committed was drug possession, followed by handling stolen goods.
The aims of the pilot study were to test the suitability, validity and timing of the instrument delivery;  
the efficacy of the structures and procedures in place to collaborate with external sources in a timely 
manner; and the quality and reliability of the data management process. A substantial amount of time  
was invested in the planning and design phase of the ROSIE project. Evidence of the benefits of this 
investment was found in the successful completion of the pilot instrument in a range of varied external 
settings, and the smooth execution of the data input and analysis. However obstacles and limitations must 
also be considered and acted upon. Given interview length and the slow speed of respondent enrolment 
during the pilot phase a revised plan on the timing and enrolment of participants was devised. In addition, 
the training of additional interviewers was set as a priority. With regard to the data collected, amendments 
to the demographic questions were made to enable a more accurate demographic data analysis.
Following the pilot phase the intake survey instrument was refined. The instrument contained several 
sections including locator information, demographic characteristics, index treatment, drug treatment 
history, drug use, injecting-related risk behaviour, physical and mental health, and contact with family,  
social care and other services. A brief description of these sections is provided.
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 Locator Information
To facilitate follow-up, the following information was sought from participants at intake interview; full 
name/nickname, street name, current address and participants’ telephone numbers (mobile and landline), 
the name, address and telephone number of a parent (or other family member), the name and address of 
the treatment referrer, the name and address of the respondent’s GP, the name and address of their social 
worker (if any) and the name and address of a key worker/drug worker who would be able to contact the 
participant.
 Demographic Characteristics
Demographic variables included age, gender, country of birth, nationality, ethnic origins, age at which  
the participant left school, the highest level of educational qualifications, current employment status, 
respondents’ usual occupation over the previous six months, their employment status in the last 90 days,  
the ways in which participants financially supported themselves over the preceding 90 days, current 
accommodation, accommodation during the previous 90 days, any housing problems, who they lived  
with, any problems in the area where they resided, marital status, contact/conflict with family/friends, 
whether they had children under 18 years and the number of children in their care.
 Index Treatment
Participants were asked a number of questions in relation to their index treatment including the type  
of index treatment they were receiving, the type of treatment that they wanted, their reasons for coming  
to index treatment, the duration of the index treatment, the length of time they had attended the index 
treatment at the time of the intake interview, the time they expected to be in index treatment, if they had 
been on a waiting list prior to commencing the index treatment and how long they had spent waiting.
 Drug Treatment History
Participants were asked whether they had ever had previous treatment for their drug use and/or alcohol 
consumption, what this treatment was and at what age they had the treatment. In addition, participants 
were asked whether they had ever been on a methadone programme (age of first time on methadone, 
number of episodes, treatment setting and longest period on methadone), had ever had a supervised 
detoxification (age of first time, inpatient/outpatient setting, how many detoxification episodes, was 
programme completed), had ever been in residential drug treatment (age of first time, how many times,  
was treatment completed, how long was the programme) had ever had one-to-one counselling (age of first 
time, how many counsellors had participants seen, the setting, the longest period of regular attendance), 
had ever been to Narcotics Anonymous (age of first time) and had ever been to Alcoholics Anonymous  
(age of first time). Participants were also asked whether they had commenced any form of treatment, 
excluding their index treatment, in the six months prior to interview.
 Drug Use
Participants were asked to provide a detailed drug-using history. To this end, they were asked whether  
they had ever used or consumed a list of 12 substances (heroin, ‘street’ methadone, other opiates, 
benzodiazepines, cocaine, crack, amphetamines, ecstasy, LSD, cannabis, tobacco and alcohol), age of  
first use or consumption, whether they had ever considered their drug use to be a problem, and the age  
at which they first thought use was a problem. In addition, for all 12 substances, participants were asked  
to report on their frequency of use over the preceding 90 days, the amount used on a typical using day  
and the usual route of administration. Respondents were asked to identify what drug they considered  
to be their ‘main’ drug over the previous 90 days, and what drug had caused them the most problems in 
that time period. Participants were also asked about their drug use in the previous three days and about 
their prescribed medication over the previous four weeks (including frequency and dose). This section also 
contained questions regarding lifetime history of non-fatal overdose and frequency of overdose in the 
previous 90 days.
 Injecting-related Risk Behaviour
Participants were asked about their drug injecting history (ever injected, age at which first injected, frequency 
of injecting over the previous 90 days, and frequency of injecting on an average injecting day). Participants 
were also asked to identify all of the drugs (if any) that they had injected over the preceding 90 days.
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This section examined the injecting-related risk behaviour of the participants by asking if participants had 
ever engaged in a range of activities associated with injecting (used a needle/syringe that had been used  
by somebody else, passed on used injecting equipment to others, re-used own injecting equipment, used 
filter, spoon or flush water used by somebody else) and about the frequency of such behaviour over the 
preceding 90 days. Finally, participants were asked about needle-exchange attendance (age at which first 
attended and frequency of attendance over the last six months).
 Physical and Mental Health
Participants were asked to rate their general health. In addition, individuals were presented with a ten-item 
physical health and a ten-item mental health assessment, and asked to report the frequency with which 
they suffered each symptom over the preceding 90 days. While these questions captured important  
data regarding participants’ perception of their physical and mental health, this approach meant that no 
aggregate health score could be assigned to each individual and used as an objective comparative measure.
Additional questions in the health section were concerned with suicidal ideation, suicide attempts and 
sleeping and eating patterns. Participants were also asked an open-ended question about any specific 
health problems they might have had during the preceding 30 days.
 Contact with Family, Social Care and Other Services
Participants were asked about the frequency of contact and conflict with family members and attendance 
at a range of social care services (stayed overnight in hospital, hospital accident and emergency departments, 
GP, social services, employment/training services, housing services and church/religious groups) over two 
time periods, in the 12 months prior to the intake interview and in the preceding 90 days. Participants were 
also asked if they had ever had HIV, hepatitis B and hepatitis C tests, when their last test was taken and the 
results of the tests.
 Criminal Activity
Participants were asked if they had ever committed a list of offences (including drug dealing, acquisitive 
crime, assault, fraud/forgery/deception, soliciting and criminal damage) and how frequently they had 
committed these crimes in the preceding 90 days. Participants were asked if they had ever been arrested  
for any of the aforementioned crimes and the frequency of arrest over the preceding 90 days. Participants 
were asked if they had a prison history, the total length of time they had spent in custody, if they had any 
legal issues at the time of intake interview, if they had had any contact with the criminal justice system in 
the preceding 90 days, and if they had been the victim of a crime in the same time period.
2.3 Designing the Study
The design of the ROSIE study is longitudinal and prospective in nature. It is a cohort study comparing 
within-treatment effectiveness in different treatment modalities and a range of treatment settings. Pre-  
and post-treatment comparisons were made without a control group, since it was considered unethical  
to have a control group who were opiate users but were excluded from treatment.
2.3.1 Experimental Design and Study Extension
In order to measure changes in the treated group, differences between intake responses and between  
each set of interviews were analysed. ROSIE recruited opiate users within 30 days of commencing a new 
treatment episode.
It was originally planned that participants would then be interviewed on two subsequent occasions  
at six months and at one year following recruitment. In Chapter Three it will be seen that following  
the 1-year interviews, the study was extended and participants were interviewed again three years after 
treatment-intake. An overview of the study execution process is given in Figure 2.1.
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government agencies
Protocol Development  
to include instrument work 
plan and other aspects
Project Management  
Plan, including recruiting  
of agencies and staff etc
Data and Statistical  
Analysis Plan
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reliability and validity  
of instrument
n Statistical Programme Design
n Preliminary Analysis
n Data Cleaning Test
Review and discussion of 
protocol (general meeting)
Interim Report to include 
preliminary findings
Full Scale Study
Data collection,  
monitoring and validation
n Statistical Analysis
n Production of Tables  
and Listings
Review and  
discussion of findings
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Figure 2.1 Overview of the Study Execution Process
2.3.2 Statistical Power and Sample Size Calculations and Plans
Following discussions on best practice at the RAG meeting in June 2003, it was decided that ROSIE would focus 
on retaining participants at the follow-up time points, rather than concentrating on maximising numbers 
recruited to the study, once sufficient respondents were available to permit valid statistical analysis. This 
approach may be unique in the drug treatment evaluation arena. Given that NTORS had recruited approximately 
1,100 participants from a population of 50 million individuals (0.0022% of overall population), the RAG decided 
that a recruitment sample of 500 participants was more than sufficient for a population of four million 
(0.0125% of overall population). Resources would then be concentrated on securing a high percentage of 
follow-up. ROSIE allocated a full calendar year to recruitment. If 500 participants were recruited before the 
end of this period then the project would halt further recruitment. However, if at the end of the first calendar 
year of recruitment, recruited numbers were less than 500, focus would be switched to follow-up rather 
than additional recruitment.
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Tables 2.3(a) and 2.3(b) summarise the optimal sample size planned for the study, that is, the initial sample 
size aimed for by ROSIE. The sample sizes are accompanied in each table by the percentage that the sample 
size represents of the overall population. It is important to note that the planned allocation of sample sizes 
to modalities and treatment settings were chosen to broadly reflect the known distributions of the available 
services, while providing adequate numbers and sufficient sample size to allow comparisons. Sample sizes 
in Tables 2.3(a) and 2.3(b) broadly reflect the data published by the Alcohol and Drug Research Unit 
(ADRU)2 of the Health Research Board (HRB), demonstrating that the majority of participants’ treatment 
settings are non-residential and the treatment modality of the majority of participants is drug substitution 
therapy within the former Eastern Regional Health Authority (ERHA) and counselling outside this region. 
However, as discussed earlier (see Section 2.2.1), counselling was omitted as a treatment modality.
 Table 2.3(a) Planned Sample Sizes within Settings at Recruitment
Setting Total
Inpatient Outpatient
Hospital Prison Community GPs Community
Health 
Board
Optimal sample size
50  
(11.1%)
25 
(5.6%)
75  
(16.7%)
50 
(5.6%)
75  
(16.7%)
225 
(50%) 500
 Table 2.3(b) Planned Sample Sizes within Modalities at Recruitment
Modality* Total
Methadone
Structured 
detoxification Abstinence
Needle 
exchange
Optimal sample size 325 (72.2%) 50 (11.1%) 50 (11.1%) 25 (5.6%) 450*
 * The counselling modality was not included in ROSIE. Thus, the optimal sample size total is the sample size total including 
counselling, minus the counselling sample size: 500-50 = 450.
In order to ensure that sample sizes were sufficient to register significant changes within treatment settings, 
statistical calculations were performed to estimate the required sample sizes. Taking any key variable at an 
individual level, say risk of death from accidental overdose, the following assumptions were made:
1. Treatment lowers the risk of death, that is, the average number of episodes per group after treatment  
(x
_
2) is lower than before treatment (x
_
1).
2. A reduction of one or two in the mean numbers of episodes is significant, (x
_
1 - x
_
2 = 1 or x
_
1 - x
_
2 = 2).
3. Pre- and post-treatment groups are independent.
4. Numbers within groups pre- and post-treatment do not change.
5. The standard deviation of the mean number of episodes pre- and post-treatment is less than four. 
While this assumption was the most likely of all the assumptions to be violated, the ROSIE pilot  
study provided extra validation that it was true.
Given these assumptions, estimates of the required sample sizes are provided in Table 2.3(c). For ethical 
reasons, this particular parameter was used to perform the sample size calculations since risk of death to a 
participant through overdose or suicide is the most important outcome variable. Furthermore, a reduction 
of one or two in the mean number of episodes within a group is clinically significant.
2 Formerly the Drug Misuse Research Division (DMRD).
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 Table 2.3(c) Required Sample Sizes within Modality
Size of the reduction in  
mean number of episodes
Standard deviation  
estimate
Required minimum sample  
size within a modality
x
_
1 - x
_
2 = 1 s=1 6
x
_
1 - x
_
2 = 1 s=2 22
x
_
1 - x
_
2 = 1 s=3 49
x
_
1 - x
_
2 = 1 s=4 87
x
_
1 - x
_
2 = 2 s=1 2
x
_
1 - x
_
2 = 2 s=2 6
x
_
1 - x
_
2 = 2 s=3 13
x
_
1 - x
_
2 = 2 s=4 22
2.3.3 Statistical Analysis Plan (SAP)
The SAP provides a full description of the data analysis procedure for the ROSIE study. Although analysis 
procedures can change throughout a study, the general overall procedure and the analytical techniques 
applied to the collected data were as described in the SAP. The contents of the SAP included an overview  
of the analysis process, a statistical analysis schedule, a description of population subsets of analytical 
interest, criteria to decide if subjects would be evaluated, statistical methodology, methods for testing 
statistical assumptions and a description of the appropriate statistical evaluation software.
The SAP summarises the statistical analysis in two parts. Firstly, the establishment of intake figures 
determined the severity and nature of addiction. This allowed collection of appropriate data in follow-up  
for the purposes of comparison within treatment modalities and settings. Secondly, comparison analysis 
evaluates treatment effectiveness within either treatment modality or setting. No analysis has to date been 
made across settings. This comparative analysis was extended at 3-year follow-up to include comparison 
between 1-year follow-up and 3-year follow-up.
For the purpose of identifying sub-populations of interest, participants were defined according to their 
eligibility (see Section 2.2.2 for description of study eligibility criteria). The two main types of sample 
populations considered for analysis were the per-protocol population (participants who completed all 
interviews and are deemed to have no major protocol violations), intent-to-follow population (participants 
who completed any part of the study and provided data for at least one time-point). Other sub-populations 
were defined on an ad hoc basis throughout the study.
The eligibility and compliance of participants was considered when examining criteria to decide whether 
data were suitable for evaluation. These criteria were:
n The inclusion criteria and exclusion criteria based on the interviewer’s impression of the nature of the 
interview and its validity.
n Acceptable timing for visit dates: Intake interview must be conducted within four weeks from the start 
of the new treatment episode. Follow-up visits were scheduled to take place as close as possible to the 
six month or 1-year due visit date. For flexibility, an interval of time of +/- four weeks was accepted 
during which the follow-up interview could take place.
n Concomitant treatments: Section C17 of the questionnaire requests details of concomitant drug 
treatment undergone by the participants during the study.
n Participants entering the study on multiple occasions.
Listings of deviations from the protocol (violation of eligibility criteria and other deviations) were provided 
by the Project Manager in monthly reports and a decision on whether these protocol deviations were 
minor or major were made by the Project Manager following consultation with the Principal Investigators. 
Inferential statistics were then performed on sets of key variables. These are summarised in the coming 
chapters of this report. The inferential statistical analysis was generally performed on the intent-to-follow 
(ITF) population sub-sample. Details of the methods of analysis are given in the next section. Specific 
details on the per-protocol population are also provided in later chapters.
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2.3.4 Statistical Methodologies
A number of statistical methodologies were used for the purpose of data analysis. The ROSIE data required 
statistical techniques that were suitable for the repeated aspect of the study. For example, the proportion 
that used heroin at intake and the proportion that used heroin at 1-year cannot be considered independent 
as there was an overlap in the subjects at these time points: the overlap being that all those investigated at 
1-year are a sub-sample of those at intake. Thus, statistical techniques which considered this aspect of the 
data were the most suitable. Statistical significance refers to a p-value of less than 0.05. Each of the tests 
used in the remainder of the report are now detailed.
Consider the tabular form of the data displayed in Table 2.3(d). Only differences in the number using at 
time point one and not using at time point two, and the number not using at time point one and using at 
time point two, will give an indication of a time effect in the data. In other words, a significant difference  
in n12 and n21 will indicate that there is something other than random variation contributing to a change in 
the using habits of those in this sub-sample. In this situation, McNemar’s test is the appropriate analytical 
tool. Necessarily, only those participants appearing at both time point one and two were considered for 
the ROSIE analysis. This had implications in that, in some circumstances, the proportion of participants  
who displayed a particular characteristic at time point one, whilst differing largely from the proportion  
of participants who displayed the same characteristic at time point two, were not significantly different. 
This was often a consequence of the fact that the proportions do not correspond to the participants who 
completed interviews at both time points and it is that set of participants’ responses on which analysis was 
carried out.
 Table 2.3(d) McNemar’s Test
Using heroin at time point one
No Yes
Using heroin at time point two No n11 n12
Yes n21 n22
When comparing data of the same nature but across three time points in the per-protocol group  
(Chapter Nine), Cochran’s Q test statistic was applied. This is simply an extension of McNemar’s testing 
procedure. In the event of a significant or close to significant Cochran’s Q test, further analysis of all  
pair-wise comparisons between time points was performed.
When comparing sample means at two time points, a paired sample t-test was performed. This procedure, 
again, considered only those participants with recorded measurements at the two corresponding time points 
under analysis. For some of the comparisons considered, there were insufficient numbers of participants 
with recorded measurements at each of the considered time points for an analysis to be undertaken.
In circumstances where the data were ordinal and comparisons were to be performed between time points, 
the Friedman’s Test was used.
This procedure considers the score given by a participant to a particular question at each time point  
under consideration. These scores are then ranked across time points. This is performed for each  
participant contributing a score to each time point and the ranks summed over each time points for all  
of the participants. If the time points have summed ranks that do not differ largely, then there will not be  
a significant time effect. On the other hand, if the summed ranks differ largely across time points this will 
result in a significant test statistic.
It should be noted that the results when comparing 1-year and 3-year follow-up for the per-protocol  
group are identical to the same comparisons between 1-year and 3-year follow-up for the full population. 
The per-protocol group encompasses those participants for whom data were collected at intake, 1-year and 
3-year follow-up and thus coincides with the members of the full population who completed interviews at 
each time point and on whom comparative analysis was conducted.
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It should also be noted that the data presented refer to the full cohort who completed each interview  
and that statistical comparisons were made on matched data or dependent pairs. In terms of presenting 
statistical comparisons, time points with a common letter subscript are statistically significant while those 
with no common letter subscript are not statistically significant. As an example, consider Table 2.3(e), 
which is an excerpt from an analysis presented later in the report. For wage/salary, there is a statistically 
significant difference between intake and 3-years as they both have subscript ‘b’. Similarly, there is a 
statistically significant difference between 1-year and 3-years for the wage/salary category as both time 
points contain the common subscript ‘c’. However, there is not a significant difference between intake and 
1-year for wage/salary as they do not have a common letter subscript (if there was, it would have subscript 
‘a’). For social welfare, intake does not significantly differ from either 1-year or 3-years as they do not have 
common subscripts, however, 1-year and 3-years do significantly differ from each other as they both have 
the common letter subscript ‘c’.
 Table 2.3(e) Analysis Example
Intake 1-year 3-years
n % n % n %
Main sources of income in the last 90 days
Wage/salary 83 20.9b 59 19.3c 95 26.7bc
Social welfare 309 77.4 236 77.4c 260 72.8c
 Note: matching subscript letters denote statistical significance.
2.4 Data and Project Management
In this section, the data management required for the study is considered. The compliance of the study 
with the Data Protection Act is discussed in detail. Next, the set-up of the participant information database 
and the associated security issues surrounding this are described. The Data Management Plan is introduced 
and the section concludes with a discussion on data quality control and the auditing process used when 
performing quality control checks on the data.
2.4.1 Data Protection Act
The Data Protection Act was established in 1988 to ensure individuals’ privacy. Part of the Act states  
that organisations that maintain information on an individual must comply with data protection principles  
(for further information see http://www.dataprotection.ie). This Act clearly applied to ROSIE and as  
such, it was necessary to ensure compliance in terms of data protection.
The Data Protection Act as it pertains to the ROSIE study can be summarised in eight guidelines.  
These state that the data controller must:
1. Obtain and process the information fairly.
a. At the time when information about individuals is collected, are they made aware of the uses  
for that information?
b. Are people made aware of any disclosures of their data to third parties?
c. Has people’s consent for any secondary uses of their personal data, which might not be obvious  
to them, been obtained?
d. Can the data collection practices be described as open, transparent and up-front?
2. Keep it only for one or more specified and lawful purposes.
a. Is the purpose (or purposes) for which personal information is kept made clear?
b. Are the individuals on the database also clear about this purpose?
c. If it is a requirement to register with the Data Protection Commissioner, does the register  
entry include a proper, comprehensive statement of the purpose?
d. Has responsibility been assigned for maintaining a list of all datasets and the purpose associated 
with each?
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3. Process it only in ways compatible with the purposes for which it was given initially.
a. Are there defined rules about the use and disclosure of information?
b. Are all staff aware of these rules?
c. Are the individuals aware of the uses and disclosures of their personal data? Would they be 
surprised if they learned about them? Consider whether the consent of the individuals should  
be obtained for these uses and disclosures.
d. If it is a requirement to register with the Data Protection Commissioner, does the register entry 
include a full list of persons to whom personal data may need to be disclosed?
4. Keep it safe and secure.
a. Is there a list of security provisions in place for each dataset?
b. Is someone responsible for the development and review of these provisions?
c. Are these provisions appropriate to the sensitivity of the personal data kept?
d. Are computers and databases password-protected, and encrypted if appropriate?
e. Are computers and our servers securely locked away from unauthorised people?
5. Keep it accurate and up-to-date.
a. Is all the information needed to serve the purpose collected effectively, and are individuals  
dealt with in a fair and comprehensive manner?
b. Has a check been made to ensure that all the information collected is relevant, and not excessive, 
for the specified purpose?
c. If an individual asked for the justification of every piece of information held about him or her  
on computer, can this be done?
d. Does a policy exist in this regard?
6. Ensure that it is adequate, relevant and not excessive.
a. Is the computerised data checked for accuracy?
b. Is it known how much of the personal data are time-sensitive, i.e. likely to become inaccurate  
over time unless updated?
c. Are steps taken to ensure that the databases are kept up-to-date?
7. Retain it no longer than is necessary for the specified purpose or purposes.
a. Is there a clear statement on how long items of information are to be retained?
b. Is there clear awareness about any legal requirements to retain data for a certain period?
c. Are the databases of data that are no longer needed, such as data relating to former customers  
or staff members, regularly purged?
d. Is there a policy in place on deleting personal data as soon as the purpose for which the data  
were obtained has been completed?
8. Give a copy of his/her personal data to any individual, on request.
a. Is a named individual responsible for handling access requests?
b. Are there clear procedures in place for dealing with such requests?
c. Do these procedures guarantee compliance with the Act’s requirements?
To ensure the ROSIE study complied with each of these rules, a Data Management Plan (DMP) (see Section 
2.4.3), approved protocol, information sheet and informed consent form were prepared. The DMP included 
a full description of all procedures for the management of the information collected during the project. 
The SAP included a full description of all procedures for the analysis of the data collected during this 
project. The protocol and study proposal sought and gained approval from the Ethics Committee of  
the National University of Ireland, Maynooth.
Study  
Protocol
SAP
SAP
Programming
Data Management 
Activities*
Validating  
& Testing
Database  
Release
Draft  
Tables & 
Statistical 
Analysis
Review 
Meetings
Final  
Tables  
& Stats 
Report
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The information sheet and consent form were approved by the Freedom of Information Office at the 
National University of Ireland, Maynooth. The consent of the individual participating in the study was 
obtained at the start of the study by the on-site ROSIE researcher, who had been trained in this process.  
A copy of the actual consent form, details on the assurance of confidentiality and an information sheet 
formed part of the ROSIE interview package given to each participant. Further, the consent of the 
participating treatment centres was obtained by the ROSIE team following a series of consultation  
and information exchange meetings.
To ensure that staff were aware of the rules pertaining to the study, a staff training scheme was established. 
To ensure the data were kept safe and secure, appropriate provisions were put in place. These provisions 
were based on the European Medicines Agency (EMEA) Guidelines for Good Clinical Practice. All computers 
and databases were password-protected and the computer network was isolated and not connected to the 
main National University of Ireland, Maynooth computer network. The computers and servers were secured 
in the project office which was only accessible by authorised personnel and was monitored by 24 hour security.
Finally, as the National University of Ireland, Maynooth was already registered with the Data Protection 
Commissioner, approval of ROSIE procedures was obtained through the Freedom of Information Office.
2.4.2 Database Set-up and Data Security
Each participant was assigned a unique ID number corresponding to their name, address and contact details. 
The contact information corresponding to a participant ID number was kept on a Microsoft Excel database 
for tracking and follow-up. This file was only accessible on the Project Administrator’s password-protected 
personal computer. At the end of the study this file will be destroyed.
The remaining information gathered from the questionnaires was stored in SPSS databases. These three 
databases (intake, 1-year follow-up and 3-year follow-up) were kept separately on a secure server accessible 
only by password-protected personal computers. The unique participant ID number was used in all databases 
and was used for the purpose of merging datasets when necessary. No other variables corresponding to  
an individual, that is, which could be used to identify a participant, were used in SPSS. Personal information 
was removed from the original questionnaires and stored separately in a locked safe by the Project 
Administrator. This process was undertaken prior to questionnaires being transferred to the Data 
Administrator for the purposes of data entry.
2.4.3 Data Management Plan (DMP)
The DMP was established to provide a detailed description of all procedures for the management of the 
information collected during ROSIE. These procedures included data collection, database management, 
data protection and data cleaning. The data management flowchart is displayed in Figure 2.2.
Figure 2.2 Data Management Flowchart for ROSIE Study
* Data entry, data quality control, data security and dataset mapping.
1-year follow-up. Feb 200 - Dec 200
Baseline recruitment. Mar 200 - Dec 200
-month follow-up. Sep 200 - Jun 200
VISIT 0  Mar 200:
Baseline intake
VISIT 1  Sep 200 
+1 month max deviation:
Start -month follow-up
Dec 200:
End baseline  
recruitment
VISIT 1  Feb 200 
+2 months max deviation:
Start 1-year follow-up
Jun 200:
End -month 
follow-up
Dec 200:
End 1-year 
follow-up
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The operation procedures for database management not only cover data entry but data quality control, 
data mapping, derived datasets and database lock. An annotated ROSIE interview instrument, known as  
the coding book, was produced to show SPSS dataset names, variable names, variable length and associated 
information including measure and values. The databases were then set up to conform to the coding book 
specifications. Data were entered onto the database on a regular basis, where possible, within five working 
days of receipt of the completed interview. When the database was declared complete, database lock was 
applied. This meant that the data were available for analysis but could not be accidentally modified.
2.4.4 Quality Control and Data Auditing
It was the Data Administrator’s responsibility to ensure information was entered in a timely and accurate 
fashion. If a particular situation arose where there was confusion over an answer (data point) in the 
questionnaire, the interviewer was asked for clarification. To check the accuracy of the compiled data,  
an auditing procedure was established. These data audits were performed on the intake data (at least two 
audits), the 1-year data (one audit) and the 3-year data (five audits). Each audit involved a complete check  
of every question on 12 questionnaires selected using a stratified random sampling technique. Stratification 
was by interviewer, to ensure that checks were conducted on questionnaires from each. At the 3-year 
follow-up time point, each questionnaire comprised of 665 questions. Every question, in each of 12 randomly 
selected questionnaires, was audited. This comprised a total of 7,980 data points. In addition, for every 
questionnaire in the 3-year database, 87 of the most important and 36 of the less important questions were 
audited. As the 3-year database was audited five times, this means that the total number of data points audited 
was 76,431. The percentage of errors found during the auditing process was very low: 0.14% or 107 errors/
incorrect data entries of all of the audited data points. Given this very low error rate, the ROSIE team  
are confident in the accuracy and quality of the data that were used to perform the statistical analyses.
2.4.5 Project Management and Planning
The original time frame of the study is summarised graphically on the following timeline.
Figure 2.3 Overview of the Original Project Timeline
Interview Schedule Timeline
Illustration of the visit schedule for an individual client enrolling in March 2003 and timelines for the full cohort.
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Milestones and outcomes were also planned, as follows:
 September 2002 - December 2002
1. Milestones: To prepare and submit detailed project proposal for ethical review.
 Outcome: Project proposal receives ethical approval from the NUIM Ethics Committee.
2. Milestones: To organise a preliminary meeting with relevant bodies, including the Centre for Drug 
Misuse Research (Glasgow, Scotland), National Institute for Regional and Spatial Analysis (NIRSA), NUIM, 
Merchant’s Quay Project, Baggot Street Clinic and the relevant local task forces and community agencies.
 Outcomes: Compilation of an overview of current client base and treatment modalities within Ireland, 
confirmation of collaborative parties, dissemination of information to treatment providers with regard 
to the project.
3. Milestones: To draw up a protocol detailing the Data and Project Management Plan to be applied at all 
the sites, including precise information on objectives to be reached, research questions to be answered, 
methods to be applied, staff to be dedicated and other related information.
 Outcomes: A Maudsley-based instrument for the analysis of a set of primary outcomes, a detailed work 
plan for the collection of data at relevant sites, a time schedule for interim reports and general 
meetings.
 January 2003 - December 2003
4. Milestones: To train research associates and supervise the application of the common protocol by  
two relevant bodies (Pilot Study of 60 participants) in order to ensure data compatibility, comparability, 
reliability and attrition rates. To adapt the data protocol according to experience and information 
gained from the pilot in the first six months.
 Outcomes: Report and analysis of pilot study, refinement and production of the final project instrument 
and the setting up of a central database for collating and analysing information prior to the extension 
of the protocol to all relevant sites.
5. Milestones: To extend the protocol to all relevant additional sites, by supervising recruitment of 
approximately 500 participants and the application of the common protocol in order to again ensure 
data compatibility, comparability and reliability. It was envisaged that the 500 participants would be 
recruited between March and December 2003, following a period of quality assurance, liaison and 
training within all treatment centres involved.
 Outcomes: The recruitment of 500 participants and the submission to the National Advisory Committee 
of the 1-year interim report containing synthesis and analysis of the pilot data, information on the 
implementation of the data protocol and on the gathering of primary data from the recruitment stage.
 January 2004 - December 2004
6. Milestones: To supervise the gathering of the additional information on six months and 1-year follow-ups 
at all sites. To analyse on a common basis the material from the sites, comparing pre-treatment outcomes 
with 1-year follow-up outcomes.
 Outcomes: To submit to the National Advisory Committee the two year (after the starting date) 
progress report, containing:
• Recruitment and early follow-ups.
• Synthesis and analysis of the data collected at all sites.
• Preliminary identification of key qualitative and quantitative indicators.
• Preliminary recommendation on how these might be further utilised and developed.
To complete the 1-year follow-up collection of data at all sites and supervise data cleaning and  
quality control.
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 January 2005 - June 2005
7. Milestones: To analyse the complete set of data and derive the final findings, following the Statistical 
Analysis Plan described earlier.
 Outcomes: A complete final report will be submitted to the National Advisory Committee containing:
• Measurement of the nature of opiate use and related problems in Ireland.
• Outcome measures on the effectiveness of treatment/prevention strategies, including: indicators  
of successful cessation/reduction of drug use, changes in physical and mental health symptoms, 
changes in criminal behaviour and changes in personal/social functioning.
By establishing both a timeline and a plan of milestones and outcomes the progress of the evaluation  
could be easily tracked and measured. Delays could be quickly identified and procedures relating to the 
delay either adjusted, or in some instances goals redefined. An example of how changes in follow-up 
procedures improved the overall follow-up rates is provided in the next section.
2.5 Databases and Field Methodology
This section considers the databases that were established to yield high follow-up rates in the study. 
Approaches to fieldwork are also described. As the study evolved, the follow-up strategies and databases 
developed to assist with the follow-up process were refined.
2.5.1 ROSIE Databases
 The Contact Database
Information on the individuals who participated in the study was held on two databases: the Contact  
Log and the Follow-up database (both in MS Excel), which were maintained by the Project Administrator. 
No other personnel had access to these databases and the Project Administrator was responsible for the 
input, security and filing of all participants’ details. At intake, participants were requested to provide locator 
information to ensure regular contact was maintained throughout the research period.
This information was entered onto the Contact Log and each participant was assigned a unique ID number. 
This ID number was logged on the first page of each questionnaire and the respondent’s personal details 
were entered on the following page. This page was removed after interview and filed in a secure lock-in 
safe. Thereafter the questionnaire was analysed by participant ID number only to safeguard the participant’s 
privacy. Aside from locator information, the Contact Log contained other relevant information such as 
participant date of birth, treatment setting, the original interview date and the final interview due date.
 The Follow-up Database
The Follow-up database was used to track participants’ whereabouts through the entire project from intake 
interview to final interview. Each participant’s treatment setting was also noted, including date of intake interview 
and due date for the following interview stage. Used on a daily basis, all attempts at making contact with 
respondents through either post or telephone were logged and the data, including who had been spoken 
to, time and date, were entered into the spreadsheet. This file was used as the central database to track  
all individuals over the 3-year period. The file was colour-coded to monitor the status of each participant 
at that particular time, where status referred to interview completion, tracking information and interview 
arrangement and completion. For example, yellow indicated ‘interview completed’, orange indicated ‘interview 
arranged’, green indicated ‘participants to be pursued’ and so on. This colour-coding strategy was extremely 
useful given the large number of participants in the study.
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 Database Usage
When the project commenced in 2003, the follow-up database was split between researchers. Each 
researcher tracked participants on their own list and provided feedback progress to the central database 
held by the Project Administrator. From 2006, the Project Administrator maintained full control of the 
database for the final 3-year follow-up to monitor all participants centrally. This was conducted in order  
to prevent duplication of information and to ensure that participants were followed-up. Importantly, it  
was felt that one person making contact with various centres/services would encourage familiarity with  
the study and foster further co-operation. However, towards the end of the final 3-year follow-up, another 
researcher assumed responsibility for any participants whose interviews had not taken place and who were 
thought to be homeless, and attempted to contact them through the various homeless services in Dublin. 
Any information subsequently obtained was noted on the central follow-up database.
The Follow-up database was divided according to the date when participants were due to be interviewed. 
At the onset of each new follow-up interview, participants were contacted in monthly batches by post at 
least one month prior to their due interview date. If a reply was not received within one week, attempts were 
made to contact the participant by telephone. Tracking was undertaken through a number of different avenues 
when the respondent could not be contacted directly. These methods are outlined in the next section.
2.5.2 Sources for Participant Follow-up
Prior to any follow-up information being sought, participants’ permission to be contacted directly and 
through nominated third parties was obtained at the intake interview.
 Central Treatment List at the Drug Treatment Centre Board
The Central Treatment List provides treatment details for individuals currently receiving methadone 
treatment in Ireland, including through the prison services. Each month a list was compiled of individuals 
(who could not be contacted through the traditional methods of telephone or correspondence) and this 
was submitted to the Drug Treatment Centre Board (DTCB) along with respective dates of birth. Any individuals 
who remained outstanding from the previous month were also submitted in the event that they had recently 
commenced methadone treatment. The DTCB would then check the list against those in treatment and 
provide details of treatment providers, including GPs, where study participants were currently attending  
for methadone. Contact could then be made with the participant through the treatment provider only  
if previous attempts by post and telephone had proved unsuccessful and only when prior permission  
had been received from the treatment provider.
Once permission had been obtained, a researcher went to meet the participant at the treatment site when 
his/her next appointment was due, in anticipation of undertaking the interview either on site or elsewhere. 
The participant was under no obligation to participate in the interview.
 Prison List
An additional list of outstanding participants was submitted to the Co-ordinator for Drug Treatment 
Services for Prisons who could identify any participants being held in custody around the country. At the 
end of each month a list of untracked participants was submitted which also included outstanding participants 
from previous months in the event that they had recently entered custody. In addition, current court lists 
were checked (http://www.courts.ie) and should a participant’s name appear for mention/sentence, they 
were also included on the above list. It should be noted that without a date of birth to cross-check against 
it was not known whether this was a ROSIE participant or simply a ROSIE participant’s namesake. However, 
the Co-ordinator for Drug Treatment Services would confirm any participants (along with date of birth) 
currently in custody and where they were being held. Information such as the release date of participants 
and last address given by the participant was also provided. Should this address differ from our original  
and last address, it offered another means of contacting the participant and correspondence was then 
forwarded.
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 Treatment Providers
Treatment providers were invaluable in assisting with tracking participants. At regular intervals throughout 
the research period, treatment services were contacted to identify any ROSIE participants who were 
currently accessing their services, whether the participant had accessed services in the past or received 
onward referrals. In some instances, if the individual was initially recruited at that particular treatment 
service, the service providers still had some contact with the participant either through after-care services  
or drop-in services, thus re-establishing contact for follow-up.
 Homeless Organisations
With permission obtained from ROSIE participants at the intake interview, assistance could be sought  
from homeless organisations such as the Homeless Network, Focus Ireland, the Homeless Persons Unit  
and various hostels. These organisations were able to confirm if an individual was homeless and contact 
could subsequently be made with hostels in the area or areas where participants had previously stayed.
 Community Organisations
Agencies such as the Community Drug Teams (CDTs) and Community Centres provided information on 
participants’ whereabouts. They also advised if participants were in contact with any community services.
 Health Board Services
According to the last known address of a participant, a social/outreach worker responsible for the area 
concerned was contacted to determine if the participant was known to them.
 Welfare Services
With the co-operation of the Probation and Welfare Services, ROSIE was able to make contact with 
participants released from prison and assigned to a Probation Officer, or undertaking any training courses  
or workshops. The Department of Social and Family Affairs assisted the study in forwarding ROSIE letters  
to participants who were in receipt of social welfare since the study commenced.
2.5.3 Difficulties Encountered
A lack of knowledge and awareness of the ROSIE study was an obstacle to acquiring information and 
accessing services for interview purposes. Unfamiliarity with the study along with turnover of staff in 
services meant that service providers could be reluctant to divulge personal participant information and/ 
or to facilitate arrangements to meet participants on site. In such circumstances, information and reports 
on ROSIE were forwarded to the provider and a follow-up telephone call was made a few days later.
As the research process spanned over five years, change of address and mobile telephone numbers were  
a frequent occurrence among participants. Maintaining regular contact proved to be quite challenging 
especially with a small sub-group of participants who were homeless at the recruitment stage. If someone 
was not contactable through telephone numbers or addresses, the process of tracking often proved to  
be protracted and complicated. It was not uncommon to make dozens of telephone calls over a period  
of three to six months to try to contact hard-to-reach participants through family, friends, treatment 
providers and other services.
Some participants were considered to be ‘chaotic’ users, that is, they were particularly difficult to contact  
as they were homeless, did not access services on a regular basis or did not remember the study and 
consequently did not respond to any contact. Further, other participants who had successfully undergone 
treatment, had been drug-free for some time or who were in regular employment, also proved difficult  
to contact and did not respond to contact efforts. Of these participants, many expressed the need to  
move on from that period of their lives or believed that their continued input to the study was no  
longer relevant. Furthermore, other participants were reluctant to interview if they were still using or  
felt embarrassed at their continuing use and/or lack of progress in terms of treatment. In these instances,  
the value of their contribution to the study was emphasised. A gift voucher of €20 was offered to all 
participants at the 1- and 3-year follow-up stages in recognition of their contribution to the project.  
The final follow-up rate of 90% was particularly high when compared with similar international studies.
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2.5.4 Conducting Interviews
Once contact had been established with the participant and they had agreed to be interviewed, the 
interview was arranged in a place and time of the participant’s choosing, usually in the participant’s home  
or in a café. On those occasions where contact was not directly made with the participant but they were 
known to be in treatment, contact and interview were conducted on site only with the permission of the 
treatment provider.
Questionnaires were administered through face-to-face interviews with respondents. At intake, the 
interviews took approximately one and a half hours to complete, due mainly to the lengthy background 
and demographic information required from the participant. Subsequent ROSIE interviews were considerably 
shorter and took approximately 30 minutes to complete. However, the time required to conduct the interviews 
could vary enormously if the participant was using drugs at the time (information could be difficult to obtain 
and the interviewer was required to repeat or clarify the questions) or if the participant was simply talkative 
and willing to discuss their treatment or current situation in more detail. In these situations, interviews 
could again take between one and one and a half hours to complete.
2.5.5 Ethical Concerns and Interviewer Safety
Full and informed consent was obtained from all those participating in the ROSIE study.
At the recruitment stage, all participants were informed about the study and given an information sheet 
and a consent form to sign. If at any stage of the follow-up a participant decided to withdraw from the 
study, their decision was respected and a note made on the follow-up database.
The participants in ROSIE had the right to remain anonymous and this was respected in that no identifying 
information about participants was revealed. Appropriate precautions were taken to protect the confidentiality 
of both participants and data. All data were stored in a locked room and obligations to participants under 
the Data Protection Act were followed.
Several measures were taken to ensure the safety of all interviewers at all times during the study. Firstly,  
a diary was kept with interview locations, interview times and the mobile telephone number or contact 
details of the participants involved. Secondly, interviewers were required to check-in by telephone after 
each interview both to inform the office that the interview had been successfully completed and to ensure 
the safety of the interviewer.
Participants were asked many personal questions about their drug use, homelessness and assault, including 
sexual assault, as well as sexual relationships. Personal issues surrounding these topics could be a source of 
emotion and distress and it was necessary that interviewers handle such situations with due sensitivity and 
care. This was ensured in a number of ways: more experienced fieldworkers met with participants known  
to have had emotional responses previously, or who were deemed chaotic. All researchers carried a list  
of suggested referral services for participants who felt in need of advice or assistance. Throughout all 
interviews, participants were reassured that should they feel uncomfortable about particular sections  
of the questionnaire they were under no obligation to respond.
It was important to ensure interviewers were completely comfortable with the format of the questionnaire, 
with all questions posed in the same manner to maintain consistency. New interviewers were required to 
spend a week familiarising themselves with the questionnaire and conducting role-play interviews with 
experienced fieldworkers. Meetings were held with new interviewers after their initial interviews to assess 
how the interview went and to address any questions or difficulties. A brief assessment of their completed 
questionnaires was also conducted.
Some interviews could be very long and demanding, for example, if a participant was showing signs of being 
under the influence of drugs or alcohol or if a particularly sensitive issue, such as sexual abuse, was raised. 
On such occasions, the interviewer could approach the senior fieldworker regarding any concerns or 
difficulties they encountered. Steps were also taken to ensure that interviewers were not over-stretched. 
Accordingly a usual limit of three interviews was set for any particular day. Fieldworkers also had daily 
contact with the Project Manager and were encouraged to debrief on a regular basis.
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2.5.6 Limitations of the Study
No control group was used in ROSIE and participants were not randomly allocated to particular treatment 
conditions. In addition it should be borne in mind that drug users may avail of numerous forms of treatment 
over a 3-year time period. Therefore a participant recruited from a detoxification facility at intake may be 
receiving methadone from a GP at 3-year follow-up. The design of the study does not allow for changes  
in areas such as crime, drug use and health symptoms to be attributed to the influence of a particular 
treatment factor.
The data in the ROSIE interviews are gained through self-reporting from the participants. There is some 
debate about the reliability of self-report. However, Darke (1998) found through extensive reviews of the 
international literature, that self-report relating to information about drug use, criminality and HIV risk 
behaviours was valid and reliable when compared to information obtained through urine testing and 
independent collaboration. In addition, Bell (1998) argues that self-report provides us with more in-depth 
information about frequency, amount and pattern of drug use and other variables than would be gleaned 
from the testing of biochemical markers or urine testing.
Another issue to consider is information bias and in particular recall bias. Recall can be affected by factors 
such as time delay, wording of questions and possibly qualities of the researcher (Ashworth, 2005), while 
Del Boca and Noll (2002) state that respondent recall can also be influenced by opiate withdrawal, fatigue 
and mood. However, they also suggest that recall bias can be limited by relating questions to specific time 
periods. Accordingly, participants in the ROSIE study were asked questions in relation to specific periods  
of time such as 90 days and six months.
2.6 Closing Remarks
In this chapter, the design, research and management of the ROSIE study have been considered in detail. 
Throughout any study, there is a learning curve, and ROSIE was no different in that respect. At an early stage in 
the process, the importance of the study design, research instrument, analytical techniques and implementation 
became abundantly clear. Through appropriate management and training, the study evolved and surpassed 
all expectations in terms of follow-up and data richness and quality. This is illustrated in both the quality 
control results and increases in follow-up rates from 1-year to 3-years which are presented in Chapter Three. 
Future researchers should be cognisant of the fact that failure to perform in-depth research into the design, 
execution and management of the study may result in situations where the data are, in effect, useless.
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CHAPTER THREE: RECRUITMENT, 
FOLLOW-UP AND MORTALITY
3.1 Introduction
This chapter provides information on the numbers recruited at intake within each of the modalities and 
settings. Some data on the level of coverage achieved and the geographical distribution of the services that 
collaborated with the research at the recruitment stage are also provided. The follow-up rates achieved at 
each time point of the original study protocol are also discussed. This chapter highlights how evaluation is 
a dynamic process that must evolve with the circumstances encountered during the longitudinal research 
process. This is illustrated by describing changes made to the original study design and discussing how these 
changes enhanced the research and the subsequent follow-up rates. Detailed results on follow-up rates at 
each time point are included, with information on those followed-up but not interviewed and data on the 
numbers and causes of death observed within the study. Finally, the reliability of results from a body of 
research should always be questioned in terms of the accuracy and quality of the data collected. Chapter 
Two details the quality assurance procedures and quality control measures that were developed for this 
study. The current chapter presents the results of these rigorous quality control checks. The data quality 
was of a very high standard and the results on treatment outcomes in Chapters Four through to Nine are 
based on clean and accurate data.
3.2 Recruitment Rates
Chapter Two established that ROSIE had initially intended to recruit 500 participants to the study within a 
nine month period. As discussed, this optimal sample size was revised to 450 due to exclusion of the counselling 
modality. Recruitment was conducted from late September 2003 to early July 2004. Originally it was planned 
that recruitment would commence in March 2003 following a brief pilot study period. However, during 
the pilot study it became apparent that many new treatment places had been fi lled in the recent past. 
Accordingly fewer eligible individuals were available for recruitment than had been anticipated and the 
Research Advisory Group (RAG) discussed the possibility of widening the inclusion criteria to include 
clients not new to treatment. This proposal, while increasing the sample size, would have substantially 
changed the study design and was rejected. As a result a total of 404 people, who met the original 
inclusion criteria, were recruited to ROSIE. The breakdown of participants recruited across treatment 
modality and setting is given in Table 3.2(a).
 Table 3.2(a) Intake Study Recruitment by Modality and Treatment Setting
Setting Modality Total
Methadone 
programmes
Structured 
detoxifi cation
Abstinence 
programmes
Needle 
exchange
Inpatient Hospital 33 33
Prison 5 14 19
Community 12 70 82
Outpatient GPs 54 54
Community 48 12 17 77
Health Board* 108 22 9 139
Total 215 81 82 26 404
* A new agency, the Health Service Executive (HSE) assumed responsibility 
for the health service in the Republic of Ireland on January 1, 2005.
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Comparisons of these results with the planned sample sizes described in Chapter Two are provided in 
Table 3.2(b) and Table 3.2(c) below. The tables summarise the optimal sample size and that achieved in 
ROSIE. The sample sizes are accompanied in each of the tables by the percentage that the sample size 
represents of the full population. While there are some clear differences in both the sample size and the 
percentages in many of the numbers in the tables, these differences are not large enough to affect the 
overall conclusions and effectiveness of model-fitting and other statistical and analytical procedures.
 Table 3.2(b) Planned and Achieved Sample Sizes by Setting at Recruitment
Setting Total
Inpatient Outpatient
Hospital Prison Community GPs Community
Health 
Board
Optimal 
sample size 50 (11.1%) 25 (5.6%) 75 (16.7%) 50 (5.6%) 75 (16.7%) 225 (50%) 500
Overall 
achieved 33 (8.2%) 19 (4.7%) 82 (18.2%) 54 (13.4%) 77 (19.1%) 139 (34.4%) 404
 Table 3.2(c) Planned and Achieved Sample Sizes by Modality at Recruitment
Modality* Total
Methadone 
programmes
Structured 
detoxification
Abstinence 
programmes
Needle  
exchange
Optimal 
sample size 325 (72.2%) 50 (11.1%) 50 (11.1%) 25 (5.6%) 450*
Overall 
achieved 215 (53.2%) 81 (20.0%) 82 (20.3%) 26 (6.4%) 404
 * The counselling modality was not considered in ROSIE. Thus, the optimal sample size total is the sample size total including 
counselling, minus the counselling sample size: 500-50 = 450.
The sample sizes achieved broadly reflect the data published by the Alcohol and Drug Research Unit 
(ADRU) of the Health Research Board (HRB).
3.3 Site Selection and Geographical Coverage
As described in Chapter Two, ROSIE was designed not as a randomised control trial with specific numbers 
of participants allocated to a treated or control group within certain geographical locations, but as a study 
that reflects the availability and distribution of treatment service provision nationally. Recruitment began  
in early 2003 with enrolment of participants to the pilot study, as discussed in Chapter Two. The majority 
of the 404 participants in ROSIE were recruited between September 2003 and July 2004. All participants 
recruited were entering a new treatment episode (see Section 2.2.2).
Study recruitment was carried out in 19 methadone clinics within the Greater Dublin area. These clinics  
had the capacity to facilitate new treatment-intakes over the recruitment period. Many clinics outside 
Dublin were full to capacity and unable to facilitate new clients over the study period. Nevertheless, study 
recruitment was undertaken in seven clinics outside the capital city. In addition GPs contacted via the 
Central Treatment List and followed-up with telephone calls and letters resulted in 30 GPs participating in 
the study and assisting the study with access to clients for study recruitment. All residential drug treatment 
facilities in the country that worked with an opiate using clientele were included in the selection process. 
Interviews were undertaken in nine such facilities.
Finally, intake study recruitment was carried out in the three main inpatient facilities in the country and  
in one outpatient facility.
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An estimated 54 different services provided by approximately 44 separate agencies and/or organisations 
participated in the ROSIE study intake recruitment. These agencies provide treatment/rehabilitation 
services to opiate users in both inpatient and outpatient settings. Agencies across all former health board 
areas (Eastern Regional Health Authority, the South-Eastern, Mid-Western, Western, Midlands and North-
Eastern Health Boards) were included with the exception of the Southern and North-Western Health Board 
areas, however clients residing in these areas were recruited to the study.
In order to provide information on the coverage of the treated population achieved by ROSIE, the ROSIE 
recruitment figures were compared, where possible, with those of the National Drug Treatment Reporting 
System (NDTRS) for 2003. The NDTRS reports that there were 4,900 cases3 of commenced or re-commenced 
treatment for problem drug use in 2003, giving ROSIE a national coverage rate of approximately 8% of all 
new treatments. In addition, NDTRS reports that there were 1,265 cases of commenced or re-commenced 
methadone-based treatment and 682 cases of detoxification programme commencement. ROSIE recruited 
215 participants within the methadone modality and 82 participants within the detoxification programme 
representing national coverage of approximately 17% and 12% respectively. The NDTRS figures are based on 
a calendar year, which does not match the time frame of ROSIE recruitment, but the data nonetheless 
provide some information on the scale of the ROSIE study in that the coverage rates achieved by ROSIE are 
well in excess of other national treatment outcome studies, where coverage rates are seldom published but 
are estimated to be in single figures and below 5% (private communication, N. McKeganey, DORIS, Scotland).
3.4 Follow-up Rates
In the previous section it was outlined that it was originally planned to recruit 500 participants, all of whom 
were new to treatment. This target of 500 individuals was not possible, primarily due to the non-availability 
of new treatment places. Furthermore, although it was originally planned to recruit participants from March 
2003, this was delayed until September 2003, since it was agreed that meticulous study design and implementation 
in the early stages would be of benefit to the ultimate success of the project and additional time was taken 
to ensure that this was done to the highest standard. Delay was also encountered as recruitment of services 
and participants was slow in the early stages of the project. The combined effect of these changes was that 
while recruitment was achieved within the intended nine month period, the time period had shifted and 
scheduled six month follow-up interviews were due to be completed at the same time as the research team 
was still recruiting to the study. Thus the six month follow-up rate was affected, since priority at that time 
was given to recruitment.
Extensive efforts were made to contact and interview all 404 individuals who had participated in study 
recruitment at six months. Table 3.4(a) shows that while a total of 82% (n=332) of participants were located 
at six months, 59% (n=237) of the study population successfully completed the interview. The follow-up rate 
was lowest in the abstinence-based modality at 49% (n=40). Across all other modalities, over half of each group 
completed the six month follow-up interview. In total 8% (n=34) of the study population was not tracked.
 Table 3.4(a) Follow-up Rates at 6-Months
6-Months
n %
Follow-up rates at six months
Successfully completed six month interview 237 58.7
Declined to be interviewed 15 3.7
Located but not interviewed 80 19.8
Not located 38 9.4
Not tracked 34 8.4
3 Number of cases includes individuals who commence more than one treatment episode in the period being measured.
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Follow-up rates improved considerably and were comparable with similar international studies at the 1-year 
follow-up time point. By this stage, respondents and services were familiar with ROSIE and it had an identity.
At 1-year the location rate rose to 92% (n=373). Full interviews were carried out with 75% (n=305) of participants, 
0.5% (n=2) were deceased, 4% (n=16) declined to be interviewed and 12% (n=50) were located but not interviewed. 
Of those participants who were located but not interviewed, five participants had left the country, ten 
participants were on a methadone programme, one participant was in residential treatment and one was  
in a detoxification programme (Cox et al, 2006). Details of these results are in Table 3.4(b) below.
 Table 3.4(b) Follow-up Rates at 1-year
1-year
n %
Follow-up rates at 1-year
Successfully completed 1-year interview 305 75.5
Declined to be interviewed 16 3.9
Located but not interviewed 50 12.4
Not located 31 7.7
Deceased 2 0.5
The low interview rate at six months suggested that data on outcomes at this time point could have biased 
results as they might not have reflected the results of the full cohort. However, higher follow-up rates were 
achieved at 1-year. Therefore the six month analysis was set aside, particularly as the international literature 
showed very little change from six months to 1-year, and 1-year was targeted for a higher follow-up rate. 
This gave the added benefit of an additional time point at which participants could be measured and also 
provided a time point at which to measure the sustainability of changes observed in the 1-year outcome 
measures. This, as shall be seen from the follow-up rates at 3-years, contributed significantly to the study 
and clearly demonstrates the necessity for a flexible study design and protocol that can react rapidly to 
both internal and external forces.
The follow-up rate and location rate obtained by ROSIE at the 3-year follow-up time point exceeded that 
of comparable international studies and was in direct contrast to the usual trend of decreasing follow-up 
rates as time progresses. At the 3-year time point 97% of all the original participants were located, of whom 
4% (n=14) withdrew from the study and 88% (n=357) successfully completed interviews. This was an improvement 
on the 1-year follow-up as some participants who had declined to be interviewed at that stage, decided 
that they would like to take part in the study at the 3-year time point. At 3-years, 1.5% (n=6) of participants 
were deceased and one participant was in a coma. Of the participants who were located but not interviewed, 
four participants were living in another country and eight participants were on a methadone programme, while 
none of those participants were in prison. The details of the results are provided in Table 3.4(c) below.
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 Table 3.4(c) Follow-up Rates at 3-years
3-years
n %
Follow-up rates at 3-years
Successfully completed 3-year interview 357 88.3
Declined to be interviewed 14 3.5
Located but not interviewed, of whom 
Living abroad n=4 
Methadone programme n= 8 
No data available n= 2 14 3.5
Not located 12 3.0
Deceased 6 1.5
Ineligible: Hospitalised/incapacitated 1 0.2
Total 404 100
3.5 Mortality Rates
Drug use increases the risk of premature death. Drug-related deaths can occur from direct causes, for 
example overdose, and indirect causes, for example infections such as hepatitis and HIV, spread from 
sharing injecting equipment, as well as from accidents, violence and suicides while under the influence  
of drugs (EMCDDA, 2004). According to the EMCDDA, drug-related deaths and deaths among drug users  
is one of the five key indicators of drug misuse in Europe. It is difficult to establish the number of deaths 
among drug users in Ireland per annum but it is estimated to be from 60 to 90 per annum (Long et al, 2005b).
From Table 3.5(a), it can be seen that the ROSIE study 3-year mortality rate was 1.5% (95% CI4: 0.5%, 3.2%).  
Six of the 404 participants died between the start of recruitment in September 2003 and the end of 3-year 
follow-up interview period in July 2007. Two of these deaths occurred within the 1-year follow-up period. 
The mortality rate for the population at 1-year was very low at 0.5% (n=2) (95% CI: 0.06%, 1.8%) when compared 
with the NTORS rate of 1.2% or the rate of 1.8% in Smyth et al’s (2005) follow-up study of opiate users seeking 
inpatient treatment in Dublin. Over a four year period, the NTORS reported annual mortality rate of 1.2% 
was six times higher than the mortality in an age-matched population (Gossop et al, 2002). However, the 
ROSIE confidence interval for the mortality rate at 1-year includes the two point estimates. In an attempt  
to ensure accuracy, the names of all participants for whom follow-up interviews were not achieved were 
checked against the General Death Register both at the 1-year and the 3-year follow-up time point.
All of the deceased were male and ranged in age between 26 and 52 years of age. There was no single 
common cause of death amongst these participants. Two participants died from a drug overdose, a further 
two died as a result of a brain haemorrhage, one died in a road traffic crash and one participant was murdered. 
In terms of treatment modality, three of the deceased were recruited from the methadone modality, two 
were recruited from the detoxification modality and one was recruited from the needle exchange modality.
4 Confidence Interval.
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 Table 3.5(a) Details of Causes of Death
Age at death Gender
Cause of death  
(per death certificate) Intake modality
52 Male Overdose Methadone
26 Male Methadone overdose Detoxification
28 Male Brain haemorrhage during 
operation
Detoxification
33 Male Beaten and stabbed 
(murdered)
Methadone
33 Male Brain haemorrhage Needle exchange
30 Male Motorbike accident Methadone
Information concerning the deaths of these individuals was obtained from a number of sources. Family 
members reported four of the deaths. A member of staff at a drug treatment facility reported another of 
the deaths while information concerning the death of one individual was obtained from newspaper reports. 
The Death Registrar in Dublin confirmed all of the deaths with the exception of one individual who died in 
the United Kingdom and who was thus not recorded on the Irish Death Register.
Overdose is the main cause of death among heroin users in the EU (EMCDDA, 2004) and this is reflected  
in the results from ROSIE. It was established that two of the participants died directly from overdose while 
another two participants developed brain haemorrhages. It was not possible to ascertain whether the other 
two deaths were caused indirectly because of their drug use. However drug users, and in particular those 
who are injecting, are ten to 20 times more likely to die from AIDS, other infectious diseases, violence, 
accidents and suicide than the general population (EMCDDA, 2004).
Each of the six deceased participants from the ROSIE study was male. This reflects the trend that male opiate 
users have a higher risk of death than female opiate users (Gossop et al, 2002). This could be explained by more 
risky behaviour among males as they are more likely to have started using drugs younger, to be engaging in 
polydrug use and consumption of alcohol and to be injecting alone (EMCDDA, 2004). Furthermore, two of 
the deceased participants were recruited in the detoxification modality. Drug users are particularly vulnerable 
to overdose after detoxification treatment or a period of time in prison. This is because drug users’ tolerance 
drops while they are abstinent from drugs and they are therefore more likely to overdose if they use after 
this period of time (EMCDDA, 2004).
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CHAPTER FOUR: TREATMENT STATUS
4.1 Introduction
Drug use is a complex problem and it is being increasingly recognised that there is no single treatment 
modality that works for all individuals undergoing treatment. A range of services is provided in Ireland 
to accommodate this understanding (Long et al, 2005). These services fall into two main philosophies: 
medication-free therapy and medically-assisted therapy (Drug Misuse Research Division, 2005). Medication-
free therapy uses models such as the Therapeutic Community or Minnesota Model. In contrast, medically-
assisted treatment includes detoxifi cation and substitution therapies such as methadone. Currently, the 
drug treatments provided in Ireland include counselling and group-work, detoxifi cation, abstinence, methadone 
maintenance and needle exchange. Since the early 1990s, Methadone Maintenance Treatment (MMT) 
has been considered to be an effective method of opioid dependence treatment in Ireland. However, 
rehabilitation is now recognised as a crucial component of all drug treatment (Report of the Working 
Group on Drugs Rehabilitation, 2007).
In this chapter, participants’ treatment status is discussed and the types of treatments that participants 
engaged in at the three time points are described. In addition treatment retention and completion rates 
are presented. Firstly, treatment status and completion rates for participants who were recruited in the 
methadone, detoxifi cation and abstinence modalities is presented. Any treatments that participants may 
have started within the six months prior to the 1-year and 3-year interview are also presented. Finally, 
participants’ drug-free status is assessed with respect to their current treatment status.
4.2 Results
 Treatment Status and Completion Rates
In Table 4.2(a), the current treatment status of participants is shown. At 3-years, there were 66% (n=217) 
of participants in methadone, detoxifi cation or abstinence-based treatment. There were 65% (n=212) of the 
population in methadone treatment, 1% (n=3) in detoxifi cation treatment and 0.3% (n=1) in abstinence-based 
treatment. Of those in methadone treatment at 3-years, 38% (n=70) were still in their intake methadone 
treatment setting. These participants attended this setting continuously and had therefore been in the 
same episode of methadone treatment for approximately three years. It is also shown that 34% (n=111) of 
participants were not attending methadone, detoxifi cation or abstinence-based treatment at the 3-year 
interview.
With regards to participants’ treatment status and recent drug use, it is shown that of the participants 
who were currently in treatment, 11% (n=24) were drug-free of all illicit drugs and alcohol, 18% (n=38) were 
drug-free from all illicit drugs and 34% (n=73) were drug-free from all illicit drugs except cannabis. In relation 
to the participants who were not attending treatment, 32% (n=35) were drug-free from all illicit drugs 
including alcohol, 46% (n=51) were drug-free from all illicit drugs and 57% (n=63) were drug-free 
from all illicit drugs except cannabis.
The ROSIE Study Drug Treatment Outcomes in Ireland
 Table 4.2(a) Treatment Status at 3-years
n %
1Current treatment
Participants currently in treatment 217 66.2
In methadone treatment 212 64.6
Still in intake methadone treatment setting 70 37.8
In detoxification programme 3 0.9
In abstinence-based programme 1 0.3
Participants not currently in treatment 111 33.8
1In treatment and recent drug use
Drug-free (all illicit drugs) 38 17.5
Drug-free (all illicit drugs excluding cannabis) 73 33.6
Drug-free (all illicit drugs and alcohol) 24 11.1
1Not in treatment and recent drug use
Drug-free (all illicit drugs) 51 45.9
Drug-free (all illicit drugs excluding cannabis) 63 56.8
Drug-free (all illicit drugs and alcohol) 35 31.5
 1 Treatment refers to methadone, detoxification and abstinence-based treatment. Other forms of treatment such as counselling  
and group-work were not included due to inconsistencies in the way they were reported.
Table 4.2(b) displays the completion rates for participants in relation to their index intake treatment. 
Completion rates were almost identical for detoxification and abstinence-based modalities. There were 
70% (n=46) of detoxification participants who had completed their treatment and 69% (n=47) who had 
completed their abstinence treatment. There were also 3% (n=5) of participants who had completed their 
methadone treatment in their recruitment site and 38% (n=70) who were still attending their methadone 
treatment in their recruitment site. However, there were 21% (n=36) of participants who did not complete 
their intake methadone treatment. There was no increase in the number of participants who completed 
their methadone treatment from 1-year to 3-year follow-up.
 Table 4.2(b) Completion Rates for Intake Treatment
Outcome
n %
1Detox modality from intake
Completed intake detox treatment 46 69.7
Didn’t complete intake detox treatment 20 30.3
1Abstinence modality from intake
Completed intake abstinence treatment 47 69.1
Didn’t complete intake abstinence treatment 21 30.9
Methadone modality from intake
Completed intake methadone treatment 5 2.9
Did not complete intake methadone treatment 36 20.6
Still attending intake methadone treatment 70 37.8
 1 These figures differ from the figures published in ROSIE Findings 2 as more information was gathered from participants at the  
3-year follow-up with regards to completion of index treatment.
The ROSIE Study Drug Treatment Outcomes in Ireland
Table 4.2(c) below illustrates other types of treatments that participants started attending in the six months 
prior to the intake, 1-year and 3-year interviews. These may be a new treatment episode or participants  
may have been starting this type of treatment for the first time. The number of participants who started 
attending one-to-one counselling increased significantly from 13% (n=44) at intake to 33% (n=99) at 1-year 
(p<0.001) and 30% (n=107) at 3-years (p<0.001). There was also a significant increase in the numbers who 
began attending group work from 9% (n=30) at intake to 27% (n=81) at 1-year (p<0.001) and 23% (n=82) at  
3-years (p<0.001).
 Table 4.2(c) New Treatment Types in the Last Six Months
Intake 1-year 3-years
n % n % n %
1,2Started the following treatments in last six months
Structured/supervised detoxification 45 13.3b 27 8.9 20 5.6b
One-to-one counselling 44 13.2ab 99 32.5a 107 30.0b
Group work 30 9.0ab 81 26.6a 82 23.0b
Residential drug treatment 20 5.9 16 5.2 10 2.8
Prescribed methadone 18 5.6 32 10.5 40 11.2
 Note: Matching subscript letters denote statistical significance.
 1 Does not include intake treatment.
 2 Categories are not mutually exclusive.
4.3 Discussion and Conclusion
The aim of Dole and Nyswander’s model of methadone treatment was to provide people with a high 
enough dose of methadone to allow them to function in regular society and participate in therapeutic and 
rehabilitative services (Ward et al, 1992). However, many methadone treatment programmes have shifted 
away from this ideology of long-term maintenance towards achieving abstinence from all drugs including 
methadone within a few years (Farrell et al, 1994). From the ROSIE results, it is evident that just under 40% 
of the participants recruited in methadone were still in their intake treatment at 3-years. Research suggests 
that retention in methadone treatment is associated with more positive outcomes (Teesson et al, 2007). 
Other research has shown that two to three years is the suggested optimal time frame for methadone 
treatment to be beneficial. Caplehorn et al (1993) state that longer time frames in treatment have more 
benefits than shorter periods. Furthermore, Ward et al (1992) found that participants who left their 
methadone treatment early had an increased likelihood of engaging in regular heroin use.
In this chapter it can be seen that approximately 70% of participants recruited within the detoxification  
and abstinence modalities completed their intake treatment. Ravndal et al (2005) state the completion  
of treatment is an important indicator for improved outcomes. They found that most facilities agree  
that ‘treatment completion is a good indicator of treatment success’. In their study, 40% was the average 
completion rate in all programmes. Thus, for those ROSIE participants who completed their detoxification 
or abstinence-based intake treatment, this is a very positive outcome. In addition, studies conducted in  
the UK show completion rates varying from 25-50% (Gossop et al, 1999; Keen et al, 2001). ROSIE compares 
favourably to this range.
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There were significant increases in the number of participants who started counselling and group work in 
the six months prior to interview at 1-year and 3-years. Those who participate in counselling services while 
undergoing methadone treatment are shown to have more effective treatment outcomes (McLellan et al, 
1999). Participants in residential treatment also showed positive outcomes when partaking in counselling 
services. Meier and Best (2006) found that clients who had individual counselling while undertaking 
treatment were likely to have higher completion rates. Group counselling was also found to be important 
with regards to completion rates. An increase in participation in one-to-one and group counselling among 
the ROSIE cohort is a very positive outcome.
With just over one-third of the participants recruited in methadone still in their methadone index 
treatment, a very positive outcome is indicated since retention in treatment is associated with better 
results. Furthermore, ROSIE completion rates for abstinence and detoxification facilities are particularly 
high in comparison to other studies. There is also a significant improvement in the numbers engaged in 
counselling, which is also recognised as a key determinant for positive treatment outcome.
Overall, the results in this chapter indicate that many of the participants in ROSIE displayed signs of 
positive treatment outcomes. While this is encouraging, the need for further research into those 
participants with less positive outcomes is recognised.
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CHAPTER FIVE: DRUG USE
5.1 Introduction
During the 1970s an opiate use problem began to appear in Ireland and by the late 1980s, the drug problem 
had reached epidemic proportions in Dublin’s inner city areas. In the general population, it is estimated that 
19% of adults have used an illegal drug in their lifetime (Drug Misuse Research Division, 2005), while for 
young adults (aged 15-34 years) this rises to 26%.
The most recent published estimate of the number of opiate users in Ireland is 14,452, based on 2000-2001 
data (Kelly et al, 2004). According to the Health Research Board (HRB), between 1998 and 2002 opiates were 
the most frequently reported main problem drug for all cases treated for problem drug use, while cannabis 
was the second most frequently reported main problem drug (Long et al, 2005a). However, a different 
pattern emerges with the number of new cases treated who reported problem drug use. Between 1998 
and 2002 opiate use decreased by 21% whereas cannabis use saw an increase of 144% for the same period. 
Although the numbers of new cases treated who reported cocaine increased consistently at this time the 
numbers remained small.
In terms of use of multiple drugs, known as polydrug use, the WHO defi nes it as ‘the use of more than one 
drug or type of drug by an individual, often at the same time or sequentially, and usually with the intention 
of enhancing, potentiating or counteracting the effects of another drug’. There is evidence to suggest that 
polydrug use is on the increase among individuals seeking treatment and the HRB estimates that the 
percentage of cases treated who reported problems with more than one drug increased from 71% in 1998 
to 76% in 2002. For the same time period, 28% reported problem use of one drug, 32% reported problem 
use of two drugs, 26% reported problems with three drugs and 15% reported problems with four or more 
drugs (Long et al, 2005a). However, the pattern of additional drug use differs among all new cases, with 
alcohol accounting for 41% of all new cases, followed by ecstasy at 37% and cannabis at 34% for the 
same time period (Long et al, 2005a).
The following chapter presents outcomes from intake, 1-year and 3-year follow-up with regard to current 
drug use (including consumption of alcohol and tobacco), polydrug use and those free of drugs. The data 
provide a snapshot of participants’ drug use at the three time periods and consequently whether their 
behaviour has altered across the time points. In the fi nal section, a summary of the results is presented.
5.2 Results
 Current Drug Use
In Table 5.2(a), results for the usage of a range of drugs are presented. Participants’ heroin use signifi cantly 
declined (p<0.001) from 77% (n=306) at intake to 48% (n=145) at 1-year, while non-prescribed methadone 
use also reduced (p<0.001) from 41% (n=162) to 13% (n=41). In the same time period similar signifi cant 
reductions (p<0.001) were also evident for cannabis, with its use decreasing from 64% (n=243) 
at intake to 54% (n=161) at 1-year and benzodiazepine use reducing (p<0.001) from 44% (n=174) 
to 23% (n=69). Reported use for cocaine also signifi cantly decreased (p<0.001) from 44% 
(n=179) to 21% (n=64) with crack cocaine also decreasing (p<0.001) from 15% (n=59) 
to 6% (n=19).
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 Table 5.2(a) Drug Use
Intake 1-year 3-years
n % n % n %
Drug use in the last 90 days
Heroin 306 76.9ab 145 47.5a 165 46.2b
Cannabis 243 64.1ab 161 53.5a 174 48.9b
Cocaine 179 44.3ab 64 21.0a 71 20.0b
Benzodiazepines 174 44.3ab 69 22.6ac 113 31.7bc
Non-prescribed methadone 162 40.6ab 41 13.4a 49 13.8b
Crack cocaine 59 14.6ab 19 6.3a 23 6.5b
 Note: Matching subscript letters denote statistical significance.
At 3-years significant results were maintained for all drugs. There were significant differences (p<0.001) 
reported for all drugs from intake to 3-year follow-up with heroin use reducing from 77% (n=306) to 46% 
(n=165), cannabis use reducing from 64% (n=243) to 49% (n=174), cocaine use reducing from 44% (n=179)  
to 20% (n=71), benzodiazepine use reducing from 44% (n=174) to 32% (n=113), non-prescribed methadone 
reducing from 41% (n=162) to 14% (n=49) and crack cocaine reducing from 15% (n=59) to 7% (n=23).
Clearly the data highlight the improvement in participants’ drug use across all categories indicating that 
treatment is having a positive impact on participants’ drug-using behaviour both at the 1- and 3-year time 
points. Only one significant difference was noted between 1- and 3-year follow-up, with benzodiazepines 
use increasing significantly (p=0.020) and respondents reporting using the drug more frequently, nevertheless 
the percentage at 3-year follow-up had not returned to the original level.
Positive outcomes were evident for mean number of days on which drugs were used for both the 
population as a whole and for participants who used each drug for the same period (see Tables 5.2(b)  
and 5.2(c), respectively). There was a significant reduction in the reported daily use of all drugs between 
intake and 1-year follow-up. Heroin use decreased from a intake average of 40.1 days to 15.5 days (p<0.001)  
at 1-year follow-up. Use of non-prescribed methadone also dropped from 11.6 days to 3.8 days (p<0.001). 
Individuals also reported using cannabis less frequently, with use of the drug declining from 39.0 days  
to 32.0 days (p<0.001). Substantially lower rates of benzodiazepines were also observed with mean days 
decreasing from 15.5 days at intake to 5.3 days at 1-year follow-up (p<0.001). Both cocaine and crack  
cocaine also showed significant declines with cocaine use decreasing from 7.6 days at intake to 3.4 days  
at 1-year follow-up (p<0.001) and crack cocaine reducing from 2.1 days at intake to 0.9 days at 1-year  
follow-up (p=0.011). This improvement continued at 3-year follow-up with significant reductions for all 
drugs except crack cocaine. In fact, all drugs except crack cocaine show a significant difference between 
intake and 3-year follow-up. However, non-prescribed methadone, crack cocaine and cocaine show no 
statistically significant difference between 1-year and 3-year follow-up, indicating that the improvement 
made between intake and 1-year follow-up was maintained but not improved upon. For heroin and 
benzodiazepine use, there was an increase in the mean number of days on which drugs were used but  
the result was still significantly lower at 3-year follow-up than at intake. Cannabis use, on the other hand, 
continued to decline. Overall, respondents’ drug use remained low at 3-year follow-up indicating that drug 
use did not return to original intake levels.
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 Table 5.2(b) Mean Days Used: Population
Intake 1-year 3-years
Mean (s.d.) Mean (s.d.) Mean (s.d.)
Mean days used in the last 90 days
Heroin 40.1 (35.8)ab 15.5 (28.0)ac 20.7 (32.8)bc
Cannabis 39.0 (40.1)ab 32.0 (39.5)ac 25.1 (36.1)bc
Benzodiazepines 15.5 (29.1)ab 5.3 (15.9)ac 9.4 (22.8)bc
Non-prescribed methadone 11.6 (23.2)ab 3.8 (15.7)a 2.6 (10.8)b
Cocaine 7.6 (17.3)ab 3.4 (13.1)a 2.9 (11.6)b
Crack cocaine 2.1 (9.9)a 0.9 (6.3)a 1.1 (6.6)
 Note: Matching subscript letters denote statistical significance.
 Table 5.2(c) Mean Days Used: Of Those Who Used
Intake 1-year 3-years
Mean (s.d.) Mean (s.d.) Mean (s.d.)
Mean days used in the last 90 days
Heroin 52.3 (32.2)a 32.7 (33.1)ab 44.7 (35.4)b
Cannabis 60.8 (34.3)ab 59.8 (35.3)ac 51.5 (36.2)bc
Benzodiazepines 35.0 (35.0)a 23.6 (26.4)a 29.9 (32.3)
Non-prescribed methadone 28.6 (29.0)b 28.5 (33.8) 19.5 (23.3)b
Cocaine 17.2 (22.7) 16.1 (24.9) 14.6 (22.5)
Crack cocaine 14.5 (22.5) 14.5 (21.3) 17.1 (21.0)
 Note: Matching subscript letters denote statistical significance.
However, the improvements in population drug use are not necessarily mirrored for the sub-sample 
population representing only those participants who used a particular drug at both time points. For this 
sub-sample population, the figures differ slightly with significant differences evident in heroin use, declining 
from 52.3 days at intake to 32.7 days at 1-year follow-up (p<0.001), cannabis use, declining from 60.8 days at 
intake to 59.8 days at 1-year follow-up (p=0.041), and benzodiazepines use, declining from 35 days at intake 
to 23.6 at 1-year follow-up (p<0.005). At 3-year follow-up, significant differences were only observed for 
respondents’ use of cannabis and non-prescription methadone. Of those using cannabis, individuals used 
this drug less frequently at 3-year follow-up than at intake (p<0.001), reducing from 60.8 days to 51.5 days, 
while the mean number of days on which non-prescription methadone was used decreased from 28.6 days at 
intake to 19.5 days at 3-year follow-up (p=0.012). Comparisons between 1-year and 3-year follow-up indicate 
that the mean number of days on which heroin was used, for those using at both time points, increased 
between 1-year and 3-years, although not to the same levels as at intake. The mean number of days on 
which using cannabis was used reduced further between 1-year and 3-years (p<0.001), from 59.8 days to  
51.5 days, respectively.
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The significant differences observed in the sub-sample are more of a reflection of change for those 
participants who used all drugs at both time periods. Although significant reductions continued to be 
maintained at 3-year follow-up for most drugs, there is a noticeable levelling out of drug use between  
1-year and 3-year follow-up indicating that greatest improvement occurred one year into treatment. 
However, it should be noted that benzodiazepines showed a significant increase between 1- and 3-year 
follow-up (Table 5.2(b)).
Tables 5.2(d) and 5.2(e) present the average amount of each substance consumed on a typical using day for 
both the population as a whole and the sub-sample in the 90 days prior to interview. For the population 
figures, comparisons between intake and 1-year follow-up showed participants’ consumption of all drugs, 
with the exception of cannabis, declined significantly.
Respondents’ reported use of heroin at 1-year follow-up reduced from 0.6g to 0.2g (p<0.001), cocaine use 
reduced from 0.9g to 0.4g (p<0.001), use of non-prescribed methadone reduced from 23.3ml to 7.1ml 
(p<0.001) and benzodiazepine use reduced from 42mg to 23mg (p=0.012).
Quantities of drugs consumed continued to improve between intake and 3-year follow-up with use of 
heroin (p<0.001), cannabis (p<0.001), cocaine (p<0.001) and non-prescribed methadone (p<0.001) all declining 
at 3-year follow-up. It should be noted however that increased consumption was observed between 1-year 
and 3-year follow-up for respondents’ use of benzodiazepines (p=0.036).
 Table 5.2(d) Mean Amounts Used: Population
Intake 1-year 3-years
Mean (s.d.) Mean (s.d.) Mean (s.d.)
1Mean amounts used per day in the last 90 days
Heroin (g) 0.6 (0.8)ab 0.2 (0.6)a 0.2 (0.4)b
Cannabis (joints) 7.7 (16.5)b 5.5 (20.8) 3.7 (11.1)b
Cocaine (g) 0.9 (2.4)ab 0.4 (1.2)a 0.3 (0.8)b
Non-prescribed methadone (ml) 23.3 (37.7)ab 7.1 (27.1)a 9.1 (29.6)b
Benzodiazepines (mg) 41.9 (105.5)a 22.6 (121)ac 39.9 (136.8)c
 Note 1: Matching subscript letters denote statistical significance.
 Note 2: Crack cocaine was excluded due to inconsistency in data reporting.
 1 These figures were based on:
a) Heroin: one bag costing €20 and containing on average 0.113g at intake and 1-year, with one bag costing €20 and containing  
on average 0.1g at 3-years.
b) Cocaine: one gram costing €110 at intake, €66 at 1-year and €70 at 3-years.
c) Cannabis: one ounce costing €110 at intake, €100 at 1-year and €198.45 at 3-years (or a joint costing approximately 39c at 
intake, approx 35c at 1-year and approx 70c at 3-years).
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 Table 5.2(e) Mean Amounts Used: Of Those Who Used
Intake 1-year 3-years
Mean (s.d.) Mean (s.d.) Mean (s.d.)
1Mean amounts used per day in the last 90 days
Heroin (g) 0.7 (0.8)ab 0.4 (0.9)a 0.4 (0.5)b
Cannabis (joints) 12.0 (19.1)b 10.4 (27.8) 7.7 (15.1)b
Cocaine (g) 2.3 (3.3) 1.8 (2.0) 1.6 (1.3)
Non-prescribed methadone (ml) 58.9 (38.6) 56.6 (55.6) 68.5 (50.5)
Benzodiazepines (mg) 116.7 (149.6) 141 (276) 151.2 (233.6)
 Note 1: Matching subscript letters denote statistical significance.
 Note 2: Crack cocaine was excluded due to inconsistency in data reporting.
 1 These figures were based on:
a) Heroin: one bag costing €20 and containing on average 0.113g at intake and 1-year, with one bag costing €20 and containing  
on average 0.1g at 3-years.
b) Cocaine: one gram costing €110 at intake, €66 at 1-year and €70 at 3-years.
c) Cannabis: one ounce costing €110 at intake, €100 at 1-year and €198.45 at 3-years (or a joint costing approximately  
39c at intake, approx 35c at 1-year and approx 70c at 3-years).
For those participants who used each substance in the previous 90 days (sub-sample), only the amount  
of heroin consumption improved at the 1-year follow-up stage, decreasing from 0.7g to 0.4g (p<0.001). 
However, at 3-year follow-up significant reductions in use were reported for both heroin use (p<0.001)  
and cannabis use (p=0.021) with a non-significant increase observed for the quantity of non-prescribed 
methadone consumed. Nevertheless, the quantities of cocaine, non-prescribed methadone and 
benzodiazepines used by participants did not significantly reduce over all time points demonstrating  
that participants who used these drugs at the corresponding time points did not change their using  
habits in terms of quantities consumed.
 Drug-free Status
The percentage of participants who were drug-free, including those who were not using any illicit drugs, 
those who were not using any illicit drugs excluding cannabis and those not using any illicit drugs or 
prescribed methadone are presented in Table 5.2(f). Significant improvements were observed in all three 
categories at 1-year follow-up with percentages drug-free (not using any illicit drug) increasing from 9% 
(n=37) at intake to 28% (n=84) at 1-year follow-up (p<0.001), drug-free (not using any illicit drug excluding 
cannabis) increasing from 13% (n=53) at intake to 41% (n=126) at 1-year follow-up (p<0.001) and drug-free  
(not using any illicit drugs or prescribed methadone) increasing from 6% (n=24) at intake to 19% (n=59) at  
1-year follow-up (p<0.001).
Improvement was maintained at the 3-year period with all drug-free figures showing significant increases 
from intake. Individuals who were drug-free (not using any illicit drug) rose from 9% (n=37) at intake to 29% 
(n=105) at 3-year follow-up (p<0.001) with drug-free (not using any illicit drug excluding cannabis) also rising 
from 13% (n=53) at intake to 43% (n=153) at 3-year follow-up (p<0.001) and drug-free (not using any illicit 
drugs or prescribed methadone) rising from 6% (n=24) at intake to 19% (n=68) at 3-year follow-up (p<0.001). 
The most marked improvements were made at the 1-year follow-up stage with levels remaining constant for 
participants who were drug-free (not using any illicit drug) between 1-year and 3-year follow-up. However, 
the significant increases in drug-free (not using any illicit drug excluding cannabis) could be attributed to 
the widespread use of cannabis among users undergoing treatment. Current research indicates that cannabis 
use is highly prevalent among opiate users in treatment (Best et al, 1999).
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 Table 5.2(f) Drug-free
Intake 1-year 3-years
n % N % n %
Drug-free in the last 90 days
Drug-free (not using any illicit drug) 37 9.3ab 84 27.6a 105 29.4b
Drug-free (not using any illicit drug 
excluding cannabis) 53 13.3ab 126 41.3a 153 42.9b
Drug-free (not using any illicit drugs 
or prescribed methadone) 24 6.0ab 59 19.4a 68 19.0b
 Note: Matching subscript letters denote statistical significance.
 Alcohol and Tobacco
The percentage of participants who had smoked tobacco or consumed alcohol in the 90 days prior to 
intake interview is shown in Table 5.2(g). At treatment-intake, 93% (n=359) of participants smoked tobacco 
and just over half of the respondents, 54% (n=204), consumed alcohol. At 1-year follow-up only alcohol 
consumption showed a significant decline with the number of participants consuming alcohol decreasing 
(p=0.008) from 54% (n=204) at intake to 46% (n=139) at 1-year follow-up. Improvements across both categories 
were found at 3-year follow-up where tobacco consumption reduced (p=0.014) from 93% (n=359) at intake 
to 89% (n=316) at 3-year follow-up and alcohol consumption reduced (p=0.002) from 54% (n=204) to 44% 
(n=157) for the same time period.
 Table 5.2(g) Alcohol and Tobacco Consumption
Intake 1-year 3-years
n % n % n %
Consumption in the last 90 days
Tobacco 359 93.0b 272 89.5 316 89.0b
Alcohol 204 53.8ab 139 46.0a 157 44.2b
 Note: Matching subscript letters denote statistical significance.
The frequency of consumption over the previous 90 days for those who used tobacco or alcohol is 
displayed in Tables 5.2(h) and 5.2(i). The population figures reveal significant reductions in the mean 
number of days of alcohol consumption at 1-year follow-up, decreasing from 13.3 days at intake to 9.9 days  
at 1-year follow-up (p=0.008). Daily consumption of tobacco also reduced but this was not significant. 
Participants’ consumption of both substances further declined at 3-year follow-up, however only alcohol 
showed a significant reduction to 10.9 days at 3-year follow-up (p=0.049).
An analysis of the sub-sample who consumed tobacco or alcohol indicates that there were no significant 
differences in the mean number of days on which both substances were consumed when comparing intake 
with both 1-year and 3-year follow-up. Therefore for those consuming alcohol or tobacco, daily consumption 
remained constant throughout the study period.
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 Table 5.2(h) Mean Days Consumed Tobacco and Alcohol: Population
Intake 1-year 3-years
Mean (s.d.) Mean (s.d.) Mean (s.d.)
Mean days used in the last 90 days
Tobacco 81.4 (25.1) 79.4 (28.4) 78.8 (28.9)
Alcohol 13.3 (23.7)ab 9.9 (20.8)a 10.9 (22.5)b
 Note: Matching subscript letters denote statistical significance.
 Table 5.2(i) Mean Days Consumed Tobacco and Alcohol: Of Those Who Consumed
Intake 1-year 3-years
Mean (s.d.) Mean (s.d.) Mean (s.d.)
Mean days used in the last 90 days
Tobacco 87.5 (11.9) 88.8 (8.2) 88.6 (8.6)
Alcohol 24.8 (27.5) 21.5 (26.4) 24.6 (28.4)
Tables 5.2(j) and 5.2(k) illustrate the average amount of tobacco and alcohol consumed on a typical day in 
the last 90 days for both the population and the sub-sample, respectively. Participants reported reductions 
in the amounts of both tobacco (p=0.021) and alcohol consumption (p=0.032) between intake and 1-year 
follow-up. At intake, population figures show that tobacco consumption was on average 18.3 cigarettes a 
day with alcohol consumption at 9.1 units of alcohol. In comparison, at 1-year follow-up, participants had 
reduced their intake of tobacco to 15.9 cigarettes per day and alcohol to 6.1 units per day. Comparison 
between intake and 3-year follow-up show similar reductions in the reported consumption of both 
substances with tobacco (p=0.010) and alcohol (p<0.001) decreasing significantly.
No significant differences were found between intake and 1-year follow-up, intake and 3-year follow-up  
or 1-year and 3-year follow-up among those participants using at both time points under investigation.  
This indicates that, overall, among the using population, consumption remained consistent across the  
three interview periods.
 Table 5.2(j) Mean Amounts of Tobacco and Alcohol Consumed Per Day: Population
Intake 1-year 3-years
Mean (s.d.) Mean (s.d.) Mean (s.d.)
Mean amounts consumed per day in the last 90 days
Tobacco 18.3 (13)ab 15.9 (10.9)a 16.1 (11.7)b
Alcohol 9.1 (15.2)ab 6.1 (13.9)a 5.8 (9.9)b
 Note: Matching subscript letters denote statistical significance.
 Table 5.2(k) Mean Amounts of Tobacco and Alcohol Consumed Per Day: Of Those Who Consumed
Intake 1-year 3-years
Mean (s.d.) Mean (s.d.) Mean (s.d.)
Mean amounts consumed per day in the last 90 days
Tobacco 19.6 (12.5) 17.8 (9.9) 18.1 (10.8)
Alcohol 16.9 (17.0) 13.3 (18.1) 13.1 (11.3)
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 Polydrug Use
The WHO defines polydrug use as ‘the use of more than one drug or type of drug by an individual, often  
at the same time or sequentially, and usually with the intention of enhancing or counteracting the effects 
of another drug’. Table 5.2(l) presents percentages of participants engaging in polydrug use across all time 
periods. Significant reductions were observed at both 1-year and 3-year follow-up in comparison with  
intake figures. The percentage engaged in polydrug use decreased between intake and 1-year (p<0.001)  
and between intake and 3-years (p<0.001), with 76% (n=308) engaging in polydrug use at intake decreasing  
to 50% (n=151) at 1-year follow-up, with a further small decrease to 47% (n=166) at 3-year follow-up.
 Table 5.2(l) Polydrug Use
Intake 1-year 3-years
n % n % n %
Engaging in polydrug use 308 76.2ab 151 49.5a 166 46.5b
 Note: Matching subscript letters denote statistical significance.
5.3 Discussion and Conclusion
The major finding, in terms of drug use outcomes, was a considerable reduction in all drug use across both 
1- and 3-year follow-up compared to intake. At treatment-intake, just over three-quarters of ROSIE study 
participants had used opiates in the last 90 days. In addition, high proportions of respondents reported 
current use of cannabis, cocaine, benzodiazepines and non-prescribed methadone. Between treatment-
intake and 3-year follow-up, the proportion of participants who reported using heroin, cannabis, cocaine, 
benzodiazepines, non-prescribed methadone and crack cocaine all significantly decreased.
Reductions were also found in the frequency of drug use at 3-year follow-up. For the population as a  
whole, there were significant decreases in the number of mean days on which drugs were used for all drugs 
except crack cocaine. However, for the sub-sample population, only heroin and non-prescribed methadone 
showed significant reductions at 3-year follow-up. Participants were also using smaller amounts with 
reductions evident for all drugs except benzodiazepines for the population as a whole. Once again,  
sub-sample figures differ with only heroin and cannabis declining significantly.
Of particular note in this chapter are the significant improvements observed for the percentages reporting 
drug-free status. Polydrug use improved markedly across the study, since over three-quarters of the study 
population reported the use of two or more substances at treatment-intake and this figure reduced 
significantly at 3-year follow-up.
In terms of alcohol and tobacco, there were few differences reported in consumption of either substance 
across the three time periods. At intake, a high proportion of the cohort smoked tobacco on a daily basis. 
By 3-year follow-up, the average number of cigarettes smoked per day had reduced but not significantly. 
Regarding alcohol consumption, just over half of all participants reported recent drinking of alcohol at 
treatment-intake. However by 3-year follow-up there was a decline, although not significant, in the amount 
of alcohol units consumed.
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CHAPTER SIX: CRIME
6.1 Introduction
The connection between crime and drugs has long been established. This connection can be seen both in 
terms of the illegality of drugs themselves and in the criminal acts that drug users often commit to fund 
their drug habit. It is therefore not surprising that a reduction in various types of criminal offences is seen 
as one of the main benefi ts of treatment for problem drug use. This reduction can have both social and 
economic benefi ts. On a social level, a reduction in crime means fewer individuals are the direct victims 
of crimes such as muggings, burglaries or thefts. On an economic level, a reduction in drug-related crime 
means that there are fewer costs incurred due to shoplifting, burglary and theft, and consequently 
substantial costs can be avoided by the criminal justice system.
Figures for drug-related offences have until very recently been produced by An Garda Síochána; however 
this role has now been assigned to the Central Statistics Offi ce. Table 6.1(a) shows the number of proceedings 
initiated under the Misuse of Drugs Act (MDA), categorised by non-headline crime (Irish Prison Service, 
2005). Non-headline crime refers to less serious offences that are tried by a judge only, whereas the more 
serious headline crimes are heard by a jury. Generally most drug users are involved in non-headline crime.
 Table 6.1(a) Proceedings Initiated Under the Misuse of Drugs Act (Non-headline)
Year
2000 2001 2002 2003 2004 2005
Offence
Possession 6,485 7,009 6,038 4,805 5,065 7,432
Supplying or dealing drugs 1,706 1,520 1,530 1,758 1,608 1,928
Obstruction 68 138 193 392 368 479
Other MDA offences 136 101 215 195 261 235
While it is relatively straightforward to estimate the volume of crime that is directly related to illegal drugs, 
such as possession or dealing, estimating the level of crime that is committed by drug users in general is 
more diffi cult. To date only two studies have been conducted on this topic. The fi rst was conducted by 
Keogh (1997) and sought to explore the link between crime and drug use in Dublin. The second such study 
was conducted by the Garda Research Unit (Furey and Browne, 2004) and sought to examine the link 
between opiate use and crime in Ireland. In terms of the amount of crime committed by drug users in 
general Keogh estimated that drug users were responsible for 66% of crime in the Dublin Metropolitan 
Area (DMA), while Furey and Browne estimate that drug users were responsible for 28% of the crime 
in the DMA.
Treatment options for drug users have been put in place by the Irish prison system. 
These include the increased availability of methadone services, vaccinations against 
hepatitis B (although this has met with limited success), the employment of registered 
nurses and the employment of a consultant psychiatrist in addiction at Mountjoy 
Prison in Dublin.
7The ROSIE Study Drug Treatment Outcomes in Ireland
6.2 Results
 Criminal Activity
Given the information above it is easy to see the importance of crime outcomes in the context of delivery 
of treatment services for problem drug users.
Table 6.2(a) shows that an analysis of crimes committed revealed significant improvements at 1-year follow-
up compared to intake in terms of selling/supplying drugs (p<0.001), theft from a person (p<0.001), theft 
from a shop or commercial property (p<0.001), theft from a vehicle (p=0.043), theft of a vehicle (p=0.003), 
handling stolen goods (p<0.001), fraud/forgery/deception (p<0.001), assault (p=0.029), criminal damage 
(p=0.001), soliciting (p=0.004) and breach of the peace (p=0.003). Theft from a house or home (p=0.052) was 
found to be borderline significant. The most notable reduction between intake and 1-year follow-up was for 
those selling/supplying drugs which reduced from 30% (n=109) to 12% (n=35). Similarly, the number of 
participants handling stolen goods also decreased significantly from 25% (n=91) to 8% (n=25).
A comparison between intake and 3-year follow-up showed that significant improvements were still evident 
three years after first entering treatment. Improvements were found for selling/supplying drugs (p<0.001), 
theft from a person (p<0.001), theft from a house or home (p=0.023), theft from a shop or commercial 
property (p<0.001), theft of a vehicle (p=0.043), handling stolen goods (p<0.001), fraud/forgery/deception 
(p<0.001), assault (p=0.005), soliciting (p=0.003) and breach of the peace (p=0.006). Criminal damage 
(p=0.052) was borderline significant. As was the case with the initial follow-up, substantial reductions were 
still evident between intake and 3-year follow-up for the number of those selling/supplying drugs which 
fell from 30% (n=109) to 13% (n=45) and for the number handling stolen goods which fell from 25% (n=91) to 
10% (n=37)  
(see Table 6.2(a)).
A comparison between 1-year and 3-year follow-up resulted in no significant differences for any crime 
category between these two time periods. This indicates that most of the observed improvements took 
place between intake and 1-year follow-up. After these initial improvements were achieved there was a 
period of stabilisation with participants sustaining these improvements three years after entering treatment.
 Table 6.2(a) Crimes Committed
Intake 1-year 3-years
n % n % n %
Crime committed in the last 90 days
Selling/supplying drugs 109 30.0ab 35 11.6a 45 12.6b
Theft from a person 39 10.8ab 9 3.0a 6 1.7b
Theft from house/home 23 6.3b 9 3.0 11 3.1b
Theft from shop/commercial property 63 17.5ab 25 8.4a 27 7.6b
Theft from a vehicle 22 6.1a 11 3.7a 13 3.7
Theft of a vehicle 22 6.0ab 7 2.3a 6 1.7b
Handling stolen goods 91 25.3ab 25 8.3a 37 10.4b
Fraud/forgery/deception 40 11.2ab 6 2.0a 10 2.8b
Assault 29 8.1ab 11 3.7a 10 2.8b
Criminal damage 26 7.2a 7 2.3a 11 3.1
Soliciting 14 3.9ab 3 1.0a 2 0.6b
Breach of the peace 24 6.7ab 6 2.0a 9 2.5b
 Note: Matching subscript letters denote statistical significance.
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In order to provide a clearer and more accurate picture of the frequency of criminal activity, outcomes are 
displayed separately for the population as a whole and the sub-sample who committed crime (see Tables 
6.2(b) and 6.2(c), respectively). In terms of comparison between two time points for this sub-sample, since 
only those who committed a particular crime at both time points under consideration were included, it  
was not expected that major differences would be apparent over time. When these differences did occur, 
that is, when there are statistically significant differences between the mean number of days on which a 
particular crime was committed for the sub-sample, this reflected the habits of those engaged in criminal 
activity rather than the habits of the opiate using population as a whole.
For the population, significant improvements were apparent between intake and 1-year follow-up for  
the mean number of days on which selling/supplying drugs (p<0.001), theft from a person (p=0.039), theft 
from a commercial property (p=0.001), theft of a vehicle (p=0.041), handling stolen goods (p<0.001), fraud/
forgery/deception (p=0.003), assault (p=0.013), criminal damage (p=0.044) and soliciting (p=0.006) were 
committed. As before, the most noticeable reduction between intake and 1-year follow-up was for the 
frequency of selling/supplying drugs which fell from 12.4 to 4.2 days and in the frequency of handling  
stolen goods which also dropped substantially from 5.3 to 0.8 days (see Table 6.2(b)).
Significant differences were still evident three years after entering treatment for selling/supplying drugs 
(p<0.001), theft from a commercial property (p=0.001), handling stolen goods (p<0.001), fraud etc (p=0.029) 
and soliciting (p=0.003) compared to intake. Similar to the initial follow-up, the most notable differences 
were again for selling/supplying drugs which fell from 12.4 to 5.9 days and for handling stolen goods which 
fell from 5.3 to 1.8 days.
No significant differences were found between 1-year and 3-year follow-up again indicating that while  
there were improvements between intake and 1-year and 3-year follow-up, most of these improvements 
took place between intake and 1-year follow-up with a period of stabilisation occurring between 1- and 
3-years.
 Table 6.2(b) Mean Days Crime Committed: Population
Intake 1-year 3-years
Mean (s.d.) Mean (s.d.) Mean (s.d.)
Mean days crime committed in the last 90 days
Selling/supplying drugs 12.4 (26.3)ab 4.2 (15.7)a 5.9 (19.9)b
Theft from a person 0.9 (6.2)a 0.1 (0.7)a 0.4 (5.5)
Theft from house/home 0.5 (4.4) 0.3 (3.5) 0.3 (2.2)
Theft from commercial property 4.4 (16.3)ab 1.5 (9.7)a 1.3 (7.4)b
Theft from a vehicle 0.4 (4.0) 0.3 (3.6) 0.5 (4.1)
Theft of a vehicle 0.1 (0.7)a 0.1 (0.6)a 0.1 (1.7)
Handling stolen goods 5.3 (17.0)ab 0.8 (6.7)a 1.8 (9.6)b
Fraud/forgery/deception 1.8 (9.6)ab 0.1 (1.7)a 0.3 (4.8)b
Assault 0.1 (0.7)a 0.0 (0.2)a 0.1 (1.1)
Criminal damage 0.3 (1.9)a 0.0 (0.3)a 0.3 (4.1)
Soliciting 1.9 (12.0)ab 0.0 (0.6)a 0.1 (2.5)b
Breach of the peace 0.3 (2.9) 0.0 (0.1) 0.0 (0.4)
 Note: Matching subscript letters denote statistical significance.
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A rather different set of results can be seen for the sub-sample, with no significant differences found for 
any crime category at any time point. This result is mainly due to low numbers committing a particular 
crime at 1-year and 3-year follow-up. Accordingly, there was an insufficient sample size to detect a statistically 
significant change (see Table 6.2(c)). However, the direction of some changes was of concern, namely theft 
from a person, criminal damage and soliciting.
 Table 6.2(c) Mean Days Crime Committed: Of Those Who Committed Crime
Intake 1-year 3-years
Mean (s.d.) Mean (s.d.) Mean (s.d.)
Mean days crime committed in the last 90 days
Selling/supplying drugs 45.7 (32.3) 41.0 (31.0) 49.3 (34.6)
Theft from a person 9.7 (18.7) 5.3 (3.7) 26.7 (36.5)
Theft from house/home 10.7 (17.2) 15.4 (25.2) 8.9 (9.0)
Theft from commercial property 28.6 (32.1) 25.6 (32.7) 18.2 (21.4)
Theft from a vehicle 8.2 (16.1) 13.5 (23.0) 14.1 (17.3)
Theft of a vehicle 2.5 (1.7) 3.4 (3.9) 8.6 (12.6)
Handling stolen goods 23.9 (29.5) 18.4 (28.3) 17.3 (25.6)
Fraud/forgery/deception 17.7 (25.7) 15.5 (20.5) 11.8 (27.7)
Assault 1.9 (1.9) 1.1 (0.4) 4.3 (7.0)
Criminal damage 4.0 (6.8) 3.0 (2.8) 14.0 (24.7)
Soliciting 50.1 (37.7) 5.5 (6.4) 48.0 (0.0)
Breach of the peace 7.3 (13.4) 1.0 (0.0) 2.1 (1.4)
 Arrests for Criminal Offences
A comparison between intake and 1-year follow-up for arrests showed there was a significant reduction  
in the number of those arrested for criminal damage (p=0.002). At intake, 4% (n=11) of participants were 
arrested for criminal damage. By 1-year follow-up this had fallen to 0% (n=0) (see Table 6.2(d)). No other 
categories of arrest showed a significant difference between intake and 1-year follow-up although all categories 
showed some reduction. However, it should be noted that significance may not have been detected due  
to the small numbers of participants reporting arrests for particular criminal activities at both intake and  
1-year. Table 6.2(d) provides a descriptive breakdown of the results for arrests by crime. It can be seen  
from these results that there was a reduction, although not statistically significant, in the number of arrests 
between intake and 1-year follow-up for theft from a person, which fell from 2% (n=7) to 0.3% (n=1) and 
theft from a commercial property, which fell from 6% (n=20) to 3% (n=9).
A comparison between intake and 3-year follow-up showed that there was a significant reduction for 
arrests for theft from a person (p=0.015). At intake, 2% (n=7) of participants were arrested for theft from a 
person falling to 0% (n=0) at 3-year follow-up. Other arrest categories showed a significant reduction in the 
number of arrests made at 3-year follow-up, although all categories, excluding theft from a house or home, 
showed some reduction at 3-year follow-up compared to intake.
Once again, a comparison between 1-year and 3-year follow-up showed that no major changes had taken 
place, with most of the improvements made at 1-year follow-up sustained at 3-year follow-up and only 
slight changes evident.
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 Table 6.2(d) Crimes Arrested For in the Last 90 days
Intake 1-year 3-years
n % n % n %
Arrests by crime in the last 90 days
Selling/supplying drugs 14 4.1 11 3.7 9 2.5
Theft from a person 7 2.3b 1 0.3 0 0.0b
Theft from house/home 4 1.3 3 1.0 5 1.4
Theft from commercial property 20 6.2 9 3.0 13 3.6
Theft from a vehicle 2 0.6 1 0.3 1 0.3
Theft of a vehicle 4 1.3 3 1.0 1 0.3
Handling stolen goods 9 2.7 1 0.3 3 0.8
Fraud/forgery/deception 4 1.3 1 0.3 4 1.1
Assault 8 2.6 6 2.0 3 0.8
Criminal damage 11 3.6a 0 0.0a 3 0.8
Soliciting 3 1.1 0 0.0 0 0.0
Breach of the peace 11 3.6 3 1.0 5 1.4
 Note: Matching subscript letters denote statistical significance.
 Current Legal Problems
Significant improvements were found between intake and 1-year follow-up for no legal problems (p=0.026), 
on bail – awaiting a trial or hearing (p=0.043) and outstanding warrants (p=0.019). The number of those 
experiencing no legal problems increased from 52% (n=199) to 62% (n=186). Those on bail – awaiting a  
trial or hearing dropped from 16% (n=60) to 10% (n=30). The number of those with outstanding warrants 
decreased from 12% (n=46) to 7% (n=21) (see Table 6.2(e)).
A comparison of intake and 3-year follow-up showed that significant differences were still evident for no 
legal problems (p<0.001), on bail – awaiting a trial or hearing (p<0.001) and outstanding warrants (p=0.049). 
Those experiencing no legal problems increased from 52% (n=199) to 64% (n=227), while those on bail – 
awaiting trial or hearing decreased from 16% (n=60) to 5% (n=17). However, those with outstanding fines 
increased from 6% (n=22) to 11% (n=39).
 Table 6.2(e) Current Legal Status
Intake 1-year 3-years
n % n % n %
1Current legal problem
None 199 51.6ab 186 62.2a 227 63.6b
On probation/community service 37 9.8 28 9.4 30 8.4
On bail – awaiting trial/hearing 60 16.0ab 30 10.0ac 17 4.8bc
On bail – awaiting sentencing 24 6.4 14 4.7 12 3.4
On temporary release 10 2.7 2 0.7 7 2.0
Outstanding warrants 46 12.2ab 21 7.1a 23 6.5b
Outstanding fines 22 5.9b 23 7.7 39 11.0b
 Note: Matching subscript letters denote statistical significance.
 1 These categories are not mutually exclusive.
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Between 1-year and 3-year follow-up, further significant improvements were found for the number of  
those on bail – awaiting a trial or hearing (p=0.011). It was found that 10% (n=30) of participants were  
on bail or awaiting a trial or hearing at 1-year follow-up compared with 5% (n=17) at 3-year follow-up.
6.3 Discussion and Conclusion
It can be seen from the preceding results that improvements were made between intake and 1- and 3-year 
follow-up for the majority of crime outcome measures, with significant reductions in criminal activity evident. 
Most noticeably, a substantial reduction was found for the number of participants selling/supplying drugs. 
In terms of the frequency of criminal activity, significant improvements could be seen for the population  
as a whole. Once again the most noticeable reduction was for the frequency of selling/supplying drugs. 
Unfortunately no significant differences were evident for the sub-sample who committed crime between 
intake and either 1- or 3-year follow-up. The reason for this result was mainly due to the small sample size 
of those who had committed crime at both time points.
Similarly, no significant improvements were found for arrests for criminal offences between intake and 
either 1- or 3-year follow-up. This result was primarily due to the small sample size of those arrested. For 
those who were experiencing legal problems other than being arrested, significant improvements were 
evident for three of the eight legal problem categories. Most notably, those experiencing no legal problems 
increased at 1-year follow-up and increased slightly again at 3-year follow-up.
When these significant improvements for crime and legal status are examined in more detail, it can be seen 
that most of the improvements for crime took place between the initial intake interview and 1-year follow-
up. This indicates that while there were significant differences between intake and 3-year follow-up, most 
of the reductions in crime and legal problems took place during the first year after entering treatment. 
After these initial improvements were achieved, there was a period of stabilisation with no significant 
differences evident between 1-year and 3-year follow-up.
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CHAPTER SEVEN: HEALTH 
AND RISK BEHAVIOUR
7.1 Introduction
Illicit drugs carry many serious health risks and their use can cause numerous physical and mental health 
problems. Substance use is related to respiratory problems, cancer of the mouth, stomach and lungs, 
cardiovascular disease, stroke, HIV/AIDS and hepatitis. Although the use of drugs produces euphoric effects on 
the brain, constant drug use can affect memory, attention and decision-making abilities. The effect of any 
drug varies according to the pattern of drug taking, the amount of the drug taken, how it is administered, 
the physical and mental condition of the drug user, the age of the user, the environment or context in 
which the drug is being used and the concurrent use of other drugs.
Withdrawal from regular use of drugs can lead to a variety of health complaints including restlessness, 
headaches, tremors, mood swings, weight loss, fatigue, changes in appetite, muscle and bone pain, insomnia, 
diarrhoea, and vomiting. Aside from the physical effects of drug use, chronic use of drugs can cause long-
term mental health symptoms such as anxiety, memory problems and disrupted sleep patterns, as well as 
more serious symptoms such as paranoia, aggression and depression. Mental problems such as depression 
and anxiety are prevalent among participants in substance abuse treatment programmes (Darke et al, 1994; 
Farrell et al, 1998).
This link between drug use and psychiatric illness is refl ected in the numbers of those with drug dependency 
issues accessing psychiatric services in Ireland. The European Monitoring Centre for Drugs and Drug Addiction 
(EMCDDA) notes that rates of fi rst admissions to inpatient psychiatric services with a diagnosis of drug 
dependence between 1990 and 2003 increased steadily and were almost four times higher in 2001 than 
in 1990 (EMCDDA, 2004).
Injecting drug users (IDUs) are at further risk of serious medical problems since impurities and adulterants 
can cause abscesses and, in more serious cases, clots in the lungs. One of the more serious health risks of 
drug use is the consequences of drug injection and the transmission of HIV and other infectious diseases, 
notably hepatitis B and C. Hepatitis C and HIV occur in high proportions among injecting drug users as a 
result of unsafe injecting practices and needle sharing. The social context of injecting is an important 
predictor of hepatitis C virus status as close relationships with other IDUs increase the possibility of 
engaging in risk behaviour (Smyth et al, 2005).
7.2 Results
 General Health Self-assessment
All participants were self-assessed in terms of their general health at intake, 1-year and 3-year follow-up 
(see Table 7.2(a)). There was evidence of an improvement in general health at both 1-year (p=0.003) and 
3-year follow-up (p=0.038) compared with intake. For example, at intake 16% (n=64) rated their own 
health as poor in comparison to 11% (n=32) at 1-year and 14% (n=49) at 3-year follow-up. There was 
an increase also in the percentages reporting good or excellent health at 1-year and 3-year 
follow-up compared to intake with good increasing from 45.6% (n=180) at intake to 50% 
(n=150) at 1-year and 49% (n=176) at 3-year follow-up and those reporting excellent 
health increasing from 5% (n=19) at intake to 8% (n=23) at 1-year and 6% (n=21) 
at 3-year follow-up.
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 Table 7.2(a) Self-assessment of Health
Intake 1-year 3-years
n % n % n %
Participants’ self-assessment of health
Excellent 19 4.8 23 7.6 21 5.9
Good 180 45.6 150 49.7 176 49.4
Fair 132 33.4 97 32.1 110 30.9
Poor 64 16.2 32 10.6 49 13.8
 Physical Health Outcomes
From Table 7.2(b), it is evident that there was a marked decrease between intake and 1-year follow-up in the 
reporting of all physical health symptoms, with statistically significant differences noted for poor appetite 
(p=0.002), tiredness/fatigue (p=0.027), joint/bone pains (p=0.008), muscle pains (p=0.004) and tremors/
shakes (p<0.001). Comparing intake and 3-year follow-up, there was a significant reduction in poor appetite 
(p<0.001), nausea (p=0.018), joint/bone pains (p=0.017), muscle pains (p=0.001) and tremors/shakes (p=0.047). 
These reductions, with the exception of nausea and tremors/shakes, were also significant between intake 
and 1-year follow-up although were not significant between 1- and 3-year follow-up, indicating that the 
initial improvement between intake and 1-year follow-up was maintained between 1-year and 3-years. 
However, it should be noted that there was a significant increase in the proportion of participants reporting 
tiredness/fatigue (p=0.038), numbness/tingling (p<0.001) and tremors/shakes (p=0.007) when comparing  
1- and 3-years, although neither tremors/shakes nor tiredness/fatigue reached the levels reported at intake. 
Although not significant, there was a larger proportion of participants reporting numbness/tingling at 3-years.
 Table 7.2(b) Number and Percentage Experienced Physical Health Symptoms
Intake 1-year 3-years
n % n % n %
Physical health symptoms experienced in the last 90 days
Poor appetite 269 71.7ab 175 59.5a 194 55.6b
Tiredness/fatigue 268 71.5a 185 63.4ac 239 68.5c
Nausea 148 39.8b 97 32.9 114 32.6b
Stomach pains 148 39.8 101 34.2 127 36.5
Difficulty breathing 105 28.2 74 25.1 105 30.2
Chest pains 85 22.7 57 19.3 74 21.3
Joint/bone pains 135 36.0ab 78 26.4a 95 27.3b
Muscle pains 122 32.7ab 71 24.1a 77 22.0b
Numbness/tingling 84 22.6 53 18.0c 95 27.4c
Tremors/shakes 105 28.7ab 48 16.3ac 80 22.9bc
 Note: Matching subscript letters denote statistical significance.
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 Table 7.2(c) Mean Days Physical Health Symptoms Experienced: Population
Intake 1-year 3-years
Mean (s.d.) Mean (s.d.) Mean (s.d.)
Physical health symptoms experienced in the last 90 days
Poor appetite 47.3 (38.6)ab 37.2 (39.0)ac 31.9 (37.7)bc
Tiredness/fatigue 43.0 (38.5)a 38.3 (39.1)a 39.6 (38.1)
Nausea 14.2 (27.2) 15.2 (29.5) 12.6 (27.3)
Stomach pains 14.5 (26.6) 15.1 (29.1) 15.9 (29.5)
Difficulty breathing 13.4 (28.6) 13.8 (29.6)c 17.5 (32.6)c
Chest pains 8.2 (21.4) 8.2 (22.9) 6.8 (19.8)
Joint/bone pains 13.4 (27.7) 11.4 (26.0) 14.3 (29.9)
Muscle pains 9.8 (22.1) 10.4 (25.5) 10.1 (25.0)
Numbness/tingling 8.5 (22.6) 7.7 (21.8)c 11.5 (26.3)c
Tremors/shakes 10.2 (23.5) 7.3 (21.2)c 11.2 (26.8)c
 Note: Matching subscript letters denote statistical significance.
 Table 7.2(d) Mean Days Physical Health Symptoms Experienced: Of Those Who Experienced
Intake 1-year 3-years
Mean (s.d.) Mean (s.d.) Mean (s.d.)
Physical health symptoms experienced in the last 90 days
Poor appetite 66.0 (29.0)ab 62.4 (31.2)a 57.4 (33.1)b
Tiredness/fatigue 60.1 (32.2) 60.4 (32.8) 57.8 (32.7)
Nausea 35.6 (33.2) 46.1 (35.1) 38.6 (35.9)
Stomach pains 36.4 (31.4)b 44.2 (34.4) 43.6 (34.5)b
Difficulty breathing 47.4 (35.9) 55.2 (34.7) 58.0 (34.1)
Chest pains 36.3 (31.6) 42.4 (35.6) 32.1 (32.1)
Joint/bone pains 37.3 (35.2) 43.0 (34.7) 52.2 (36.0)
Muscle pains 30.0 (29.8) 43.3 (35.8) 45.7 (34.7)
Numbness/tingling 37.7 (34.1) 43.1 (33.5) 42.0 (35.3)
Tremors/shakes 35.4 (32.2) 44.4 (33.5) 49.2 (36.0)
 Note: Matching subscript letters denote statistical significance.
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For physical health outcomes, participants were scored across ten categories (see Tables 7.2(c) and 7.2(d)). 
For the population, a comparison between intake and 1-year revealed a statistically significant reduction  
in the mean number of days on which participants experienced poor appetite over the previous 90 days 
(p<0.001), decreasing from just over 47 days at intake to just over 37 days at 1-year, as well as a significant 
decrease in those reporting tiredness/fatigue (p=0.023). The reporting of the mean number of days on 
which tremors/shakes were experienced had a borderline significant reduction (p=0.051). Similarly, the  
mean number of days of poor appetite significantly reduced between 1- and 3-years (p=0.01) and also 
between intake and 3-years (p<0.001). Further comparisons of note between 1- and 3-years are the significant 
increases for difficulty breathing (p=0.025), numbness/tingling (p=0.005) and tremors/shakes (p=0.007).  
The mean days reported of experiencing nausea, stomach pains, chest pains, joint/bone pains and muscle 
pains remained relatively constant across the three interview time points.
An analysis of the sub-sample who experienced physical health symptoms (see Table 7.2(d)) revealed 
improvements in the numbers of days on which particular health complaints were experienced, given that 
the participant suffered from them at both time points under comparison, for example, the mean number 
of days of poor appetite improved between intake and 1-year (p=0.032) and between intake and 3-years (p=0.01).
There was also a significant increase in the mean days on which stomach pains were experienced, from  
36.4 days at intake to 43.6 days at 3-years (p=0.038).
 Mental Health Outcomes
From Table 7.2(e), it can be seen that most mental health symptoms improved at 1-year with significant 
reductions in the numbers reporting feeling tense (p<0.001), suddenly scared for no reason (p=0.002), 
nervousness or shakiness inside (p=0.014), feelings of worthlessness (p=0.003), feeling lonely (p=0.017)  
and thoughts of ending your life (p=0.010), with feeling fearful showing a borderline significant reduction 
(p=0.05). Between intake and 3-years, there was a significant reduction in some depression symptoms with 
feeling hopeless about the future reducing from 56% to 49% (p=0.022), feeling lonely reducing from 57%  
to 48% (p<0.001) and thoughts of ending your life reducing from 25% to 19% (p=0.016). The latter two 
reductions were significant between intake and 1-year but were not significant between 1- and 3-years, 
indicating that the significant results between intake and 3-years were a reflection of improvements 
sustained from 1-year follow-up.
 Table 7.2(e) Number and Percentage Experienced Mental Health Symptoms
Intake 1-year 3-years
n % n % n %
Mental health symptoms experienced in the last 90 days
Feeling tense 234 65.2a 144 51.4ac 231 67.3c
Suddenly scared for no reason 129 35.6a 70 24.7ac 122 35.3c
Feeling fearful 149 42.3a 98 35.1ca 163 47.4c
Nervousness or shakiness inside 153 42.6a 91 32.6ac 143 41.6c
Spells of terror/panic 90 24.5 69 24.6 80 23.3
Feeling hopeless about the future 196 55.8b 138 49.1 169 49.0b
Feeling of worthlessness 188 52.8a 120 42.6a 165 48.0
Feeling no interest in things 206 57.4 152 54.1 192 55.8
Feeling lonely 202 57.4ab 137 49.3a 165 48.1b
Thoughts of ending your life 88 25.4ab 52 18.1a 65 18.8b
 Note: Matching subscript letters denote statistical significance.
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Between 1- and 3-years there was a significant increase in four mental health symptoms, with each of these 
related to feelings of anxiety. Those reporting feeling tense significantly increased between 1- and 3-years 
(p<0.001) with levels at 3-years returning to around those reported at intake. Similar results were observed 
for those reporting suddenly scared for no reason (p=0.008), feeling fearful (p=0.002) and nervousness or 
shakiness inside (p=0.02).
Analysis of Table 7.2(f), reveals statistically significant reductions in the mean number of days of reporting 
feeling tense (p<0.001), suddenly scared for no reason (p=0.001), feeling fearful (p=0.024), nervous/shakiness 
inside (p<0.001), feeling hopeless about the future (p=0.006), feelings of worthlessness (p<0.001), feeling no 
interest in things (p=0.044), feeling lonely (p<0.001) and thoughts of ending your life (p=0.002), with the only 
non-significant reduction observed being for reported spells of terror/panic. For the depression-related 
symptoms, these improvements remained significant when comparing intake and 3-years but were not 
significant when comparing 1- and 3-year follow-up, with the exception of thoughts of ending your life. 
This, while showing improvement, was not statistically significant. These results indicated that the majority 
of improvement was over the one year period after intake to treatment and this improvement was 
sustained at 3-years for depression-related symptoms.
 Table 7.2(f) Mean Days Mental Health Symptoms Experienced: Population
Intake 1-year 3-years
Mean (s.d.) Mean (s.d.) Mean (s.d.)
Mental health symptoms over previous 90 days
Feeling tense 36.8 (38.0)ab 21.9 (31.0)ac 31.5 (35.4)bc
Suddenly scared for no reason 15.5 (29.7)a 9.2 (22.8)ac 13.1 (27.1)c
Feeling fearful 19.6 (31.7)a 13.7 (26.7)ac 18.6 (31.0)c
Nervous/shakiness inside 19.8 (32.3)ab 11.4 (24.9)ac 16.3 (29.7)bc
Spells of terror/panic 9.0 (23.0)b 7.9 (20.6) 6.3 (19.3)b
Feeling hopeless about future 29.6 (37.0)ab 20.8 (32.2)a 22.2 (33.4)b
Feelings of worthlessness 28.6 (37.1)ab 18.6 (31.4)a 21.4 (32.3)b
Feeling no interest in things 31.1 (36.7)ab 26.1 (35.1)a 25.7 (34.3)b
Feeling lonely 32.7 (37.8)ab 23.4 (33.6)a 23.4 (34.1)b
Thoughts of ending your life 8.1 (22.3)a 3.2 (13.9)a 5.7 (18.4)
 Note: Matching subscript letters denote statistical significance.
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For anxiety related symptoms, there was a significant decrease in the mean number of days of reported 
symptoms of feeling tense (p=0.018), nervousness/shakiness inside (p=0.035) and panic attacks (p=0.023), 
when intake and 3-year follow-up were compared. It should be noted, however, that both the mean number 
of days of feeling tense (p<0.001) and the mean number of days of nervousness or shakiness inside (p=0.008) 
increased significantly between 1-year and 3-year follow-up, although they were both significantly smaller 
than the levels reported at intake.
On a less positive note, the mean days reporting suddenly scared for no reason (p=0.029) and feeling  
fearful (p=0.016) each increased significantly between 1-year and 3-year, returning to levels similar to  
that at baseline. Of the proportions reporting depressive-type symptoms (feelings of worthlessness  
and thoughts of ending your life), there was a similar decline after 1-year with a slight increase at the  
3-year stage.
 Table 7.2(g) Mean Days Mental Health Symptoms Experienced: Of Those Who Experienced
Intake 1-year 3-years
Mean (s.d.) Mean (s.d.) Mean (s.d.)
Mental health symptoms over previous 90 days
Feeling tense 56.4 (33.2)ab 42.6 (31.5)a 46.8 (33.9)b
Suddenly scared for no reason 43.6 (35.5) 37.2 (32.6) 37.1 (34.6)
Feeling fearful 46.2 (33.8) 39.1 (32.3) 39.3 (34.9)
Nervous/shakiness inside 46.6 (34.7)a 34.9 (32.8)a 39.2 (35.0)
Spells of terror/panic 36.8 (33.9) 32.2 (30.8) 27.3 (32.2)
Feeling hopeless about future 53.1 (34.8)ab 42.3 (34.7)a 45.3 (35.1)b
Feelings of worthlessness 54.1 (35.0)ab 43.7 (35.0)a 44.5 (33.8)b
Feeling no interest in things 54.2 (33.0)ab 48.2 (34.8)a 46.0 (34.3)b
Feeling lonely 57.0 (33.2)b 47.6 (33.8) 48.7 (34.4)b
Thoughts of ending your life 31.9 (34.6) 17.6 (28.9) 30.3 (32.7)
 Note: Matching subscript letters denote statistical significance.
Comparisons were next performed for the sub-samples experiencing each symptom (Table 7.2(g)). 
Comparing intake and 1-year, there were significant reductions in the mean number of days reporting  
feeling tense (p=0.025), nervousness/shakiness inside (p=0.002), feeling hopeless about the future (p=0.014), 
feelings of worthlessness (p<0.001) and no interest in things (p=0.039), given that the particular symptom 
was experienced at both time points.
When comparing intake and 3-year follow-up, significant improvements were again observed for feeling 
tense (p=0.003), feeling hopeless about the future (p=0.003), feelings of worthlessness (p=0.001) and  
no interest in things (p=0.001), with significant improvements also evident for feeling lonely (p=0.025).  
No significant improvements were observed when comparing 1-year and 3-year follow-up. This indicated  
that improvements made between intake and 1-year follow-up were sustained at 3-years.
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 Table 7.2(h) HIV, Hepatitis B and Hepatitis C Status
Intake 1-year 3-years
n % n % n %
HIV status
Positive 7 1.7 10 3.3 16 4.5
Negative 310 76.7 122 40.0 91 25.5
Awaiting results 10 2.5 5 1.6 9 2.5
Never tested at intake/not tested in 
last six months at 1-year and 3-years 43 10.6 162 53.1 234 65.5
Do not know if tested 13 3.2 2 0.7 1 0.3
Tested but missing value answered 21 5.2 4 1.3 6 1.7
Hepatitis B status
Positive 9 2.2 3 1.0 4 1.1
Negative 239 59.2 79 25.9 97 27.2
Awaiting results 23 5.7 8 2.6 9 2.5
Never tested at intake/not tested in 
last six months at 1-year and 3-years 72 17.8 208 68.2 240 67.2
Do not know if tested 30 7.4 3 1.0 5 1.4
Tested but missing value answered 31 7.7 4 1.3 2 0.6
Hepatitis C status
Positive 144 35.6 114 37.4 129 36.1
Negative 122 30.2 42 13.8 50 14.0
Awaiting results 20 5.0 3 1.0 7 2.0
Never tested at intake/not tested in 
last six months at 1-year and 3-years 69 17.1 141 46.2 165 46.2
Do not know if tested 26 6.4 2 0.7 2 0.6
Tested but missing value answered 23 5.7 3 1.0 4 1.1
 Note: Some of these results are implicit from other responses. For example, if it was reported on a questionnaire that a respondent ‘has 
HIV problems’, then that participant is deemed to be HIV-positive. If HIV-negative at 3-years, then HIV-negative at 1-year and at intake.
 Risk Behaviour
At intake participants were asked in relation to HIV, hepatitis B and hepatitis C whether they had ever been 
tested for these infections, if they had ever received a positive or negative response to a blood test and if 
they were awaiting the results of such a test(s). At 1- and 3-year follow-up, participants were asked slightly 
different questions in that they were asked whether, in the last six months, they had been tested for HIV, 
hepatitis B or hepatitis C. If they responded that they had, they were asked if they had received the results 
of those tests and what the test outcome had been.
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From Table 7.2(h), it can be seen that respondents who tested positive for HIV increased from 2% (n=7/404) 
of the cohort at intake to 3% (n=10/305) of those interviewed at 1-year and again increased to 5% (n=16/357) 
of those interviewed at 3-years. Of those positive at 1-year, four had not indicated a positive status at intake 
(one was HIV-negative, one did not know their status and two had never been tested). Of those positive at 
3-years, ten had not indicated a positive status at intake (six were negative, two were awaiting test results, 
one did not know their status and one had never been tested).
Also of the group who were positive at 3-years, three had not indicated a positive result at 1-year follow-up 
(one was negative, and two had not been tested).
Individuals who had a negative status for HIV showed a noticeable reduction from 77% (n=310) at intake to 
40% (n=112) at 1-year and again reduced to 26% (n=91) at 3-years. This reduction in negative test results for 
HIV is explained by 11% (n=43) reporting never tested at intake, 53% (n=162) reporting they were not tested  
in the last six months at 1-year, and 66% (n=234) reporting they were not tested in the last six months at  
3-year follow-up.
The percentage that tested positive for hepatitis B was 2% (n=9) at intake, 1% (n=3) at 1-year and 1% (n=4) at  
3-year follow-up, while the figures for those who tested negative were 59% (n=239) at intake, 26% (n=79)  
at 1-year and 27% (n=97) at 3-year follow-up. These reductions from intake to 1- and 3-year follow-up for 
positive and negative outcomes are explained by 18% (n=72) never tested at intake, 68% (n=208) were not 
tested in the last six months at 1-year and 67% (n=240) were not tested in the last six months at 3-year 
follow-up.
Hepatitis C results highlight the larger percentage of respondents infected with hepatitis C in comparison 
to hepatitis B or HIV, with those testing positive remaining relatively constant at about 36% over the 
duration of the study. At intake 17% (n=69) were never tested, at 1-year 46% (n=141) were not tested in the 
previous six months, and at 3-years 46% (n=165) were not tested in the previous six months.
With so many reporting they were not tested at 1-year and 3-years, the proportion of participants positive 
for HIV, hepatitis B, and hepatitis C could be higher than just those who recently tested positive.
 Injecting-related Risk Behaviour
An improvement in injecting-related risk behaviour is evident in Table 7.2(i). There was a decline in the 
number of participants reporting injecting any drug over time. In the 90 days leading up to intake, 44% 
(n=177) of the cohort were injecting with 27% (n=46) injecting on a daily basis and 38% (n=65) injecting on a 
very frequent basis. At 1-year, 29% (n=88) of participants were injecting, representing a significant reduction 
(p<0.001), with 19% (n=16) injecting daily and 27% (n=23) injecting very frequently. A significant reduction 
(p<0.001) can also be seen between intake and 3-years with 28% (n=98) injecting at the 3-year time point,  
of whom 28% (n=27) were injecting infrequently, 22% (n=21) were injecting frequently, 21% (n=20) were 
injecting between 25 and 79 days and 30% (n=29) were injecting on a daily basis.
The figures reported for borrowing and lending of needles vary in terms of frequency, with participants 
reporting using needles after someone else on one occasion rising from 7% (n=11) at intake to 8% (n=7) at  
1-year follow-up and decreasing to 5% (n=5) at 3-year follow-up. Respondents using needles after someone 
else more than once showed a reduction from 5% (n=9) at intake to 1% (n=1) at 1-year follow-up and rose  
to 7% (n=7) at 3-year follow-up.
In terms of the reporting of shared needles among those respondents who reported injecting in the last  
90 days prior to interview, 88% (n=150) reported never using a needle after someone in the last 30 days  
at intake and 10% (n=17) reporting that needles they used had been used by someone after them. These 
percentages remained fairly constant across the three interview time points. Among those respondents 
who reported injecting in the last 90 days, the number of participants who reported re-using their own 
needles showed an increase across time. At intake, 37% (n=49) re-used their own needles more than once 
compared to 41% (n=32) at 1-year follow-up and 58% (n=50) at 3-year follow-up.
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 Table 7.2(i) Injecting-related Risk Behaviour
Intake 1-year 3-years
n % n % n %
Injected in the last 90 days 177 44.0ab 88 28.9a 98 27.5b
1Frequency of injecting in the last 90 days
Infrequent (1-9 days) 40 23.5 32 37.2 27 27.8
Frequent (10-24 days) 19 11.2 15 17.4 21 21.6
Very frequent (25-79 days) 65 38.2 23 26.7 20 20.6
Daily (80-90 days) 46 27.1a 16 18.6a 29 29.9
1Used needle after someone in last 30 days
No times 150 88.2 75 90.4 82 87.2
One time 11 6.5 7 8.4 5 5.3
More than once 9 5.3 1 1.2 7 7.4
1Someone used needle after you in last 30 days
No times 150 89.8 72 86.7 82 87.2
One time 9 5.4 5 6.0 4 4.3
More than once 8 4.8 6 7.2 8 8.5
1Re-used own needles in last 30 days
No times 81 61.4b 43 54.4 31 36.0b
One time 2 1.5 4 5.1 5 5.8
More than once 49 37.1 32 40.5 50 58.1
1Used filter, spoon or flush water after someone
No times 137 89.0 74 91.4 77 81.9
One time 6 3.9 1 1.2 6 6.4
More than once 11 7.1 6 7.4 11 11.7
 Note: Matching subscript letters denote statistical significance.
 1 Of those who injected in the last 90 days.
There was a decrease in the proportions who reported re-using their own needles from intake to 1-year 
(p=0.025) among the sub-population of respondents who reported injecting in the last 90 days prior to 
interview. This appears to be attributable to a reduction in the number of times individuals reported never 
re-using own needles from 61% (n=81) to 36% (n=31) at 3-year follow-up and an increase in those re-using 
needles more than once. In contrast, for those who shared injecting paraphernalia a different pattern 
emerges. While the figure for participants who reported never sharing filter/spoon/flush water after 
someone else is relatively high at intake – 89% (n=137) – the figure falls, although not significantly, to  
just under 82% (n=77) at 3-year follow-up. Frequency figures for those who shared both at one time  
and more than once show an increase, although insignificant, between intake and 3-year follow-up.
 Table 7.2(j) Mean Number of Days Injecting
Intake 1-year 3-years
Mean (s.d.) Mean (s.d.) Mean (s.d.)
1Days injected in the last 90 days 47.3 (33.8)a 31.9 (32.6)a 39.6 (36.3)
1Times injected on typical day in the last 90 days 4.0 (4.8) 2.9 (4.3) 3.0 (2.4)
 Note: Matching subscript letters denote statistical significance.
 1 Of those who have injected in the last 90 days.
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Among respondents who injected in the last 90 days analysis of the mean number of injecting days  
revealed a significant reduction from 47.3 days at intake to 31.9 days at 1-year follow-up.
A reduction is also evident for the number of times injecting on a daily basis, although not significant,  
with the mean number of times injecting on a day reducing from approximately four times a day at intake 
to three times a day at both 1-year and 3-year follow-up (see Table 7.2(j)).
 Sexual Health
Table 7.2(k) provides information on the sexual behaviour of participants across a number of categories. 
While the percentage of participants engaging in sexual activity with a regular partner is similar across  
all time periods, the percentage of those having sex with someone other than a regular partner reduced 
significantly from 33% (n=76) at intake to just over 19% (n=45) at 3-year follow-up. Sexual history in the  
last 90 days, observed frequencies of condom usage with a regular partner and observed frequencies  
of condom usage with someone other than a regular partner remained relatively consistent over the  
three interview time points.
 Table 7.2(k) Sexual Health
Intake 1-year 3-years
n % n % n %
Sexual history in the last 90 days
Participants having sex 261 68.1 185 64.0 235 68.3
Participants not having sex 122 31.9 104 36.0 109 31.7
1,2Sexual partners in the last 90 days
Having sex with a regular partner 203 82.5 152 84.0 202 86.0
Having sex with someone  
other than a regular partner 76 33.2b 39 12.8 45 19.2b
2Condom use with regular partner
Always used condom 47 24.4 37 28.0 44 22.4
Sometimes used condom 19 9.8 13 9.8 17 8.7
Never used condom 127 65.8 82 62.1 135 68.9
2Condom use with someone other than regular partner
Always used condom 29 46.0 13 46.4 25 58.1
Sometimes used condom 11 17.5 6 21.4 9 20.9
Never used condom 23 36.5 9 32.1 9 20.9
 Note: Matching subscript letters denote statistical significance.
 1 These categories are not mutually exclusive.
 2 Refers only to those who reported having sex in the last 90 days.
 Overdose
Table 7.2(l) displays the incidence of non-fatal overdose at intake, 1-year and 3-year follow-up. At intake, 
93% (n=366) of respondents had not overdosed in the last 90 days with 7% (n=26) recording an overdose 
one or more times. These percentages remained fairly constant throughout the study with 4% (n=13) and  
6% (n=22) reporting overdose one or more times at 1-year and 3-year follow-up, respectively. However,  
there was no evidence of a significant difference between these percentages across any of the time points.
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 Table 7.2(l) Non-fatal Overdose
Intake 1-year 3-years
n % n % n %
Non-fatal overdose in the last 90 days
Zero 366 93.4 287 95.7 334 93.8
One or more times 26 6.6 13 4.3 22 6.2
At 1-year, 18% (n=6/33) of those not in treatment had experienced an overdose in the last 90 days. This 
compares with 4% (n=7/182) of those in treatment and using drugs experiencing an overdose in the same 
time frame and the result is significant (p=0.007). The same analysis carried out at 3-years shows that 7% 
(n=4/60) of those not in treatment had experienced an overdose in the last 90 days, while 9% (n=17/191)  
of those in treatment and using drugs had had such an experience, however, this result was not significant.
Overdose is often associated with recent detoxification programmes or leaving prison. Individuals may 
return to use at the levels to which they were accustomed before stopping for a period of time, and thus 
accidentally overdose. ROSIE asked participants if they had started a detoxification in the last six months. 
At 1-year 8% (n=1/12) of those who had recently completed a detoxification had experienced an overdose  
in the last 90 days, while at 3-years 0% (n=0/9) of those who reported finishing a detoxification programme 
in the last six months had overdosed.
7.3 Discussion and Conclusion
Improved health outcomes are a crucial element of the treatment process. Physical or mental health 
problems can affect the treatment given and are frequently associated with poorer treatment outcomes. 
For the population as a whole, only poor appetite significantly reduced for the reported mean number of 
days on which physical symptoms were experienced at 3-year follow-up. Figures for the sub-sample reveal a 
corresponding significant decline in poor appetite while the mean number of days experienced on which 
stomach pains were experienced showed a significant rise at 3-year follow-up. Interestingly, all symptoms 
with the exception of poor appetite showed a non-significant increase at 1-year follow-up, indicating 
improvements did not occur one year into treatment.
With regard to the mental health outcomes, the frequency of anxiety and depression symptoms showed 
considerable differences at 3-year follow-up. In terms of anxiety symptoms for the population as a whole, 
feeling tense, nervous/shakiness inside and panic attacks showed considerable reductions at 3-year follow-up. 
Similar improvements were observed for depressive symptoms such as feeling hopeless about the future, 
feelings of worthlessness, feeling no interest in things and feeling lonely, with participants experiencing fewer 
of these symptoms. Within the sub-sample, only feeling tense showed a significant reduction. On the other 
hand all depressive symptoms, with the exception of thoughts of ending your life, reduced significantly at 
3-year follow-up. Thus, the improvements observed in depressive symptoms were not mirrored in anxiety 
symptoms at 3-year follow-up.
With regard to infections such as HIV, hepatitis B and hepatitis C and sexual health, there were no notable 
results. Improvements in injecting-related risk behaviour of participants were evident throughout the study. 
For example, the proportion of participants injecting decreased at 3-year follow-up and reductions were also 
found for those injecting on a very frequent basis. In terms of sharing needles, the number of respondents 
who never shared or borrowed needles was high at treatment-intake and remained stable at 3-year follow-up. 
Furthermore, the proportion of participants who never shared other injecting paraphernalia remained 
consistently high throughout. Respondents’ injecting behaviour revealed a non-significant reduction in the 
number of times injecting on a daily basis, dropping from four to three times a day. Incidents of overdose 
remained fairly constant across time with figures showing a minor reduction at 1-year follow-up but 
increasing back to intake level at 3-years.
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CHAPTER EIGHT: SOCIAL FUNCTIONING
8.1 Introduction
With the emergence of the National Drugs Strategy (2001-2008), the importance of rehabilitation, 
employment and social functioning of drug users has become increasingly acknowledged. This chapter 
provides information on outcomes of particular relevance to the National Drugs Strategy.
In order for drug users to enter recovery they must believe that being abstinent from drugs is more 
desirable than using drugs and they must ‘fi nd a purpose in their drug-free lives’ (Keane, 2007). In a recent 
study conducted in Scotland, it was found that working was integral to recovery as it provided a distraction 
and structure to the day (Neale, 2002). It also gave participants self-esteem and pride and enabled them 
to avoid being stigmatised. Furthermore, the National Drugs Strategy (2001-2008) highlights that access to 
accommodation is central to the drug treatment process. In other words, lack of accommodation for drug 
users can undermine their treatment process.
Social support from the family and wider social networks is also increasingly seen as an important factor 
in the overall rehabilitation process. Research shows that those suffering from addiction problems but 
who have strong social support are more likely to be retained in treatment (McLellan et al, 1998) and are 
less likely to relapse (Havassy & Hall, 1991). The report of the Working Group on Drug Rehabilitation (2007) 
emphasises that drug use may deteriorate if a person has diffi culties such as unemployment, access to 
housing and poor relationships with family and friends.
In this chapter the key outcomes that impact on social functioning are considered. These are participation 
in training and employment, accommodation status and relationship with family, friends and children. 
These fi ndings will be presented for intake, 1-year and 3-years, describing any differences across the time 
points. Finally, there is a brief discussion relating the ROSIE fi ndings to the current international literature.
8.2 Results
 Training and Employment
Table 8.2(a) shows that there is a signifi cant increase in the number of participants undertaking training 
courses at 1-year (p<0.001) and 3-years (p<0.001) in comparison to intake. At 3-years, 11% (n=40) of participants 
were attending some sort of vocational training, 8% (n=30) were attending community employment (CE) 
schemes, 8% (n=29) a personal development and life skills course and 4% (n=15) further education. In many 
cases, these fi gures were more than double those reported at intake.
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 Table 8.2(a) Training and Education Status
Intake 1-year 3-years
n % n % n %
Been on training courses over the last six months
Yes 63 15.6ab 88 29.0a 117 32.8b
No 340 84.4 215 71.0 240 67.2
Type of training course in last six months
Community employment scheme 15 3.7 23 7.5 30 8.4
Personal development/life skills 11 2.7 18 5.9 29 8.1
Second/third level course 5 1.2 21 6.9 15 4.2
Vocational: computers 9 2.2 6 2.0 11 3.1
Vocational: building/machinery/driving 10 2.5 7 2.3 16 4.5
Vocational: other 9 2.2 11 3.6 13 3.6
 Note: Matching subscript letters denote statistical significance.
 Table 8.2(b) Employment and Income Status
Intake 1-year 3-years
n % n % n %
1Usual occupation in the last 90 days
Working (full-time/part-time) 73 18.3 57 18.7 85 23.8
Casual work (cash-in-hand work) 71 17.8 62 20.3 69 19.3
Community employment scheme 15 3.8 23 7.5 30 8.4
In prison 36 9.0 20 6.6 27 7.6
In residential treatment 5 1.3 5 1.6 2 0.6
Home duties 4 1.0 8 2.6 8 2.2
Student 0 0.0 3 1.0 1 0.3
Disability 24 6.0 22 7.2 26 7.3
Not working 171 42.9 105 34.4 109 30.5
Recent employment
Employed at some point  
in the last 90 days 84 21.3b 70 23.0c 107 30.1bc
Currently employed 64 16.0b 65 21.3c 102 28.7bc
2Main sources of income in the last 90 days
Wage/salary 83 20.9b 59 19.3c 95 26.7bc
Family/partner 113 28.3ab 57 18.7ac 42 11.8bc
Social welfare 309 77.4 236 77.4c 260 72.8c
Drug dealing 101 25.3ab 31 10.2a 28 7.9b
Other crime 142 35.7ab 32 10.5a 45 12.6b
 Note: Matching subscript letters denote statistical significance.
 1 This refers to participants’ usual occupations in the last 90 days i.e., what their employment status was for most of the time.
 2 These categories are not mutually exclusive.
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From Table 8.2(b), improvements in participants’ recent employment status can be seen and there is a 
significant increase (p<0.001) between intake and 3-years for those currently employed, with figures rising 
from 16% (n=64) to 29% (n=102). It is also evident that the number of participants deemed ‘not working’ 
decreased from 43% (n=171) at intake to 31% (n=109) at 3-years. In this case, participants were regarded as 
‘not working’ if they had not engaged in any type of employment, for example, casual work or a community 
employment scheme, in the last 90 days and there was no specific reason why they could not work, for 
example, that they were in prison or in treatment.
Regarding main sources of income, the proportion reporting drug dealing and other crime as a main source 
of income reduced significantly (p<0.001) at 1-year and 3-years in comparison to intake.
Income from family/partner also dropped significantly when comparing intake and 1-year (p=0.001), intake 
and 3-years (p<0.001) and 1-year and 3-years (p=0.030). Furthermore, a significantly smaller proportion of 
participants reported social welfare as a main source of income when comparing 1-year and 3-years (p=0.023). 
It is interesting to note that the proportion of participants reporting a wage/salary as a main source of 
income was significantly higher at 3-years when compared to the figures reported for intake (p=0.018)  
and 1-year (p<0.001). These figures indicate that participants are becoming more self-sufficient.
 Table 8.2(c) Accommodation Status
Intake 1-year 3-years
n % n % n %
Current accommodation
Family home 118 29.7 85 28.1 95 26.6
Drug treatment residence 115 29.0 9 3.0 4 1.1
Own house/flat or rental 101 25.4 131 43.4 168 47.1
Prison 19 4.8 22 7.3 28 7.8
3Insecure tenure 11 2.8 21 7.0 25 7.0
4Homeless 33 8.3 34 11.3 37 10.4
1Accommodation in the last 90 days
Family home 182 46.8ab 105 34.5a 113 31.7b
Drug treatment residence 120 30.2ab 24 7.9ac 7 2.0bc
Own house/flat or rental 134 33.8ab 137 45.1a 175 49.0b
Prison 49 12.4 27 8.9 34 9.5
3Insecure tenure 40 10.2 29 9.5 30 8.4
4Homeless 58 14.7b 36 11.8 40 11.2b
Usually lives with
Partner/spouse 30 7.6 27 9.0 45 12.7
Parents 148 37.7 85 28.4 83 23.4
Alone 47 12.0 49 16.4 53 14.9
2Children 32 8.1 24 8.0 26 7.3
2Parents and children 17 4.3 6 2.0 12 3.4
2Partner/spouse and children 44 11.2 52 17.4 62 17.5
Other 75 19.1 56 18.7 74 20.9
 Note: Matching subscript letters denote statistical significance.
 1 These categories are not mutually exclusive.
 2 Includes children over the age of 18 years.
 3 Insecure tenure refers to participants who were living with friends.
 4 Homeless refers to participants who were living in hostels, shelters, bed and breakfast accommodation or who had no fixed abode.
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Table 8.2(c) shows that there is a significant increase in the number of participants who reported living in 
their own or rented accommodation in the last 90 days when comparing intake and 1-year (p=0.005), and 
intake and 3-years (p<0.001), with figures rising from 34% (n=134) at intake to 45% (n=137) at 1-year and 49% 
(n=175) at 3-years. The number of homeless participants decreased significantly from intake to 3-years from 
15% (n=58) at intake to 11% (n=40) at 3-years (p=0.040).
 Social Support
Table 8.2(d) displays the participants’ contact with family and friends. There is a significant decrease in 
contact with father when comparing intake and 1-year (p=0.002), and intake and 3-years (p=0.015), with 
participants having contact with their father on a mean of 43.4 days at intake, 35.2 days at 1-year and 37.4 
days at 3-years. There was also a significant decrease in contact with siblings from 44.9 days at baseline to  
41.3 days at 3-years (p=0.007). These differences may be explained by the number of participants who have 
moved out of the family home.
 Table 8.2(d) Contact with Family and Friends
Intake 1-year 3-years
Mean (s.d.) Mean (s.d.) Mean (s.d.)
Number of days contact in the last 90 days
Partner 75.5 (26.4)b 81.6 (20.9) 82.0 (19.2)b
Mother 54.1 (37.5) 52.9 (37.7) 52.4 (36.4)
Father 43.4 (39.6)ab 35.2 (38.2)a 37.4 (37.3)b
Siblings 44.9 (39.1)b 42.0 (37.1) 41.3 (36.1)b
Friends 41.6 (39.1) 40.9 (39.9) 45.2 (38.6)
 Note: Matching subscript letters denote statistical significance.
 Table 8.2(e) Conflict with Family and Friends
Intake 1-year 3-years
Mean (s.d.) Mean (s.d.) Mean (s.d.)
Number of days conflict in the last 90 days
Partner 10.1 (21.6) 6.7 (17.6) 5.5 (13.3)
Mother 8.2 (19.9)ab 4.1 (14.6)a 3.6 (13.9)b
Father 8.2 (20.8)b 5.4 (17.1) 3.9 (15.7)b
Siblings 5.2 (18.1)b 3.2 (12.4) 2.0 (11.1)b
Friends 2.0 (9.4)b 1.4 (9.2) 0.5 (3.4)b
 Note: Matching subscript letters denote statistical significance.
Table 8.2(e) presents the reduction in conflict across time with family and friends. Mean days conflict with 
mother has reduced significantly from 8.2 days at intake to 4.1 days at 1-year (p=0.032) and 3.6 days at 3-years 
(p=0.010). Mean days conflict with father (p=0.003), siblings (p=0.005) and friends (p=0.028) also decreased 
significantly from intake to 3-years, with the largest decrease occurring in the number of days conflict with 
mother. These differences may be explained through the decreased contact participants had with family 
members.
77The ROSIE Study Drug Treatment Outcomes in Ireland
Table 8.2(f) displays participants’ self-assessment of relationships with their children. When analysing the 
data, a significant difference in the quality of the relationships with children reported for participants at 
intake and at 3-years (p=0.004) was found. This difference appears to be due to a difference in the percentage 
of participants reporting a very good relationship at intake and those reporting a very good relationship at 
3-years (57% at intake versus 68% at 3-years). This indicates an overall improvement in relationships between 
participants and their children.
 Table 8.2(f) Relationship with Children
Intake 1-year 3-years
n % n % n %
Type of relationship with children
Very good 119 56.9 111 63.1 148 67.6
Good 41 19.6 36 20.5 36 16.4
Okay/alright 19 9.1 11 6.3 9 4.1
Poor 7 3.3 8 4.5 5 2.3
Very poor 23 11.0 10 5.7 21 9.6
Table 8.2(g) describes the type of contact participants had with their children. Participants who had 
contact with all their children daily increased from 47% (n=96) at intake to 57% (n=95) at 1-year and 53% 
(n=116) at 3-years.
It is also evident that the number of participants who did not see any of their children in the last 90 days 
improved from 14% (n=29) at intake to 10% (n=17) at 1-year. However, this figure reduced back to 14% (n=31)  
at 3-years.
 Table 8.2(g) Contact with Children
Intake 1-year 3-years
n % n % n %
Contact with children in the last 90 days
Contact with all children daily 96 46.8 95 56.9 116 53.0
Contact with all children at least one day 166 82.2 143 85.6 176 80.4
No contact with at least one child 36 17.8 24 14.4 41 18.7
Did not see any of children 29 14.1 17 10.1 31 14.1
 Contact with Services
Table 8.2(h) presents the services attended by participants for a medical condition in the last 90 days. It is 
shown that the number of participants attending hospital and staying overnight increased significantly from 
9% (n=34) at intake to 16% (n=56) at 3-years (p=0.004). The amount of participants attending a GP other than 
their methadone GP also increased significantly from 34% (n=124) at intake to 46% (n=140) at 1-year (p=0.012). 
Finally, the number of participants visiting an outpatient department/receiving community treatment also 
increased significantly from 13% (n=49) at intake to 20% (n=73) at 3-years (p=0.006). However, the reasons for 
these increases are unclear and may be due to a number of differing reasons. For example, this could indicate 
an improvement in care for conditions such as HIV or hepatitis rather than an increase in health problems.
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 Table 8.2(h) Treatment for a Medical Condition
Intake 1-year 3-years
n % n % n %
Treatment received in the last 90 days
Attended hospital and stayed overnight 34 8.7b 34 11.1 56 15.7b
Attended Accident and Emergency unit 67 17.4 53 17.4 82 23.0
Visited a GP (not methadone GP) 124 33.6a 140 45.9a 140 39.2
Visited an outpatient department/
received community treatment 49 12.7b 59 19.4 73 20.4b
 Note: Matching subscript letters denote statistical significance.
 Table 8.2(i) Number of Times Attended a Medical Service
Intake 1-year 3-years
Mean (s.d.) Mean (s.d.) Mean (s.d.)
1Number of times attended service in the last 90 days
Number of days overnight stay in hospital 6.3 (8.7) 6.9 (10.8) 11.2 (19.0)
Number of visits to Accident and Emergency unit 1.3 (0.8) 1.4 (1.2) 1.4 (1.0)
Number of visits to a GP (not methadone GP) 3.7 (4.1) 4.2 (4.8) 4.2 (11.1)
Numbers of visits for outpatient appointment/
community treatment 4.2 (7.4) 5.0 (14.0) 3.5 (5.5)
 1 Of those who attended these services in the last 90 days.
Table 8.2(i) displays the number of times participants attended a medical service in the last 90 days.  
There was an increase in the number of days participants spent overnight in a hospital from 6.3 days  
at intake to 11.2 days at 3-years. However, this difference was not statistically significant.
 Table 8.2(j) Social Support Contacts
Intake 1-year 3-years
n % n % n %
Social support contacts in the last 90 days
Had contact with social services 25 6.4 33 10.9 35 9.8
Had contact about employment, 
training or education 37 10.4ab 131 43.2ac 115 32.2bc
Had contact about social welfare 115 31.1 85 28.1 98 27.5
Had contact about housing issues 55 14.7ab 93 30.7a 96 26.9b
 Note: Matching subscript letters denote statistical significance.
Table 8.2(j) shows a significant increase in the number of participants who had contact with someone about 
employment, training or education issues between intake and 1-year (p<0.001) and intake and 3-years (p<0.001), 
with a significant decrease between 1- and 3-years (p=0.002). However, it should be noted that this decrease was 
minimal in comparison to the increase between intake and 1-year, and the proportion in contact with someone 
regarding employment, training or education at 3-years was significantly larger than the proportion at intake.
In terms of figures, 10% (n=37) reported contact with someone regarding employment, training or education 
at intake compared to 43% (n=131) at 1-year and 32% (n=115) at 3-years. Further, it was to be expected that this 
figure would reduce at 3-years since more people were in stable employment by this time. There was also 
an increase in the numbers seeking advice about housing issues when comparing intake and 1-year (p<0.001) 
and intake and 3-years (p<0.001).
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 Table 8.2(k) Number of Times Attended a Social Service
Intake 1-year 3-years
Mean (s.d.) Mean (s.d.) Mean (s.d.)
1Number of times attended service
From social services 3.3 (3.8) 5.1 (5.4) 8.7 (16.2)
About employment, training or education 9.2 (14.3) 7.7 (15.0)c 21.4 (31.3)c
About social welfare 3.6 (8.6) 3.1 (3.2) 2.6 (3.1)
About housing issues 10.3 (19.3) 6.6 (13.7) 6.8 (13.8)
 Note: Matching subscript letters denote statistical significance.
 1 Of those who attended these services in the last 90 days.
Table 8.2(k) shows the mean number of times on which participants attended particular services. The mean 
number of times participants saw someone about employment, training or education in the last 90 days 
increased significantly (p=0.018) from 7.7 times at 1-year to 21.4 times at 3-years. This may show an increased 
desire to participate in employment, training or education by respondents. There is also a decrease in the 
number of times participants saw someone about housing issues. This decreased from 10.3 times at intake 
to 6.8 times at 3-years. However, this reduction was not statistically significant.
8.3 Discussion and Conclusion
The various aspects of social functioning which include training, education, employment, accommodation 
status and social support from family and friends, are all regarded as important in the overall treatment 
process. Outcomes at 1- and 3-years showed considerable improvements were made in all these areas. 
Results indicated that drug users who had participated in treatment were both willing and able to take  
up training, education and employment opportunities.
This is evident from the increases in the numbers of those participating in training courses and engaging  
in employment. Since access to employment is an important aspect of a successful recovery process  
(Cox & Lawless, 2000), there is clearly an encouraging picture emerging with respect to the prospects  
of drug users following treatment.
Positive results were also evident for the acquirement of secure accommodation and the move towards a 
more independent lifestyle. Findings from ROSIE show that the number of those with insecure accommodation 
in the last 90 days decreased significantly between intake and 3-years. Significant increases were apparent 
for those living in their own house or in rented accommodation between intake and 1-year and 1-year and  
3-years. Obtaining secure accommodation is important if improved treatment outcomes are to be achieved, 
as according to Keane (2007), ‘insecure accommodation is closely associated with problematic drug use’, insecure 
accommodation is defined as being in an institution such as prison or residential treatment, being in homeless 
accommodation or having unstable accommodation. ROSIE showed improvements for all of these categories, 
with the exception of being in prison, which remained relatively unchanged over the 3-year period.
Finally, levels of social support, defined as ‘resources provided by other persons’ (Cohen and Syme, 1985), 
also increased over the 3-year period. Levels of contact with family members and friends were generally 
found to have increased while levels of conflict with family and friends had decreased. This result was also 
very positive as higher levels of social support are linked to better treatment outcomes and to better 
health outcomes in general (Stansfield, 2006).
Social functioning is an important aspect of the drug treatment process. Significant improvements were 
seen over time regarding involvement in training and employment. Participants appeared to be more self-
sufficient and less dependent on family and social welfare for sources of income and accommodation, with 
increased numbers of participants currently living in their own house or rented accommodation. Relationships 
with family, friends and children had also all improved over time. On the whole, participants’ social functioning 
improved significantly over the 3-year follow-up period.
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CHAPTER NINE: OUTCOMES FOR 
THE PER-PROTOCOL POPULATION
9.1 Introduction
While the previous chapters present fi ndings for the full population, that is, those who completed an 
intake interview and who may or may not have completed interviews at 1-year and 3-years, this chapter 
presents results for only those participants who completed all three interviews, that is, the per-protocol 
group (n=289). This is particularly useful when tracking changes over the 3-year follow-up period, as results 
for these individuals are present at each of the three time points.
A more comprehensive view of treatment impact is provided by the per-protocol population. In order 
to better illustrate the effects of treatment, fi ndings in this chapter are presented in a manner which 
focuses on changes as they occurred at different points over time. Knowledge of how and when these 
changes occur is vital in understanding how drug users respond to treatment over an extended period, 
as improvements that are evident early on are not always sustained in the long term. Furthering this 
knowledge is invaluable to those responsible for planning treatment services as provision may be put 
in place to meet the changing needs of individuals in treatment over time. Other than this emphasis 
on changes over time, results in this chapter are presented in the order of drug use, crime, health and 
risk behaviour and fi nally, social functioning.
9.2 Drug Use
 Current Drug Use
A comparison between intake and 1-year follow-up for various types of drug use over the 90 days prior 
to interview showed that there were signifi cant improvements for heroin (p<0.001), cocaine (p<0.001), crack 
cocaine (p<0.001), non-prescribed methadone (p<0.001), benzodiazepines (p<0.001) and cannabis (p<0.001). 
At 1-year the most notable reductions were for heroin use which dropped from 81% (n=229) at treatment-
intake to 47% (n=135) and cocaine which dropped from 44% (n=128) at treatment-intake to 20% (n=58). 
Substantial reductions were also evident at 1-year follow-up for non-prescribed methadone which fell from 
44% (n=127) at treatment-intake to 14% (n=41) and also for benzodiazepines which fell from 44% (n=124) at 
treatment-intake to 23% (n=67) (see Table 9.2(a)).
A comparison between intake and 3-year follow-up showed that signifi cant improvements were still 
evident three years after the fi rst treatment episode. Reductions were found for the use of heroin (p<0.001), 
cocaine (p<0.001), crack cocaine (p<0.001), non-prescribed methadone (p<0.001), benzodiazepines (p<0.001) 
and cannabis (p<0.001). Similar to 1-year follow-up, the most notable reductions at 3-year follow-up were 
for heroin use which reduced from 81% (n=229) to 47% (n=135), cocaine which reduced from 44% (n=128) 
to 19% (n=54) and non-prescribed methadone which fell from 44% (n=127) to 13% (n=36).
A comparison between 1-year and 3-year follow-up revealed that there was a signifi cant difference 
for the use of benzodiazepines (p=0.020) which increased from 23% (n=67) at 1- year follow-up 
to 30% (n=87) at 3-year follow-up. However, despite the increased use of benzodiazepines 
at 3-year follow-up, this still represents a signifi cant improvement compared to intake 
use. No signifi cant differences were found for any other form of drug use. This 
indicates that following the initial follow-up, participants experienced a period 
of stabilisation whereby improvements achieved at 1-year follow-up were 
retained at 3-year follow-up with no further signifi cant differences found 
at this point.
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 Table 9.2(a) Drug Use
Intake 1-year 3-years
n % n % n %
Drug use in the last 90 days
Heroin 229 80.6ab 135 46.7a 135 46.7b
Cannabis 175 65.3ab 151 52.8a 146 50.7b
Cocaine 128 44.3ab 58 20.1a 54 18.8b
Benzodiazepines 124 43.7ab 67 23.2ac 87 30.2bc
Non-prescribed methadone 127 44.4ab 41 14.2a 36 12.5b
Crack cocaine 46 15.9ab 17 5.9a 18 6.3b
 Note: Matching subscript letters denote statistical significance.
In order to provide a more accurate picture of the findings for the frequency of drug use over the 90 days 
prior to interview, the results for the population as a whole and the sub-sample who consumed these drugs 
are presented separately. Regarding the sub-sample, it should be noted that only those who were using at 
the particular time points under investigation were included. Therefore, it was not expected that major 
differences would be apparent over time. However when these differences did occur, it reflected the  
drug users’ habits, rather than the habits of the opiate using population in treatment as a whole.
A comparison between intake and 1-year follow-up for the frequency of drug use over the 90 days prior to 
interview showed significant improvements for the mean number of days drugs were used. Heroin (p<0.001), 
cocaine (p<0.001), crack cocaine (p=0.019), non-prescribed methadone (p<0.001), benzodiazepines (p<0.001) 
and cannabis (p<0.001) all showed significant reductions compared to intake levels. The most substantial 
reduction was for the frequency of heroin use which fell from 42.3 to 15.2 days. Substantial reductions  
at 1-year follow-up were also evident for cocaine which reduced from 7.9 to 3.3 days, for benzodiazepines 
which reduced from 15.5 to 5.3 days, and for non-prescribed methadone which reduced from 13.2 to 4 days 
(see Table 9.2(b)).
A comparison between intake and 3-year follow-up also showed significant reductions in the mean  
number of days on which drugs were used. Reductions were apparent for heroin (p<0.001), cocaine (p<0.001), 
non-prescribed methadone (p<0.001), benzodiazepines (p=0.001) and cannabis (p<0.001). The only drug which 
did not have a significant reduction at 3-year follow-up, compared to intake, was crack cocaine. The most 
notable reductions were for the frequency of heroin use which reduced from 42.3 to 20.1 days, cannabis  
use which reduced from 40.4 to 25.4 days and non-prescribed methadone which fell from 13.2 to 2.0 days.
A comparison of 1- and 3-year follow-up revealed a number of significant differences. There was a significant 
improvement in the mean number of days on which cannabis was used with a reduction from 32.1 to 25.4 
days (p=0.002). However, both the frequency of heroin use (p=0.009) and benzodiazepine use (p=0.008) 
increased significantly at 3-year follow-up compared to 1-year follow-up, with frequency of heroin use 
increasing from 15.2 to 20.1 days while frequency of benzodiazepine use increased from 5.3 to 9.2 days. It 
should be noted that although there were increases between 1- and 3-year follow-up, the levels did not 
reach those reported at intake. This perhaps indicates that the greatest improvements are achieved within 
the first year after treatment entry, after which there may be some disimprovement in outcomes, but not  
to such an extent that the individual returns to intake levels of drug use.
For the sub-sample who had used drugs in the last 90 days, significant differences were found between intake 
and 1-year follow-up for frequency of use of heroin (p<0.001) with the frequency of heroin use decreasing 
from 52.7 days at intake to 32.5 days at 1-year follow-up and for frequency of use of benzodiazepines (p=0.005), 
decreasing from 35.4 days at intake to 22.8 days at 1-year.
Significant differences were also evident for the sub-sample between intake and 3-year follow-up for cannabis 
(p<0.001) and non-prescribed methadone (p=0.020) but not for heroin use. Here frequency of cannabis use 
decreased from 61.9 days to 50.3 days and frequency of non-prescribed methadone decreased from 29.7 days 
to 16.2 days (see Table 9.2(c)).
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A comparison between 1-year and 3-year follow-up showed that there were significant differences for 
frequency of heroin use (p=0.015) and cannabis use (p<0.001). The frequency of heroin use increased from 
32.5 days at 1-year follow-up to 42.9 days at 3-year follow-up. While this increase still represents a reduction 
compared to intake, it should be noted that intake and 3-year follow-up were not statistically different in 
terms of frequency of heroin use. However, cannabis use decreased from 60.7 days at 1-year follow-up to 
50.3 days at 3-year follow-up. No significant differences were found for the frequency of use of other drugs.
 Table 9.2(b) Mean Days Used: Population
Intake 1-year 3-years
Mean (s.d.) Mean (s.d.) Mean (s.d.)
Mean days used in the last 90 days
Heroin 42.3 (35.3)ab 15.2 (27.6)ac 20.1 (32.3)bc
Cannabis 40.4 (40.3)ab 32.1 (39.8)ac 25.4 (36.0)bc
Benzodiazepines 15.5 (29.3)ab 5.3 (15.9)ac 9.2 (23.2)bc
Non-prescribed methadone 13.2 (24.6)ab 4.0 (16.1)a 2.0 (8.7)b
Cocaine 7.9 (18.0)ab 3.3 (13.0)a 2.9 (12.0)b
Crack cocaine 2.3 (10.8)a 0.9 (6.4)a 1.2 (7.3)
 Note: Matching subscript letters denote statistical significance.
 Table 9.2(c) Mean Days Used: Of Those Who Used
Intake 1-year 3-years
Mean (s.d.) Mean (s.d.) Mean (s.d.)
Mean days used in the last 90 days
Heroin 52.7 (31.7)a 32.5 (32.7)ac 42.9 (35.3)c
Cannabis 61.9 (34)b 60.7 (35.4)c 50.3 (36.3)bc
Benzodiazepines 35.4 (35.5)a 22.8 (26.4)a 30.8 (33.7)
Non-prescribed methadone 29.7 (29.5)b 28.5 (33.8) 16.2 (20)b
Cocaine 17.8 (23.7) 16.4 (25.3) 15.2 (24.3)
Crack cocaine 14.9 (23.8) 15.6 (22.3) 20.4 (22.8)
 Note: Matching subscript letters denote statistical significance.
In order to provide a more accurate picture of the findings for the mean amounts of drugs used in the last 
90 days prior to interview, the results for the population as a whole and the sub-sample who consumed 
these drugs are presented separately (see Tables 9.2(d) and 9.2(e), respectively).
For the population as a whole, a comparison for the amount of drugs used at intake and 1-year follow-up 
revealed that there were significant differences for heroin (p<0.001), cocaine (p<0.001), non-prescribed 
methadone (p<0.001) and benzodiazepines (p=0.013). No significant differences were found for the amount  
of cannabis used. The amount of heroin used reduced from 0.7 g to 0.2 g, cocaine reduced from 0.9 g to  
0.3 g, non-prescribed methadone reduced from 25.4ml to 7.5ml and benzodiazepines reduced from 38.4mg  
to 23.8mg (see Table 9.2(d)).
A comparison of amounts used at intake and 3-year follow-up revealed somewhat similar results with 
significant improvements for heroin (p<0.001), cocaine (p<0.001), non-prescribed methadone (p<0.001)  
and cannabis (p=0.019).
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Unlike 1-year follow-up however, no significant changes were found for the amount of benzodiazepines used. 
It was found that the amount of heroin used reduced from 0.7g to 0.2g, cocaine use reduced from 0.9g to 
0.3g, non-prescribed methadone reduced from 25.4ml to 7.6ml and cannabis reduced from an average of  
7.1 joints per day to an average of 3.8 joints per day.
A comparison between 1- and 3-year follow-up revealed a significant increase in the amount of benzodiazepines 
used (p=0.036), with the mean amount increasing from 23.8mg at 1-year follow-up to 40.7mg at 3-year 
follow-up. No other significant differences were evident between 1- and 3-years, indicating improvements 
were sustained. The exception to this pattern was cannabis, which did not reduce significantly until 3-year 
follow-up.
 Table 9.2(d) Mean Amounts Used: Population
Intake 1-year 3-years
Mean (s.d.) Mean (s.d.) Mean (s.d.)
1Mean amount used per typical using day in the last 90 days
Heroin (g) 0.7 (0.8)ab 0.2 (0.6)a 0.2 (0.4)b
Cannabis (joints) 7.1 (15.9)b 5.6 (21.3) 3.8 (11.4)a
Cocaine (g) 0.9 (2.3)ab 0.3 (1.1)a 0.3 (0.8)b
Non-prescribed methadone (ml) 25.4 (39.2)ab 7.5 (27.8)a 7.6 (24.8)b
Benzodiazepines (mg) 38.4 (107.5)a 23.8 (124.1)ac 40.7 (147.1)c
 Note 1: Matching subscript letters denote statistical significance.
 Note 2: Crack cocaine was excluded due to inconsistency in how data were reported.
 1 These figures were based on:
a) Heroin: one bag costing €20 and containing on average 0.113g at intake and 1-year, with one bag costing €20 and containing  
on average 0.1g at 3-years.
b) Cocaine: one gram costing €110 at intake, €66 at 1-year and €70 at 3-years.
c) Cannabis: one ounce costing €110 at intake, €100 at 1-year and €198.45 at 3-years (or a joint costing approx 39c at intake, 
approx 35c at 1-year and approx 70c at 3-years).
 Table 9.2(e) Mean Amounts Used: Of Those Who Used
Intake 1-year 3-years
Mean (s.d.) Mean (s.d.) Mean (s.d.)
1Mean amount used per typical using day in the last 90 days
Heroin (g) 0.8 (0.9)ab 0.4 (0.9)a 0.4 (0.5)b
Cannabis (joints) 11.3 (19.0) 10.8 (28.6) 7.6 (15.3)
Cocaine (g) 2.3 (3.2) 1.8 (2.0) 1.7 (1.3)
Non-prescribed methadone (ml) 58.5 (40.1) 56.6 (55.6) 63.7 (40.2)
Benzodiazepines (mg) 111 (159.8) 141 (276.0) 166.7 (261.3)
 Note 1: Matching subscript letters denote statistical significance.
 Note 2: Crack cocaine was excluded due to inconsistency in how data were reported.
 1 These figures were based on:
a) Heroin: one bag costing €20 and containing on average 0.113g at intake and 1-year, with one bag costing €20 and containing  
on average 0.1g at 3-years.
b) Cocaine: one gram costing €110 at intake, €66 at 1-year and €70 at 3-years.
c) Cannabis: one ounce costing €110 at intake, €100 at 1-year and €198.45 at 3-years (or a joint costing approx 39c at intake, 
approx 35c at 1-year and approx 70c at 3-years).
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For the sub-sample who used drugs over the 90 days prior to interview, a comparison of intake and 1-year 
follow-up indicated a significant reduction in the amount of heroin used (p<0.001), with the amount consumed 
decreasing from 0.8g to 0.4g. This result also held between intake and 3-years, although no significant 
differences were found between 1- and 3-years.
 Drug-free Status
A comparison of intake and 1-year follow-up revealed significant differences for drug-free (not using any 
illicit drug) (p<0.001), drug-free (not using any illicit drug excluding cannabis) (p<0.001) and drug-free (not 
using any illicit drugs or prescribed methadone) (p<0.001). Those who were drug-free (not using any illicit 
drug) increased from 7% (n=19) to 29% (n=83). Those who were drug-free (not using any illicit drug excluding 
cannabis) increased from 10% (n=29) to 42% (n=121) and those who were drug-free (not using any illicit drugs 
or prescribed methadone) increased from 4% (n=11) to 20% (n=58) (see Table 9.2(f)). This represents a very 
positive outcome with substantial percentages of participants moving towards a drug-free lifestyle.
Significant differences were also found between intake and 3-years. As was the case at 1-year, drug-free  
(not using any illicit drug) (p<0.001), drug-free (not using any illicit drug excluding cannabis) (p<0.001) and 
drug-free (not using any illicit drugs or prescribed methadone) (p<0.001) were all found to have improved 
significantly compared to intake. Those who were drug-free (not using any illicit drug) increased from 7% 
(n=19) to 29% (n=85). Those who were drug-free (not using any illicit drug excluding cannabis) increased  
from 10% (n=29) to 44% (n=127) and those who were drug-free (not using any illicit drugs or prescribed 
methadone) increased from 4% (n=11) to 20% (n=58).
No significant differences were found between 1-year and 3-year follow-up which shows that improvements 
gained at 1-year were maintained at 3-years. While there was a minor increase between 1- and 3-years for 
some categories of drug-free, increases were not significant. Again, this suggests a period of stabilisation 
following the improvements seen at 1-year.
 Table 9.2(f) Drug-free
Intake 1-year 3-years
n % n % n %
Drug-free in the last 90 days
Drug-free (not using any illicit drug) 19 6.7ab 83 28.8a 85 29.4b
Drug-free (not using any illicit drug 
excluding cannabis) 29 10.2ab 121 41.9a 127 43.9b
Drug-free (not using any illicit drugs 
or prescribed methadone) 11 3.9ab 58 20.1a 58 20.1b
 Note: Matching subscript letters denote statistical significance.
 Alcohol and Tobacco
A comparison of intake and 1-year follow-up for tobacco and alcohol consumption revealed a significant 
difference for alcohol consumption (p=0.002). It was found that the number consuming alcohol decreased 
from 57% (n=153) at intake to 44% (n=126) at 1-year follow-up. However, there was no significant difference 
found for those who smoked tobacco. A more positive result was found between intake and 3-year follow-up 
with significant differences found for both tobacco (p=0.024) and alcohol (p<0.001). The numbers of those 
consuming alcohol reduced from 57% (n=153) to 44% (n=126), while the numbers of those consuming 
tobacco reduced from 93% (n=254) to 88% (n=253) (see Table 9.2(g)).
A comparison between 1- and 3-year follow-up for tobacco and alcohol revealed no significant changes. 
The number of those consuming alcohol remained exactly the same at both time points. This indicates that 
improvements evident at 1-year follow-up were sustained at 3-years. With respect to the numbers smoking 
tobacco, while there was a significant difference between intake and 3-year follow-up, the difference 
between 1-year follow-up and 3-year follow-up was not large enough to be regarded as significant.
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 Table 9.2(g) Alcohol and Tobacco Consumption
Intake 1-year 3-years
n % n % n %
Consumption in the last 90 days
Tobacco 254 92.7b 257 89.2 253 88.2b
Alcohol 153 56.9ab 126 43.9a 126 43.9b
 Note: Matching subscript letters denote statistical significance.
In order to provide a more accurate picture of the findings for the frequency of tobacco and alcohol consumption 
over the 90 days prior to interview, the results for the population as a whole and the sub-sample who 
consumed tobacco and alcohol are presented separately. Regarding the sub-sample, in terms of analysis, 
only those who consumed tobacco or alcohol at the two time points being analysed were considered. 
Therefore, it was not expected that major differences would be apparent over time. However, when these 
differences did occur, they reflected the habits of those who smoke tobacco or drink alcohol rather than 
the habits of the opiate using population in treatment as a whole.
For the per-protocol population as a whole, a comparison between intake and 1-year follow-up revealed 
significant differences for the frequency of alcohol consumption (p=0.006) but not for the frequency of 
tobacco consumption. It was found that the frequency of alcohol consumption reduced from an average  
of 13.6 days in the last 90 days at intake, to 9.3 days at 1-year follow-up. A comparison between intake and  
3-year follow-up showed significant differences for the frequency of consumption of tobacco (p=0.039)  
and alcohol (p=0.010), with the frequency of tobacco reduced from 81.5 to 77.8 days and the frequency of 
alcohol consumption fell from 13.6 to 9.7 days for intake and 3-years follow-up, respectively. A comparison 
between 1- and 3-years revealed no significant differences. In terms of alcohol consumption, improvements 
evident at 1-year were maintained at 3-year follow-up. For the frequency of tobacco consumption, while 
there was a significant difference between intake and 3-year follow-up, the difference between 1-year 
follow-up and 3-year follow-up was not large enough to be regarded as significant (see Table 9.2(h)).
For the sub-sample who consumed tobacco and alcohol, no significant differences were found between 
intake and either 1-year or 3-year follow-up, or between 1- and 3-years (see Table 9.2(i)). This indicates  
that those consuming tobacco and alcohol did so at the same levels over the three years since ROSIE 
recruitment.
 Table 9.2(h) Mean Days Consumed Tobacco and Alcohol: Population
Intake 1-year 3-years
Mean (s.d.) Mean (s.d.) Mean (s.d.)
Mean days consumed in the last 90 days
Tobacco 81.5 (25.3)b 79.3 (28.5) 77.8 (29.9)b
Alcohol 13.6 (23.2)ab 9.3 (20)a 9.7 (20.4)b
 Note: Matching subscript letters denote statistical significance.
 Table 9.2(i) Mean Days Consumed Tobacco and Alcohol: Of Those Who Consumed
Intake 1-year 3-years
Mean (s.d.) Mean (s.d.) Mean (s.d.)
Mean days consumed in the last 90 days
Tobacco 87.9 (11.2) 88.9 (7.5) 88.3 (9.5)
Alcohol 23.9 (26.6) 21.1 (25.8) 22.1 (26)
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In order to provide a more accurate picture of the findings for the amount of tobacco and alcohol 
consumed over the 90 days prior to interview, the results for the population as a whole and the sub-sample 
who consumed tobacco and alcohol are presented separately (see Tables 9.2(j) and 9.2(k), respectively).
For the population as a whole, a comparison between intake and 1-year follow-up revealed a significant 
reduction in the amount of alcohol consumed (p=0.032) with a reduction from 8.5 units per day at intake  
to 6.0 units per day at 1-year. No significant reduction was evident from the amount of tobacco consumed 
(p=0.052), however it should be noted that this result was borderline significant. When intake and 3-year 
follow-up were compared, it was found that significant reductions were evident for both tobacco (p=0.022) 
and alcohol (p=0.001) with alcohol consumption reduced from 8.5 units per day to 5.6 units per day while 
tobacco consumption reduced from 17.3 cigarettes per day to 15.7 cigarettes per day. A comparison between 
1-year follow-up and 3-year follow-up revealed no significant differences. This indicates that improvements 
evident at 1-year follow-up stabilised thereafter and were still apparent at 3-years.
For the sub-sample who consumed tobacco and alcohol, no significant differences were found for the 
amounts consumed between intake and either 1-year or 3-year follow-up or between 1- and 3-years. This 
indicates that those consuming tobacco and alcohol were consuming approximately the same quantities  
of these substances over the three year study period.
 Table 9.2(j) Mean Amounts Consumed Tobacco and Alcohol: Population
Intake 1-year 3-years
Mean (s.d.) Mean (s.d.) Mean (s.d.)
Mean amount consumed per typical day in the last 90 days
Tobacco 17.3 (11.3)b 15.8 (11) 15.7 (11.7)b
Alcohol 8.5 (12.4)ab 6 (14.2)a 5.6 (10)b
 Note: Matching subscript letters denote statistical significance.
 Table 9.2(k) Mean Amounts Consumed Tobacco and Alcohol: Of Those Who Consumed
Intake 1-year 3-years
Mean (s.d.) Mean (s.d.) Mean (s.d.)
Mean amount consumed per typical day in the last 90 days
Tobacco 18.6 (10.5) 17.8 (10.0) 17.9 (10.9)
Alcohol 15.0 (12.9) 13.7 (18.9) 12.8 (11.6)
 Polydrug Use
A comparison between intake and 1-year follow-up revealed a significant reduction in the number of those 
engaging in polydrug use (p<0.001), with 78% (n=224) of participants engaging in polydrug use at intake which 
reduced to 50% (n=143) at 1-year follow-up. A comparison between intake and 3-year follow-up also revealed 
significant reductions for polydrug use (p<0.001), with 78% (n=224) of participants engaging in polydrug use 
at intake compared with 45% (n=131) at 3-year follow-up. A comparison between 1-year and 3-year follow-up 
revealed that while there had been a further small reduction in the percentage of those engaging in polydrug 
use, this reduction was not significant. However, this shows that improvements with regard to polydrug use 
one year after intake to treatment were still evident at the 3-year time point.
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 Table 9.2 (l) Polydrug Use
Intake 1-year 3-years
n % n % n %
Engaging in polydrug use 224 77.5ab 143 49.5a 131 45.3b
 Note: Matching subscript letters denote statistical significance.
9.3 Crime
 Criminal Activity
Comparison of intake and 1-year follow-up for crimes committed over the 90 days prior to interview showed 
significant improvements for selling/supplying drugs (p<0.001), theft from a person (p<0.001), theft from a 
house or home (p=0.010), theft from a shop/commercial property (p<0.001), theft from a vehicle (p=0.024), 
theft of a vehicle (p=0.001), handling stolen goods (p<0.001), fraud/forgery/deception (p<0.001), assault 
(p=0.007), criminal damage (p=0.001), soliciting (p=0.004) and breach of the peace. The most notable 
reduction was for selling/supplying drugs which reduced from 31% (n=81) at intake to 11% (n=31) at 1-year 
follow-up. Notable reductions were also apparent for all other forms of criminal activity (see Table 9.3(a)).
Similar positive results were evident between intake and 3-year follow-up with selling/supplying drugs 
(p<0.001), theft from a person (p<0.001), theft from a house or home (p=0.031) theft from a shop/commercial 
property (p<0.001), theft of a vehicle (p<0.001), handling stolen goods (p<0.001), fraud/forgery/deception 
(p=0.001), assault (p=0.023), soliciting (p=0.004) and breach of the peace (p=0.011) all showing significant 
improvements. As at 1-year, the most notable reduction was for selling/supplying drugs which reduced  
from 31% (n=81) to 11% (n=31). All other types of criminal activity, excluding theft from a vehicle and criminal 
damage, showed significant reductions compared to intake levels.
 Table 9.3(a) Crimes Committed
Intake 1-year 3-years
n % n % n %
Crimes committed in the last 90 days
Selling/supplying drugs 81 31.0ab 31 10.8a 31 10.8b
Theft from a person 31 11.8ab 7 2.5a 5 1.7b
Theft from house/home 18 6.9ab 7 2.5a 9 3.1b
Theft from shop/commercial property 50 19.1ab 24 8.5a 22 7.6b
Theft from a vehicle 21 8.0a 9 3.2a 12 4.2
Theft of vehicle 21 7.9ab 5 1.8a 6 2.1b
Handling stolen goods 68 26.2ab 21 7.3a 30 10.4b
Fraud/forgery/deception 28 10.8ab 4 1.4a 8 2.8b
Assault 20 7.7ab 8 2.8a 8 2.8b
Criminal damage 18 6.9a 5 1.7a 11 3.8
Soliciting 12 4.6ab 3 1.1a 2 0.7b
Breach of peace 20 7.7ab 5 1.8a 8 2.8b
 Note: Matching subscript letters denote statistical significance.
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A comparison between 1-year and 3-year follow-up for crimes committed revealed that while there were 
some minor increases and decreases, there were no significant changes between these two time points. 
Thus any improvements in criminal activity evident at 1-year were maintained at 3-years.
In order to provide an accurate picture of the findings for the frequency of crimes committed in the 90 days 
prior to interview, the results for the per-protocol population as a whole are presented separately from the 
sub-sample who committed crime (see Table 9.3(b)). Regarding the sub-sample, in terms of comparative 
analysis, only those who committed the same particular crime at the two time points being analysed were 
considered. Therefore, it was not expected that major differences would be apparent over time. However, 
when these differences did occur, it reflected a change in the frequency of a particular crime being committed 
by those respondents who committed that crime at both time points, rather than a change for all participants.
For the per-protocol population as a whole, a comparison between intake and 1-year follow-up showed 
that improvements were apparent for nine of the 12 crime categories with selling/supplying drugs (p<0.001), 
theft from a person (p=0.043), theft from a commercial property (p=0.001), theft of a vehicle (p=0.035), 
handling stolen goods (p<0.001), fraud/forgery/deception (p=0.007), assault (p=0.005), criminal damage 
(p=0.030) and soliciting (p=0.006) all showing improvement. The most notable reduction was for the 
average number of days selling/supplying drugs in the last 90 days, which reduced from 12.7 to 3.9 days  
(see Table 9.3(b)).
A comparison between intake and 3-year follow-up showed that fewer significant reductions were evident 
than at 1-year, with only selling/supplying drugs (p<0.001), theft from a commercial property (p=0.001), 
handling stolen goods (p=0.002) and soliciting (p=0.004) showing significant differences for the frequency  
at which they were committed. However, it should be noted that fraud/forgery/deception (p=0.056) was 
borderline significant. As at 1-year follow-up, the most notable reduction was for selling/supplying drugs 
which reduced from 12.7 to 4.3 days.
No further reductions or increases were evident between 1- and 3-years. This indicates that a period of 
stabilisation took place after the initial improvements were achieved and that these were still evident at  
3-year follow-up.
 Table 9.3(b) Mean Days Crimes Committed: Population
Intake 1-year 3-years
Mean (s.d.) Mean (s.d.) Mean (s.d.)
Mean days crime committed in the last 90 days
Selling/supplying drugs 12.7 (26.5)ab 3.9 (15.6)a 4.3 (16.5)b
Theft from a person 1.0 (7.1)a 0.1 (0.7)a 0.5 (6.1)
Theft from house/home 0.6 (4.8) 0.3 (3.6) 0.3 (2.3)
Theft from shop/commercial property 4.9 (17.3)ab 1.6 (10.0)a 1.2 (7.3)b
Theft from a vehicle 0.6 (4.7) 0.3 (3.6) 0.5 (3.9)
Theft of a vehicle 0.2 (0.8)a 0.1 (0.6)a 0.1 (1.9)
Handling stolen goods 5.6 (17.8)ab 0.8 (6.8)a 2.0 (10.5)b
Fraud/forgery/deception 1.8 (9.7)a 0.1 (1.8)a 0.4 (5.4)
Assault 0.1 (0.4)a 0.0 (0.2)a 0.1 (1.2)
Criminal damage 0.3 (2.3)a 0.0 (0.1)a 0.4 (4.5)
Soliciting 2.6 (14.0)ab 0.0 (0.6)a 0.2 (2.8)b
Breach of the peace 0.4 (3.5) 0.0 (0.1) 0.0 (0.3)
 Note: Matching subscript letters denote statistical significance.
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No significant results were found for the sub-sample of those who committed crime at any time point  
(see Table 9.3(c)). This was primarily due to the small number of those committing crimes for the particular 
categories at both time points being analysed, which rendered the statistical tests inconclusive.
 Table 9.3(c) Mean Days Crimes Committed: Of Those Who Committed Crime
Intake 1-year 3-years
Mean (s.d.) Mean (s.d.) Mean (s.d.)
Mean days crime committed in the last 90 days
Selling/supplying drugs 44.9 (32.2) 42.2 (32.2) 44.1 (32.2)
Theft from a person 9.7 (20.5) 5.3 (4.5) 31.3 (38.8)
Theft from house/home 11.1 (18.5) 18.8 (27.8) 8.9 (9.9)
Theft from shop/commercial property 29.3 (32.9) 25.6 (32.7) 16.7 (22.3)
Theft from a vehicle 8.2 (16.1) 15.2 (25.3) 11.8 (15.9)
Theft of a vehicle 2.5 (1.8) 4.0 (4.2) 8.6 (12.6)
Handling stolen goods 23.9 (30.3) 20.0 (29.2) 19.3 (27.8)
Fraud/forgery/deception 19.2 (26.4) 15.5 (20.5) 14.4 (30.8)
Assault 1.6 (0.8) 1.2 (0.4) 5.4 (8.3)
Criminal damage 5.3 (7.9) 1.0 (0.0) 14.0 (24.7)
Soliciting 56.3 (37.0) 5.5 (6.4) 48.0 (0.0)
Breach of the peace 8.1 (14.4) 1.0 (0.0) 1.7 (1.1)
 Arrests for Criminal Offences
Significant results were found for two categories only with respect to arrests by crime in the last 90 days. 
Theft from a person showed a significant decrease (p=0.031) from 3% at intake to 0% at 3-years, while 
criminal damage showed a significant decrease (p=0.004) from 4% at intake to 0% at 1-year. This increased 
to 1% at 3-years, but the increase was not significant. Once again, the small number of those who were 
arrested may have made statistical tests less sensitive at detecting any significant differences over time  
(see Table 9.3(d)).
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 Table 9.3(d) Crimes Arrested For in the Last 90 days
Intake 1-year 3-years
n % n % n %
Arrests by crime in the last 90 days
Selling/supplying drugs 8 3.3 10 3.5 5 1.7
Theft from a person 6 2.8b 1 0.4 0 0.0b
Theft from house/home 2 0.9 2 0.7 3 1.0
Theft from commercial property 14 6.1 9 3.2 9 3.1
Theft from a vehicle 2 0.9 0 0.0 0 0.0
Theft of a vehicle 4 1.8 3 1.1 1 0.3
Handling stolen goods 7 2.9 1 0.3 3 1.0
Fraud/forgery/deception 3 1.3 1 0.3 3 1.0
Assault 7 3.2 6 2.1 3 1.0
Criminal damage 9 4.1a 0 0.0a 3 1.0
Soliciting 2 1.0 0 0.0 0 0.0
Breach of the peace 7 3.2 3 1.1 4 1.4
 Note: Matching subscript letters denote statistical significance.
 Current Legal Problems
A comparison of current legal problems between intake and 1-year follow-up showed that there were 
significant differences for no legal problems (p=0.040), serving a sentence in prison (p=0.004), and 
outstanding warrants (p=0.026).
Two of these categories showed positive results with those experiencing no legal problems increasing from 
55% (n=151) at intake to 62% (n=176) at 1-year follow-up and those with outstanding warrants reducing from 
13% (n=36) at intake to 7% (n=21) at 1-year follow-up. However, there was an increase in the number of those 
serving a sentence in prison with 2% (n=6) serving a sentence in prison at intake compared to 7% (n=21) at  
1-year follow-up (see Table 9.3(e)).
A comparison of current legal problems between intake and 3-year follow-up showed that improvements 
were evident across a wider range of categories than at 1-year follow-up. Significant differences were found 
for no legal problems (p=0.008), serving a sentence in prison (p=0.027), outstanding warrants (p<0.001) and 
also on bail – awaiting trial (p<0.001). Again, reductions were evident for those experiencing legal problems 
and those with outstanding warrants, although the most notable positive results were for those on bail – 
awaiting trial reducing from 16% (n=44) to 5% (n=15). However, there was an increase in the number of those 
serving a sentence in prison with 2% (n=6) in prison at intake compared to 7% (n=20) at 3-year follow-up.
A comparison between 1-year and 3-year follow-up showed that there was a further reduction of the number 
on bail – awaiting trial from 11% (n=30) to 5% (n=15). No other significant results were evident for any other 
legal problems. Again this indicates a period of stabilisation after initial improvements were achieved.
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 Table 9.3(e) Current Legal Status
Intake 1-year 3-years
n % n % n %
1Current legal problems
None 151 54.5ab 176 62.0a 186 64.4b
On probation/community service 26 9.6 27 9.5 24 8.3
Serving sentence in prison/ 
in prison on remand 6 2.2ab 21 7.4a 20 6.9b
On bail – awaiting trial/hearing 44 16.2b 30 10.6c 15 5.2bc
On bail – awaiting sentencing 10 3.7 14 4.9 10 3.5
On temporary release/parole 6 2.2 2 0.7 5 1.7
Outstanding warrants 36 13.2ab 21 7.4 a 16 5.6b
Outstanding fines 19 7.0 22 7.8 30 10.4
 Note: Matching subscript letters denote statistical significance.
 1 Categories are not mutually exclusive.
9.4 Health and Risk Behaviour
 Physical Health Outcomes
A comparison of intake and 1-year follow-up for reported physical health symptoms revealed significant 
differences for poor appetite (p=0.007), tiredness/fatigue (p=0.031), joint/bone pains (p=0.003), muscle 
pains (p=0.002) and tremors/shakes (p<0.001). It should also be noted that nausea (p=0.064) was borderline 
significant (see Table 9.4(a)).
Improvements were still evident at 3-year follow-up, with significant differences between intake and 3-years 
for poor appetite (p<0.001), nausea (p=0.047), joint and bone pains (p=0.001), muscle pains (p=0.004) and 
tremors/shakes (p=0.045). However, no reduction was apparent for tiredness and fatigue. Again positive 
results were evident for all significant categories, in particular for poor appetite which reduced from 72% 
(n=193) to 56% (n=158).
There were also significant differences between 1-year and 3-year follow-up, with tremor/shakes (p=0.006), 
tiredness/fatigue (p=0.038) and numbness and tingling (p<0.001) all showing deterioration compared to  
1-year follow-up. The most notable increase was for numbness and tingling which increased from 17% (n=48) 
to 29% (n=80). These findings are contradictory to results found for other outcome measures such as crime 
or drug use. Instead of a period of stabilisation following 1-year results, there seemed to be a marked 
deterioration in some health categories.
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 Table 9.4(a) Number and Percentage Experienced Physical Health Symptoms
Intake 1-year 3-years
n % n % n %
Physical health symptoms experienced in the last 90 days
Poor appetite 193 72.3ab 167 60.1a 158 55.8b
Tiredness/fatigue 194 72.4a 174 62.8ac 198 70.0c
Nausea 107 40.1b 91 32.5 94 33.1b
Stomach pains 99 37.2 94 33.6 107 37.9
Difficulty breathing 79 29.9 69 24.6 82 29.0
Chest pains 59 22.2 51 18.2 55 19.4
Joint/bone pains 100 37.5ab 71 25.4a 74 26.2b
Muscle pains 91 34.3ab 66 23.6a 67 23.6b
Numbness/tingling arms/legs 60 22.5 48 17.1c 80 28.5c
Tremors/shakes 75 28.8ab 44 15.8ac 65 22.9bc
 Note: Matching subscript letters denote statistical significance.
A comparison of intake and 1-year follow-up for the frequency of reported physical health problems 
revealed significant differences for poor appetite (p=0.001) and tiredness and fatigue (p=0.042). It was found 
that poor appetite reduced from 49.2 days to 37.6 days and tiredness and fatigue reduced from 45.0 days to 
38.0 days. No other significant differences were found between intake and 1-year follow-up (see Table 9.4(b)).
A comparison of intake and 3-year follow-up showed that there were significant differences for poor appetite 
(p<0.001) and numbness and tingling (p=0.040), with poor appetite reducing from 49.2 days to 30.9 days  
and numbness and tingling increasing from 8.2 days to 12.3 days. No significant results were found for the 
other variables.
A comparison between 1-year and 3-year follow-up showed significant differences for poor appetite 
(p=0.010), difficulty breathing (p=0.025), numbness and tingling (p=0.005) and tremors/shakes (p=0.007).  
It was found that there was a further reduction for poor appetite, however all other significant variables 
showed an increase in the frequency of symptoms of approximately 4 to 5 days. In terms of the frequency 
of reported health problems, it would appear that the most positive results are evident at 1-year follow-up, 
after which deterioration takes place.
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 Table 9.4(b) Mean Days Physical Health Symptoms Experienced: Population
Intake 1-year 3-years
Mean (s.d.) Mean (s.d.) Mean (s.d.)
Mean days reported in the last 90 days
Poor appetite 49.2 (38.8)ab 37.6 (39.2)ac 30.9 (37.2)bc
Tiredness/fatigue 45.0 (38.8)a 38.0 (39.3)a 41.3 (38.4)
Nausea 14.2 (27.7) 14.6 (28.9) 12.6 (27.4)
Stomach pains 14.0 (26.6) 14.4 (28.3) 16.5 (30.3)
Difficulty breathing 14.3 (29.5) 13.7 (29.5)c 17.4 (32.7)c
Chest pains 7.6 (20.5) 8.0 (22.8) 6.3 (19.4)
Joint/bone pains 13.2 (27.1) 10.8 (25.3) 14.1 (29.9)
Muscle pains 9.6 (21.7) 9.9 (24.7) 11.4 (26.7)
Numbness/tingling arms/legs 8.2 (22.3)b 7.4 (21.1)c 12.3 (27.3) bc
Tremors/shakes 10.0 (23.4) 7.2 (21.2)c 11.3 (27.0)c
 Note: Matching subscript letters denote statistical significance.
 Mental Health Outcomes
A comparison between intake and 1-year follow-up for mental health complaints showed that there were 
significant differences for feeling tense (p=0.001), suddenly scared for no reason (p=0.004), feeling nervous/
shakiness inside (p=0.016), feelings of worthlessness (p=0.003), feeling lonely (p=0.012) and thoughts of 
ending your life (p=0.018). It should also be noted that feeling fearful (p=0.059) was borderline significant. 
All of these results showed an improvement on intake scores (see Table 9.4(c)).
A comparison between intake and 3-year follow-up showed that a narrower range of improvements were 
apparent than at 1-year follow-up. However, there were significant differences for feeling hopeless about 
the future (p=0.003), feeling lonely (p=0.001) and thoughts of ending your life (p=0.010). It should also be 
noted that feelings of worthlessness (p=0.054) was borderline significant.
A comparison between 1-year and 3-year follow-up also showed significant differences for feeling tense 
(p<0.001), suddenly scared for no reason (p=0.008), feeling fearful (p=0.002) and nervous/shakiness inside 
(p=0.020). However, all of these results showed deterioration with feeling tense and feeling fearful 
increasing beyond intake levels.
This result was in line with similar comparisons of 1-year and 3-year follow-ups for physical health outcome 
measures. As before, after improvements evident at 1-year, deterioration was apparent at 3-year follow-up.
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 Table 9.4(c) Number and Percentage Experienced Mental Health Symptoms
Intake 1-year 3-years
n % n % n %
Mental health symptoms experienced in the last 90 days
Feeling tense 169 65.3a 134 50.4ac 184 66.2c
Suddenly scared for no reason 90 34.6a 67 24.9ac 98 34.8c
Feeling fearful 107 42.8 93 35.1c 131 46.8c
Nervous/shakiness inside 110 43.0a 87 32.8ac 117 41.9c
Panic attacks 63 24.0 66 24.7 68 24.3
Feeling hopeless about the future 144 57.1b 132 49.4 131 46.6b
Feelings of worthlessness 136 53.8a 113 42.2a 131 46.8
No interest in things 152 59.4 142 53.2 151 53.7
Feeling lonely 150 59.8ab 132 50.0a 137 49.1b
Thoughts of ending your life 64 25.9ab 49 17.9a 50 17.8b
 Note: Matching subscript letters denote statistical significance.
A comparison between intake and 1-year follow-up for the frequency of reported mental health symptoms 
showed that there were significant differences for feeling tense (p<0.001), suddenly scared for no reason 
(p=0.002), feeling fearful (p=0.038), nervous/shakiness inside (p<0.001), feeling hopeless about the future 
(p=0.015), feelings of worthlessness (p<0.001), no interest in things (p=0.029), feeling lonely (p=0.001) and 
thoughts of ending your life (p=0.003). All of these results showed improvement between intake and 1-year 
follow-up. The frequency of feeling tense showed the most notable reduction decreasing from 37.2 to 21.9 
days (see Table 9.4(d)).
A comparison between intake and 3-year follow-up revealed less significant differences than at 1-year 
follow-up. However, reductions were still evident for feeling tense (p=0.021), feeling hopeless about the 
future (p<0.001), feelings of worthlessness (p=0.001), no interest in things (p=0.001), feeling lonely (p<0.001) 
and thoughts of ending your life (p=0.032). The most notable reductions were for feeling lonely which 
reduced from 34.3 to 23.8 days and for feelings of worthlessness which reduced from 29.3 to 19.9 days. 
Between 1-year and 3-years however, deterioration was apparent for feeling tense (p<0.001), suddenly  
scared for no reason (p=0.029), feeling fearful (p=0.016) and nervous/shakiness inside (p=0.008). Of these 
significant results, the greatest increases were for feeling fearful which increased from 14.0 to 18.5 days, 
nervous/shakiness inside which increased from 11.7 to 16.4 days and feeling tense which increased from  
21.9 to 30.5 days. This result is in line with other comparisons between 1-year and 3-year follow-up for 
health outcome measures.
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 Table 9.4(d) Mean Days Mental Health Symptoms Experienced: Population
Intake 1-year 3-years
Mean (s.d.) Mean (s.d.) Mean (s.d.)
Mean days reported in the last 90 days
Feeling tense 37.2 (37.9)ab 21.9 (31.4)ac 30.5 (35.5)bc
Suddenly scared for no reason 15.8 (30.2)a 9.3 (23.1)ac 13.4 (28.0)c
Feeling fearful 20.1 (32.2)a 14.0 (27.2)ac 18.5 (31.2)c
Nervous/shakiness inside 19.8 (31.8)a 11.7 (25.3)ac 16.4 (29.8)c
Panic attacks 9.3 (23.3) 8.0 (20.9) 7.2 (21.0)
Feeling hopeless about the future 29.2 (36.7)ab 21.4 (32.8)a 20.5 (32.6)b
Feelings of worthlessness 29.3 (37.7)ab 18.9 (31.7)a 19.9 (31.5)b
No interest in things 32.6 (37.4)ab 25.9 (35.2)a 24.1 (34.1)b
Feeling lonely 34.3 (38.4)ab 24.1 (33.9)a 23.8 (34.4)b
Thoughts of ending your life 8.9 (23.8)ab 3.3 (14.3)a 5.6 (18.8)b
 Note: Matching subscript letters denote statistical significance.
 Injecting-related Risk Behaviour
A comparison of intake and 1-year follow-up for injecting-related risk behaviour over the 90 days prior  
to interview showed that there was a significant difference for whether or not participants had injected 
(p<0.001). It was found that there was a substantial reduction in the number of those injecting drugs with 
58% (n=131) injecting at intake reducing to 29% (n=83) at 1-year follow-up. No significant differences were 
found for other injecting-related risk behaviour categories (see Table 9.4(e)).
 Table 9.4(e) Injecting-related Risk Behaviour
Intake 1-year 3-years
n % n % n %
Injecting behaviour in the last 90 days
Injected 131 58.0ab 83 28.7a 77 26.7b
1Injecting-related risk behaviour the last 30 days
Borrowed used injecting equipment 11 8.7 8 10.3 10 13.5
Lent used injecting equipment 10 8.1 10 12.8 10 13.5
Re-used own needles/syringes 34 34.4 35 46.1 45 64.3
Used filter, spoon or flush water  
after someone 11 9.6 7 9.0 14 18.9
Overdosed in the last 90 days 20 7.2 11 3.9 15 5.2
 Note: Matching subscript letters denote statistical significance.
 1 Of those who injected in the last 90 days.
A comparison between intake and 3-year follow-up showed that reductions in the number of those injecting 
(p<0.001) were still evident, with 27% (n=77) still injecting at 3-years compared to 58% (n=131) at intake. 
However, a comparison between 1-year and 3-year follow-up revealed no significant differences. This indicates 
that following improvements at 1-year, individuals’ behaviour stabilised and results were sustained.
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 Sexual Health
A comparison of intake and 1-year follow-up for sexual-related health revealed that there were no 
significant differences for any categories. An examination of the figures in Table 9.4(f) shows that there  
was very little alteration in respondents’ sexual behaviour one year after first entering treatment. However,  
a comparison of intake and 3-year follow-up showed that there was a significant difference for having sex 
with someone other than a regular partner (p=0.001). It was found that participants were less likely to  
have sex with someone other than a regular partner at 3-year follow-up, with 32% (n=54) having sex with 
someone other than a regular partner at intake compared to 20% (n=38) at 3-year follow-up. As before  
there were no other significant differences evident at 3-year follow-up. Similarly, no significant differences 
were evident between 1-year and 3-year follow-up.
 Table 9.4(f) Sexual Health
Intake 1-year 3-years
n % n % n %
Sexual history in the last 90 days
Participants having sex 190 68.8 175 63.4 189 68.0
Participants not having sex 86 31.2 101 36.6 89 32.0
1,2Sexual partners in the last 90 days
Having sex with a regular partner 149 82.8 143 83.6 160 84.7
Having sex with someone other than a 
regular partner 54 32.3b 37 24.2 38 20.1b
2Condom use with regular partner
Always used condom 37 26.1 34 27.6 37 23.7
Sometimes used condom 14 9.9 12 9.8 14 9.0
Never used condom 91 64.1 77 62.6 105 67.3
2Condom use with someone other than a regular partner
Always used condom 20 45.5 13 50.0 22 61.1
Sometimes used condom 7 15.9 5 19.2 6 16.7
Never used condom 17 38.6 8 30.8 8 22.2
 Note: Matching subscript letters denote statistical significance.
 1 These categories are not mutually exclusive.
 2 Refers only to those who reported having sex in the last 90 days.
9.5 Social Functioning
 Training and Education Status
A comparison between intake and 1-year follow-up for training and education status over the last six 
months showed that there was a significant difference for the number of those that had been on a training 
course (p<0.001). This result was quite positive with 15% (n=43) of participants attending a training course  
at intake compared to 29% (n=84) at 1-year follow-up. No other significant results were found for the 
remaining training and education status categories (see Table 9.5(a)).
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A comparison between intake and 3-year follow-up showed that again there was a significant difference  
for the number of those that had been on a training course (p<0.001). As at 1-year, this result was quite 
positive with 33% (n=96) of participants attending a training course at 3-year follow-up compared to  
15% (n=43) at intake. As at 1-year, no other significant differences were found between intake and 3-years. 
Similarly, a comparison between 1-year and 3-year follow-up revealed that while there was a general 
increase in the uptake of training and educational courses: these changes were not significant.
 Table 9.5(a) Training and Education Status
Intake 1-year 3-years
n % n % n %
Been on training courses over the last six months
Yes 43 14.9ab 84 29.2a 96 33.2b
No 245 85.1 204 70.8 193 66.8
Type of training course in the last six months
Community employment scheme 11 3.8 20 6.9 27 9.3
Personal development/life skills 8 2.8 18 6.2 24 8.3
Second/third level course 3 1.0 20 6.9 13 4.5
Vocational: computers 6 2.1 6 2.1 7 2.4
Vocational: building/machinery/driving 7 2.4 6 2.1 12 4.2
Vocational: other 5 1.7 11 3.8 11 3.8
 Note: Matching subscript letters denote statistical significance.
 Employment and Income Status
A comparison between intake and 1-year follow-up for employment and income status over the 90 days 
prior to interview revealed that there were significant differences for participants’ main sources of income 
in terms of family/partner (p<0.001), drug dealing (p<0.001) and other crime (p<0.001). These results were 
very positive with improvements ranging from approximately 13% to 27% for all significant categories (see 
Table 9.5(b)). This indicates that participants were far more self-reliant one year after entering treatment.
Further improvements were evident at 3-year follow-up with significant differences evident for paid legal 
employment in the last 90 days (p<0.001), currently employed (p<0.001) and main sources of income in 
terms of wage/salary (p=0.001), family/partner (p<0.001), social welfare (p=0.004), drug dealing (p=0.001) 
and other crime (p=0.001). Again these results were very positive, with improvements ranging from 
approximately 10% to 25% for all significant categories.
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 Table 9.5(b) Employment and Income Status
Intake 1-year 3-years
n % n % n %
Usual occupation in the last 90 days
Working (full-time/part-time) 52 18.0 51 17.6 74 25.6
Casual work 50 17.3 58 20.1 51 17.6
Community employment scheme 11 3.8 20 6.9 27 9.3
In prison 15 5.2 19 6.6 23 8.0
In treatment 3 1.0 5 1.7 2 0.7
Home duties 4 1.4 8 2.8 5 1.7
Student 0 0.0 3 1.0 1 0.3
Disability 18 6.2 22 7.6 22 7.6
Not working 133 46.0 103 35.6 84 29.1
Recent employment
Employed in the last 90 days 58 20.5b 64 22.1c 95 33.0bc
Currently employed 43 15.0b 58 20.1c 90 31.3bc
1Main sources of income in the last 90 days
Wage/salary 56 19.6b 54 18.7c 85 29.5bc
Family/partner 89 31.0ab 53 18.3ac 34 11.8bc
Social welfare 236 82.2b 229 79.2c 209 72.3bc
Drug dealing 74 25.8ab 27 9.3a 18 6.3b
Other crime 108 37.8ab 30 10.4a 35 12.2b
 Note: Matching subscript letters denote statistical significance.
 1 These categories are not mutually exclusive.
A comparison between 1-year and 3-year follow-up showed significant differences for paid legal 
employment in the last 90 days (p<0.001), currently employed (p<0.001) and main sources of income in 
terms of wage/salary (p<0.001), family/partner (p<0.030) and social welfare (p=0.0023). Unusually, compared 
to results from other comparisons of 1-year and 3-year follow-ups, further improvements were evident for 
all significant categories, with improvements ranging from approximately 7% to 11%. It should be noted that 
a number of participants were in residential treatment at intake and thus were unable to work. As a result, 
an increase in the number of those working is to be expected.
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9.6 Discussion and Conclusion
Overall results for drug use in terms of drugs used, frequency of use and amount used were quite positive. 
For the per-protocol population as a whole, reductions in the use of heroin and cocaine were particularly 
encouraging. However, while the largest improvements were observed at 1-year follow-up, some deterioration 
was evident between 1-year and 3-year follow-up for frequency of heroin use and for the use of benzodiazepines, 
in both frequency and quantity. It should be noted that these increases did not signify a return to intake 
levels of consumption. For the sub-sample who used drugs over the 90 days prior to interview, reductions 
were found for both the frequency and amount of heroin used at 1-year follow-up. However, the frequency 
of heroin use increased at 3-years, although not to the same level as at intake. Positive results were also 
evident for those who reported being drug-free: improvements at 1-year were sustained at 3-year follow-up. 
Similar results were observed for polydrug use and the consumption of alcohol and tobacco.
As with drug use, there were clear improvements in criminal behaviour and legal problems. Results for 
criminal activity were particularly positive, as any improvements found at 1-year were still evident at 3-years. 
Improvements were also found for legal problems with participants experiencing less legal problems at 
both 1- and 3-year follow-up. Due to the small numbers committing crime and being arrested, statistical 
tests were unable to detect any significant differences for these sub-groups.
Unlike the findings for crime and drug use, results for health and risk behaviour indicated that improvements 
found at 1-year were not always maintained at 3-year follow-up. While both physical and mental health 
showed improvements in terms of types and frequency of complaints at 1-year follow-up, there was marked 
deterioration at 3-years for a wide range of health problems. In terms of injecting-related health, fewer 
individuals were injecting at 1-year and at 3-years. Regarding sexual health, fewer individuals reported  
having sex with someone other than a regular partner at 1-year and at 3-years compared to intake.
The pattern of the findings for social functioning also differed from drug use and crime. In terms of the 
uptake of training and education, improvements were evident at 1-year follow-up and were sustained 
thereafter. Positive results were apparent for employment and income status, with a wide range of 
categories showing improvements at 1-year follow-up. A comparison of 1-year and 3-year follow-up  
showed further improvements, which was very encouraging as it indicated that individuals were moving 
towards a more independent lifestyle.
In conclusion, overall results for the per-protocol group were positive. Most improvements were attained  
at 1-year and were sustained in many categories. Drug use, crime and social functioning on the whole 
displayed positive outcomes at 3-years, while health and risk behaviour showed less improvement in  
the long term.
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CHAPTER 10: CONCLUSION
10.1 Introduction
The aim of ROSIE was to evaluate the effect of treatment for opiate use not only on the individual 
presenting for treatment but on the community and the society within which that person resides. 
The conclusions from this study can be summarised as follows:
n It was found that the mortality rate of participants followed-up at 1- and 3-years was low at 0.5% 
and 1.5%, respectively.
n Of those interviewed at 3-years, 59% were currently in receipt of methadone treatment.
n Signifi cant reductions were observed from intake to 1-year follow-up in both the proportion using 
and the mean number of days on which participants used a range of drugs.
n With the exception of the proportion using benzodiazepines, these reductions were generally 
sustained when participants were interviewed again at 3-years.
n The proportion using benzodiazepines increased signifi cantly from 1- to 3-years but the proportion 
using at 3-years was still lower than the proportion using at intake.
n The percentage drug-free from all illegal drugs in the last 90 days increased signifi cantly from 9% 
at intake to 28% at 1-year and 29% at 3-years.
n Contrary to expectation, reductions in participants’ opiate and other drug use were not mirrored by an 
increase in cocaine use, with the proportion using at 1-year and at 3-years signifi cantly lower than at intake.
n The reduction in participants’ opiate and other drug use was not accompanied by an increase in alcohol 
consumption, with the proportion using at 1-year and at 3-years signifi cantly lower than at intake.
n Signifi cant reductions were observed from intake to 1-year follow-up in both the proportion committing 
and the mean number of days on which participants committed a range of crimes. These reductions 
were sustained at 3-year follow-up.
n Health outcomes were mixed. The proportion experiencing some physical health symptoms reduced 
signifi cantly from intake to 1-year. These were poor appetite, tiredness/fatigue, joint/bone pains, 
and tremors/shakes. There was no signifi cant reduction in feelings of nausea, stomach pains, diffi culty 
breathing, chest pains and numbness/tingling. At 3-years, the proportion experiencing some physical 
health symptoms increased signifi cantly from 1-year. These were tiredness/fatigue, joint/bone pains, 
numbness/tingling and tremors/shakes.
n A similarly mixed pattern was observed in the proportion experiencing a range of mental health 
outcomes, with some symptoms reducing signifi cantly from intake to 1-year (feeling tense, suddenly 
scared, nervousness, feeling of worthlessness, feeling lonely, thoughts of ending your life) and some 
increasing from 1-year to 3-years (feeling tense, suddenly scared, feeling fearful and nervousness).
n There were signifi cant reductions from intake to 1-year in the proportion who had injected a drug 
in the last 90 days. This reduction was sustained at 3-years.
n There was a signifi cant improvement from intake to 3-years and from 1-year to 3-years in the proportion 
  employed in the last 90 days and in the proportion currently employed. The percentage employed 
    in the last 90 days was 30% at 3-years.
n     There was a signifi cant increase in the mean number of times on which participants 
     had attended a service regarding employment, training or education from 1- to 3-years.
n     The proportion living in their own house/fl at or rental accommodation increased 
     signifi cantly from intake to 1-year and this increase was sustained at 3-years. 
     The percentage living in their own house/fl at or rental accommodation 
     was 49% at 3-years.
n     The proportion of those with no fi xed abode or living in hostels, 
     shelters or bed and breakfast accommodation in the last 90 days 
     decreased signifi cantly from intake to 3-years. At 3-years 3% 
     of respondents reported no fi xed abode and 9% reported 
     living in a hostel, shelter or bed and breakfast accommodation.
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10.2 Conclusions in an International Context
In an international context ROSIE achieved exceptionally high follow-up rates with 75% of all participants 
interviewed at 1-year and 88% interviewed at 3-years. In England and Wales, NTORS at the 2-year and 4-5 year 
follow-up points did not attempt to interview all of the original 1,075 participants recruited. The eligible 
sample for 2-year and 4-5 year follow-up was constructed using a sampling frame of 894 participants  
(83% of the intake sample) for whom definite locator information was confirmed by contact during the  
first year after intake. From this, a random stratified sample of 650 participants was selected and 76% of 
those selected were followed-up and interviewed (Gossop, M., Marsden, J. & Stewart, D. (2000)). The ROSIE 
3-year mortality rate was 1.5%. The mortality rate for the study population at 1-year was very low at 0.5% 
when compared with NTORS (1.2%) or Smyth et al’s (2005) follow-up study of opiate users seeking inpatient 
treatment in Dublin (1.8%). However, it should be noted that the confidence interval for the ROSIE mortality 
rate at 1-year did include these two point estimates.
It was observed that 40% of the participants recruited in the methadone modality were still in their  
intake treatment setting at 3-years. In addition, it was observed that 59% of those interviewed at 3-years 
were currently receiving methadone treatment. Approximately 70% of participants recruited within the 
detoxification and abstinence modalities completed their intake treatment, an encouraging result, since 
Ravndal et al (2005) state that the completion of treatment is an important indicator for improved outcomes. 
Studies conducted in the UK show completion rates varying from 25-50% (Gossop et al, 1999; Keen et al, 
2001), so the Irish completion rates reported by ROSIE compare favourably at the international level.
Reductions observed in the proportion using a range of drugs and the mean numbers of days on which drugs 
were used, between intake and 1-year, were sustained at 3-years. However, while the proportion using was 
lower at 3-years than at intake, it was found that the proportion using benzodiazepines increased significantly 
from 1-year to 3-years. The percentage drug-free from all illegal drugs in the last 90 days increased significantly 
from 9% at intake to 28% at 1-year and 29% at 3-years. In terms of alcohol consumption, it was observed 
that the proportion using at 1- and 3-years decreased significantly from intake. NTORS, in England and 
Wales, observed that decreases in opiate use were not mirrored by similar decreases in cocaine use and 
alcohol consumption, and levels at 4-5 years remained the same as at intake (Gossop, M., Stewart, D., Tracey, 
S. & Marsden, J. (2002)). However, ATOS in Australia reported that cocaine use did decrease significantly 
during the 3-year study period (Teesson et al, 2007).
A comparison between intake and 3-year follow-up showed that significant improvements in crime 
outcomes were still evident at this time point for a range of crimes, following improvements at 1-year. 
Similar, sustained reductions in crimes committed were observed by both NTORS (Gossop, M., Stewart, D., 
Tracey, S. & Marsden, J. (2002)) and ATOS (Teesson et al, 2007).
The main conclusion on health and risk is that, again, positive outcomes observed at 1-year were generally 
sustained at 3-years.
However, there is a need to continue to closely monitor health over perhaps a longer time period as some 
health measures were observed to deteriorate between the 1- and 3-year interviews. ATOS observed that 
participants who had borderline personality disorders did not exhibit the same level of improvements 
across all outcomes including health, as those without such disorders (Darke et al, 2005). Given these 
international findings, there is clearly a need for further refined analysis within the physical and mental 
health outcomes of the ROSIE study.
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With the emergence of the National Drugs Strategy (2001-2008), the role of rehabilitation, employment  
and social functioning for the improvement of quality of life of drug users has received more emphasis. 
Significant improvements in the levels of employment and education were observed in ROSIE. In addition, 
in terms of social functioning, accommodation and family, a significant increase was observed in the number 
of participants who reported living in their own or in rented accommodation in the last 90 days when 
intake and 1-year, and intake and 3-years, were compared. The main conclusion was that the various aspects 
of social functioning, which included training, education, employment, accommodation status and social 
support from family and friends, are all regarded as important to the success of the overall treatment 
process. Results at 1- and 3-years showed considerable improvements in these areas. These results are very 
positive since access to employment and other social supports is believed to be an important aspect of a 
successful recovery process (Cox & Lawless, 2000; Stansfield, 2006).
Finally, it is clear that overall improvements observed in outcomes at 1-year were generally sustained at  
3-years. That said, there remains potential to perform further refined analysis on the ROSIE data in the 
context of international findings.
10.3 Recommendations for Future Research
The results presented on outcomes for treatment for opiate use are both positive and encouraging from  
the perspective of not only the individual opiate user but the community, the treatment provider and 
society. In summary, many improvements observed at the 1-year time point following treatment entry  
were sustained. This was particularly true of outcomes for drug use, crime and social functioning. Health  
and risk behaviour initially showed improvement but this was not always sustained in the longer term.  
More focus and research is required on the long-term mental and physical health outcomes of opiate  
users in treatment.
While the majority of the participants demonstrated improvements in outcomes, there remained a  
group of participants who did not respond to treatment. This is evident in the proportion that did not 
complete or remain in their intake treatment, the proportion that continued to use opiates regularly  
and those who continued to engage in polydrug use. There is now a pressing need to perform further 
analysis on the ROSIE dataset to examine the factors that may influence outcomes and produce a  
positive treatment response.
Finally, the results presented here are a glimpse at the wealth of data collected by ROSIE. It is hoped  
that treatment users, treatment providers and policy makers will see this study as their resource and  
that this resource will continue to be used for the benefit of all those who contributed to the success  
of the ROSIE study.
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APPENDIX: KEY OUTCOMES BY GENDER
Drug Use
Table 1: Drug Use at Treatment Intake, 1-year and 3-years by Drug Type and Gender
MALE FEMALE
Intake 1-year 3-years Intake 1-year 3-years
n % n % n % n % n % n %
Heroin 228 77.0ab 116 51.8a 127 48.8b 78 76.5ab 29 35.8a 38 39.2b
Methadone 115 38.7ab 32 14.3a 36 13.8b 47 46.1ab 9 11.1a 13 13.5b
Benzodiazepines 128 43.8ab 56 25.0ac 91 35.0bc 46 45.5ab 13 16.0a 22 22.9b
Cocaine 134 44.4ab 51 22.8a 62 23.9b 45 44.1ab 13 16.0a 9 9.4b
Crack Cocaine 44 14.6ab 14 6.3a 15 5.8b 15 14.7a 5 6.2a 8 8.3
Cannabis 187 66.1ab 123 55.7a 135 51.9b 56 58.3b 38 47.5 39 40.6b
Alcohol 150 53.4ab 94 42.5a 111 42.9b 54 55.1 45 55.6 46 47.9
Polydrug use 223 73.8ab 121 54.0a 134 51.5b 85 83.3ab 30 37.0a 32 33.0b
Note: Matching subscript letters denote statistical significance.
Table 2: Mean Drug Using Days at Treatment Intake, 1-year and 3-years by Drug Type and Gender
MALE FEMALE
Intake 1-year 3-years Intake 1-year 3-years
Mean (s.d.) Mean (s.d.) Mean (s.d.) Mean (s.d.) Mean (s.d.) Mean (s.d.)
Heroin 40.0 (36.1)ab 17.3 (28.7)a 21.0 (32.8)b 40.5 (35.1)ab 10.7 (25.7)ac 19.8 (32.9)bc
Methadone 10.0 (21.1)ab 3.9 (15.5)a 2.6 (10.3)b 16.4 (28.1)ab 3.7 (16.1)a 2.6 (12.1)b
Benzodiazepines 16.2 (29.7)ab 5.3 (14.2)ac 10.7 (24.4)bc 13.5 (27)ab 5.5 (20.0)a 5.8 (17.4)b
Cocaine 7.2 (16.7)ab 3.6 (12.9)a 3.4 (12.6)b 8.6 (19.1)ab 2.8 (13.6)a 1.5 (8.3)b
Crack Cocaine 1.8 (8.5) 1.0 (7.0) 0.9 (4.8) 3.0 (13.2) 0.5 (3.4) 1.6 (9.9)
Cannabis 39.4 (40.3)ab 32.7 (39.3)ac 26.0 (35.9)bc 37.6 (39.8)ab 30.1 (40.2)a 22.8 (36.7)b
Alcohol 14.1 (23.9)ab 9.9 (21.2)a 11.1 (23)b 11.1 (23.0) 9.8 (19.9) 10.4 (21.1)
Note: Matching subscript letters denote statistical significance.
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Table 3: Mean Quantity of Drugs Consumed at Treatment Intake, 1-year and 3-years by Drug Type and 
Gender
MALE FEMALE
Intake 1-year 3-years Intake 1-year 3-years
Mean (s.d.) Mean (s.d.) Mean (s.d.) Mean (s.d.) Mean (s.d.) Mean (s.d.)
Heroin (grams) 0.6 (0.8)ab 0.2 (0.7)a 0.2 (0.5)b 0.5 (0.7)ab 0.1 (0.2)a 0.1 (0.2)b
Methadone (mls) 22.6 (37.7)ab 6.6 (21.8)a 7.9 (24.2)b 25.4 (37.7)ab 8.5 (38.4)a 12.2 (40.5)b
Benzodiazepines 
(mgs) 47.1 (116.9)a 26.2 (137.4)ac 49.3 (156.1)c 27.8 (64.3) 12.8 (56.9) 13.6 (46.0)
Cocaine (grams) 1.0 (2.7)ab 0.4 (1.2)a 0.3 (0.9)b 0.7 (1.2)ab 0.3 (1.0)a 0.1 (0.5)b
Cannabis (joints) 8.3 (17.3)b 6.7 (24.0) 4.6 (12.8)b 5.9 (14.2)ab 2.1 (5.0)a 1.2 (1.9)b
Alcohol (units) 10.0 (16.5)ab 6.0 (14.2)a 6.1 (9.6)b 6.4 (10.5) 6.6 (13.0) 4.9 (10.8)
Note: Matching subscript letters denote statistical significance.
Note 2: Crack cocaine was excluded due to inconsistency in data reporting.
1 These figures were based on
a) Heroin: one bag costing €20 and containing on average 0.113g at intake and 1-year, with one bag costing €20 and containing on average 
0.1g at 3- years.
b) Cocaine: one gram costing €110 at intake, €66 at 1-year and €70 at 3-years.
c) Cannabis: one ounce costing €110 at intake, €100 at 1-year and €198.45 at 3-years (or a joint costing approximately 39c at intake,  
approx 35c at 1-year and approx 70c at 3-years).
Table 4: Drug Abstinence Rates at Treatment Intake, 1-year and 3-years by Gender
MALE FEMALE
Intake 1-year 3-years Intake 1-year 3-years
n % n % n % n % n % n %
Drug Abstinence1 33 11.1ab 60 26.9a 76 29.2b 4 3.9ab 24 29.6a 29 29.9b
Note: Matching subscript letters denote statistical significance.
1 Drug abstinence is defined as not using any illegal drug in the last 90 days.
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CRIME
Table 5: Offending Behaviour at Treatment Intake, 1-year and 3-years by Gender
MALE FEMALE
Intake 1-year 3-years Intake 1-year 3-years
n % n % n % n % n % n %
Selling/supplying 86 31.0ab 34 15.4a 36 13.8b 23 26.7ab 1 1.3a 9 9.4b
Theft from  
a person 31 11.2ab 7 3.2a 5 1.9b 8 9.3b 2 2.5 1 1.0b
Theft from 
house/home 18 6.5 8 3.6 9 3.5 5 5.8 1 1.3 2 2.1
Theft from  
shop etc. 36 13.2a 17 7.7a 22 8.5 27 31.4ab 8 10.1a 5 5.2b
Theft from  
a vehicle 19 6.9 11 5.0 13 5.0 3 3.5 0 0.0 0 0.0
Theft of a vehicle 20 7.2ab 7 3.2a 6 2.3b 2 2.3 0 0.0 0 0.0
Handling stolen 
goods 69 24.9ab 20 9.0a 32 12.4b 22 26.5ab 5 6.3a 5 5.2b
Fraud/forgery/ 
deception 32 11.8ab 5 2.3a 8 3.1b 8 9.4 1 1.3 2 2.1
Assault 27 9.8ab 10 4.5a 10 3.8b 2 2.4 1 1.3 0 0.0
Criminal damage 23 8.4a 7 3.2a 9 3.5 3 3.5 0 0.0 2 2.1
Soliciting 2 0.7 1 0.5 1 0.4 12 14.0ab 2 2.5a 1 1.0b
Breach of the 
peace 20 7.3ab 5 2.3a 9 3.5b 4 4.7 1 1.3 0 0.0
Note: Matching subscript letters denote statistical significance.
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HEALTH AND RISK BEHAVIOUR
Table 6: Physical Health Symptoms at Treatment Intake, 1-year and 3-years by Gender
MALE FEMALE
Intake 1-year 3-years Intake 1-year 3-years
n % n % n % n % n % n %
Poor appetite 194 69.3ab 126 58.9a 134 52.8b 75 78.9ab 49 61.3a 60 63.2b
Tiredness/fatigue 192 69.1 129 60.8 170 66.9 76 78.4 56 70.0 69 72.6
Nausea  
(feeling sick) 100 36.2 72 33.5 79 31.0 48 50.0 25 31.3 35 36.8
Stomach pains 106 38.4 73 34.0 83 32.7 42 43.8 28 35.0c 44 46.8c
Difficulty 
breathing 74 26.9 51 23.7 72 28.3 31 32.0 23 28.8 33 35.1
Chest pains 68 24.4 41 19.1 54 21.3 17 17.9 16 20.0 20 21.3
Joint/bone pains 94 33.7 57 26.5 68 26.8 41 42.7 21 26.3 27 28.7
Muscle pains 86 31.0ab 48 22.3a 56 22.0b 36 37.5b 23 28.8 21 22.1b
Numbness/
tingling arms/legs 58 21.0 40 18.6c 67 26.4c 26 27.1 13 16.3c 28 30.1c
Tremors/shakes 81 29.8a 36 16.8ac 58 22.7c 24 25.5 12 15.0 22 23.2
Note: Matching subscript letters denote statistical significance.
Table 7: Mental Health Symptoms at Treatment Intake, 1-year and 3-years by Gender
MALE FEMALE
Intake 1-year 3-years Intake 1-year 3-years
n % n % n % n % n % n %
Feeling tense 171 64.8a 102 50.2ac 163 65.2c 63 66.3 42 54.5c 68 73.1c
Suddenly scared 
for no reason 95 35.2a 45 22.0ac 86 34.3c 34 37.0 25 32.1 36 37.9
Feeling fearful 114 43.3a 66 32.8ac 121 48.4c 35 39.3 32 41.0 42 44.7
Nervous/ 
shaking inside 111 41.3 64 31.8 97 38.6 42 46.7 27 34.6 46 49.5
Panic attacks 67 24.5 45 22.2 54 21.5 23 24.7 24 30.8 26 28.0
Feeling hopeless 
about future 140 53.4 96 47.3 115 45.8 56 62.9 42 53.8 54 57.4
Feelings of 
worthlessness 141 52.8ab 84 41.2a 113 45.2b 47 52.8 36 46.2 52 55.3
No interest  
in things 150 55.8 113 55.7 136 54.2 56 62.2 39 50.0 56 60.2
Feeling lonely 147 55.9ab 95 47.5a 116 46.6b 55 61.8 42 53.8 49 52.1
Thoughts of 
ending life 65 25.0ab 38 17.8a 45 17.9b 23 26.4 14 18.9 20 21.3
Note: Matching subscript letters denote statistical significance.
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Table 8: Injecting Drug Use at Treatment Intake, 1-year and 3-years by Gender
MALE FEMALE
Intake 1-year 3-years Intake 1-year 3-years
n % n % n % n % n % n %
Any drug 130 43.3ab 70 31.3a 74 28.5b 47 46.1ab 18 22.2a 24 25.0b
Heroin 124 41.1ab 63 28.1a 67 25.8b 44 43.1ab 17 21.0a 23 24.0b
Cocaine 69 22.8ab 24 10.7a 28 10.8b 17 16.7ab 4 4.9a 6 6.3b
Benzodiazepines 45 14.9ab 9 4.0a 14 5.4b 7 6.9 0 0.0 2 2.1
Note: Matching subscript letters denote statistical significance.
Table 9: Mean Times Injected at Treatment Intake, 1-year and 3-years by Gender
MALE FEMALE
Intake 1-year 3-years Intake 1-year 3-years
Mean (s.d.) Mean (s.d.) Mean (s.d.) Mean (s.d.) Mean (s.d.) Mean (s.d.)
Mean days 
injected 20.7 (32.9)ab 10.6 (23.8)a 9.7 (24.2)b 19.4 (30.5)a 4.9 (18.0)ac 14.0 (29.9)c
Mean times 
injected per day 1.7 (4.0)ab 1.0 (3.0)a 0.8 (1.9)b 1.6 (2.6)ab 0.3 (0.7)ac 0.8 (1.6)bc
Note: Matching subscript letters denote statistical significance.
Table 10: Injecting-related Risk Behaviour in the Last 30 Days, at Treatment Intake, 1-year and 3-years by Gender
MALE FEMALE
Intake 1-year 3-years Intake 1-year 3-years
n % n % n % n % n % n %
Borrowed used 
needle/syringe 16 5.7 6 2.7 10 3.9 5 5.4 2 2.5 2 2.1
Lent used 
needle/syringe 13 4.7 8 3.6 9 3.5 4 4.2 3 3.8 3 3.2
Reused own 
needle/syringe 43 17.5 29 13.4 38 15.2 9 10.6 7 8.9 17 18.1
Used filters/
spoons after 
someone 13 4.8 6 2.7 9 3.5 4 4.6 1 1.3 8 8.3
Note: Matching subscript letters denote statistical significance.
Table 11: Overdose at Treatment Intake, 1-year and 3-years by Gender
MALE FEMALE
Intake 1-year 3-years Intake 1-year 3-years
n % n % n % n % n % n %
Overdose 22 7.6 11 5.0 19 7.3 4 3.9 2 2.6 3 3.1
Note: Matching subscript letters denote statistical significance.
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CONTACT WITH SERVICES
Table 12: Contact with Health and Social Care Services at Treatment Intake, 1-year and 3-years by Gender
MALE FEMALE
Intake 1-year 3-years Intake 1-year 3-years
n % n % n % n % n % n %
Stayed overnight 
in hospital 29 9.9 22 9.8 33 12.7 5 5.1b 12 14.8 23 23.7b
Treated in A & E 52 18.0 42 18.8 60 23.1 15 15.6 11 13.6 22 22.7
Seen G.P. 77 27.7ab 97 43.3a 97 37.3b 47 51.6 43 53.1 43 44.3
Out-patients 
appointment 36 12.5 33 14.8 47 18.1 13 13.5ab 26 32.1a 26 26.8b
Contact with 
social services 16 5.4 19 8.5 17 6.5 9 9.6 14 17.3 18 18.6
Employment/
education 
services 24 9.0ab 102 45.9ac 84 32.3bc 13 14.8b 29 35.8 31 32.0b
Social welfare 
services 89 32.4 67 30.2 73 28.1 26 27.4 18 22.2 25 26.0
Housing/
homeless services 34 12.0ab 60 27.0a 67 25.8b 21 23.3 33 40.7 29 29.9
Note: Matching subscript letters denote statistical significance.
TREATMENT STATUS
Table 13: Treatment Status at 3-years by Gender
MALE FEMALE
n % n %
Participants currently in treatment 145 61.2 72 79.1
In Methadone treatment 140 59.1 72 79.1
In detoxification programme 3 1.3 0 0.0
In abstinence-based programme 1 0.4 0 0.0
Participants not currently in treatment 92 38.8 19 20.9
1Drug status in last 90 days of those in treatment at 3-years
Drug free (all illicit drugs) 18 12.4 20 27.8
Drug free (all illicit drugs excluding cannabis) 41 28.3 32 44.4
Drug free (all illicit drugs and alcohol) 12 8.3 12 16.7
1Drug status in last 90 days of those not in treatment at 3-years
Drug free (all illicit drugs) 45 48.9 6 31.6
Drug free (all illicit drugs excluding cannabis) 53 57.6 10 52.6
Drug free (all illicit drugs and alcohol) 32 34.8 3 15.8
1 Treatment refers to methadone, detoxification and abstinence-based treatment.
Other forms of treatment such as counselling and group work were not included due to inconsistencies in the way they were reported.
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